



(86) Date de dépôt PCT/PCT Filing Date: 2012/01/06
(87) Date publication PCT/PCT Publication Date: 2012/07/12
(85) Entrée phase nationale/National Entry: 2013/07/04
(86) N° demande PCT/PCT Application No.: EP 2012/050187
(87) N° publication PCT/PCT Publication No.: 2012/093169
(30) Priorité/Priority: 2011/01/07 (US61/430,670)


(51) Cl.Int./Int.Cl. *C07D 487/04* (2006.01),
A61K 31/519 (2006.01), *A61P 17/00* (2006.01),
A61P 25/00 (2006.01), *A61P 3/00* (2006.01),
A61P 35/00 (2006.01)

(71) Demandeur/Applicant:
LEO PHARMA A/S, DK

(72) Inventeurs/Inventors:
SCHOU, SOREN CHRISTIAN, DK;
GREVE, DANIEL RODRIGUEZ, DK;
NIELSEN, SIMON FELDBAEK, DK;
JENSEN, JENS BJORN, DK;
DACK, KEVIN NEIL, DK

(74) Agent: SMART & BIGGAR

(54) Titre : NOUVEAUX DERIVES DE SULFAMIDE PIPERAZINE A TITRE D'INHIBITEURS DE PROTEINES TYROSINE KINASES ET LEUR UTILISATION PHARMACEUTIQUE
(54) Title: NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF



(57) Abrégé/Abstract:

The invention relates to compounds of general Formula (I), Wherein R_1 , R_2 , R_3 , R_4 , R_5 , m , n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use - alone or in combination with one or more other



(57) **Abrégé(suite)/Abstract(continued):**

pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
12 July 2012 (12.07.2012)(10) International Publication Number
WO 2012/093169 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 17/00* (2006.01)
A61K 31/519 (2006.01) *A61P 25/00* (2006.01)
A61P 3/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/EP2012/050187

(22) International Filing Date:

6 January 2012 (06.01.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/430,670 7 January 2011 (07.01.2011) US

(71) Applicant (*for all designated States except US*): **LEO PHARMA A/S** [DK/DK]; Industriparken 55, DK-2720 Ballerup (DK).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **SCHOU, Søren Christian** [DK/DK]; c/o LEO Pharma A/S, Industriparken 55, DK-2720 Ballerup (DK). **GREVE, Daniel Rodriguez**

[DK/DK]; c/o LEO Pharma A/S, Industriparken 55, DK-2720 Ballerup (DK). **NIELSEN, Simon Feldbæk** [DK/DK]; c/o LEO Pharma A/S, Industriparken 55, DK-2720 Ballerup (DK). **JENSEN, Jens Bjørn** [DK/DK]; c/o LEO Pharma A/S, Industriparken 55, DK-2720 Ballerup (DK). **DACK, Kevin Neil** [GB/DK]; c/o LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,

[Continued on next page]

(54) Title: NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF



(57) Abstract: The invention relates to compounds of general Formula (I), Wherein R₁, R₂, R₃, R₄, R₅, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use - alone or in combination with one or more other pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

WO 2012/093169 A1



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF

FIELD OF THE INVENTION

5

This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a patient in need thereof an effective amount of said compound, and

10

to the use of said compounds in the manufacture of medicaments.

BACKGROUND OF THE INVENTION

15

This invention relates to novel compounds which are inhibitors of protein tyrosine kinases such as the Janus kinases, also referred to as JAK1, JAK2, JAK3 and TYK2. Said compounds are useful in the treatment of diseases related to activity of Janus kinases, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes and complications from diabetes, asthma, cancer,

20

autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

25

Protein tyrosine kinases are a family of enzymes catalysing the transfer of the terminal phosphate of adenosine triphosphate to tyrosine residues in protein substrates.

Phosphorylation of tyrosine residues on protein substrates leads to transduction of intracellular signals which regulate a wide variety of intracellular processes such as growth, differentiation and activation of cells of the immune system. As activation of T-

30

cells and B-cells as well as other cells of the immune system such as monocytes and macrophages is implicated in a number of inflammatory conditions and other disorders of the immune system (e.g. autoimmune diseases), modulation of the activity of protein tyrosine kinases appears to be an attractive route to the management of inflammatory diseases. A large number of protein tyrosine kinases have been identified

35

which may be receptor protein tyrosine kinases, e.g. the insulin receptor, or non-receptor protein tyrosine kinases.

The protein tyrosine kinases JAK1, JAK2, JAK3 and TYK2 have essential roles in cytokine-dependent regulation of proliferation and function of cells involved in immune response. They are critical in signal transduction in response to their activation via tyrosine phosphorylation by stimulation of interleukin receptors. (1) Schindler C. et al.

5 JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem 2007; 282(28):20059; 2) O'Shea J.J. Targeting the Jak/STAT pathway for immunosuppression Ann. Rheum. Dis. 2004; 63 Suppl 2:ii67; 3) Schindler C. Series introduction. JAK-STAT signaling in human disease. J. Clin. Invest. 2002; 109(9):1133).

10 While JAK1, JAK2 and TYK2 are ubiquitously expressed JAK3 is predominantly expressed in hematopoietic cells.

JAK1 plays a critical role in mediation of biological responses and JAK1 is widely expressed and associated with several major cytokine receptor families. It is involved in signalling by members of the IL-2 receptor family (IL-2, IL-4, IL-7R, IL-9R, IL-15R and 15 IL-21R), the IL-4 receptor family (IL-4R, IL-13R), the gp130 receptor family and class II cytokine receptors.

JAK2 is implicated in signalling by several single chain receptors (including Epo-R, GHR, PRL-R), the IL-3 receptor family, the gp130 receptor family and Class II receptor 20 cytokine family. Thus, JAK2 plays a critical role in transducing signals for Epo, IL-3, GM-CSF, IL-5 and IFN γ . JAK2 knockout mice exhibit an embryonic lethal phenotype.

JAK3 is involved in signal transduction by receptors that employ the common gamma chain of the type I cytokine receptor family (e.g. IL-2, IL-4, IL-7, IL-9, IL-15 and IL- 25 21). XSCID patient populations have been identified with reduced levels of JAK3 protein or with genetic defects to the common gamma chain, suggesting that immune suppression should result from blocking signalling through the JAK3 pathway. Animal studies have suggested that JAK3 not only plays a critical role in B and T lymphocyte maturation, but that JAK3 is constitutively required to maintain T cell function. 30 Modulation of immune activity through this novel mechanism can prove useful in the treatment of T cell proliferative disorders such as immune system diseases, in particular autoimmune diseases.

TYK2 is implicated in type I interferons, IL-6, IL-10, IL-12 and IL-23 signalling. A 35 human patient with a TYK2 deficiency has been described and this patient had a primary immunodeficiency disorder characterized as a hyper-IgE-like syndrome with many opportunistic infections by virus, bacteria and fungi. Because IL-23 has been

found to play an important role in many chronic inflammatory conditions, a TYK2 inhibitor could conceivably be very effective in treating diseases influenced by IL-23.

5 Inhibitors of the Janus kinases are accordingly expected to show utility in the treatment of inflammatory and non-infectious autoimmune diseases wherein these kinases are involved.

10 It is further envisaged that compounds of the present invention may be useful as inhibitors of other kinases, such as Src family kinases (Src, Yes, Fyn, Lyn, Fgr, Blk, Lck and/or Hck) responsible for receptor mediated signalling in T, B and other immune cells; Raf-1/Ras, MAP kinase signalling pathway; Syk and ZAP70 kinases responsible of activation of immune cells.

15 WO1999065908A1, WO1999065909A1, and WO2001042246A2 disclose pyrrolo[2,3-d]pyrimidine compounds as inhibitors of the enzyme protein tyrosine kinases such as Janus kinase 3 and as useful therapy as immunosuppressive agents.

20 WO2003022214A3 discloses piperazine and homopiperazine compounds for use in the treatment of thrombosis.

WO2004035740A3 discloses aromatic bicyclic heterocycles to modulate IL-12 production.

25 WO2004099205A1 discloses azaindole compounds as kinase inhibitors.

WO 2005112938A3 discloses disalt nitrogen-heteroaryl inhibitors of IL-12 production.

30 WO2005051393A1 discloses a method of treatment of atherosclerosis by administering a pyrrolo[2,3-d]pyrimidine compound.

WO2005060972A2 discloses a method of treating or preventing chronic, acute or hyperacute organ transplant rejection using pyrrolo[2,3-d]pyrimidine compounds.

35 WO2006096270A1 discloses pyrrolopyrimidines useful as inhibitors of protein kinase.

WO2006069080A2 discloses pyrrolo[2,3-d]pyridine-4-yl amines and pyrrolo[2,3b]pyrimidine-4-yl amines useful in the treatment of diseases related to activity of Janus kinases.

WO2006127587A1 discloses pyrrolopyrimidines useful as inhibitors of protein kinase.

WO2007077949A1 discloses heterocyclic Janus kinase 3 inhibitors being useful for the
5 treatment or prevention of various immune diseases.

WO2007117494A1 discloses deazapurines useful as inhibitors of Janus kinases.

WO2007104944A1 discloses pyrrolopyrimidine derivatives having HSP90 inhibitory
10 activity and useful in the treatment of inter alia cancer.

WO2008128072A3 discloses heterocyclic compounds as AXL kinase inhibitors useful for
the treatment of cancer or hyperproliferative disorders.

15 WO2009021169A2 discloses heterocyclic compounds useful as kinase inhibitors.

US2004/0058922 A1 discloses pyrrolo[2,3-d]pyrimidine compounds as inhibitors of
protein tyrosine kinases, such as the enzyme Janus Kinase 3 and as useful therapy as
immunosuppressive agents.

20

US2005/0130954 A1 discloses AKT protein kinase inhibitors for the treatment of
hyperproliferative diseases such as cancer.

US2006/0189638 A1 discloses 4-piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
25 and their use for e.g. treatment of hyperproliferative disorders.

SUMMARY OF THE INVENTION

The present inventors have surprisingly found that a novel class of compounds exhibit a
30 high inhibitory activity on one or more of the Janus kinase receptors JAK1, JAK2, JAK3
and TYK2.

It is further envisaged that compounds of the present invention may be useful as
inhibitors of other kinases, such as Src family kinases (Src, Yes, Fyn, Lyn, Fgr, Blk, Lck
35 and/or Hck) responsible for receptor mediated signalling in T, B and other immune
cells; Raf-1/Ras, MAP kinase signalling pathway; Syk and ZAP70 kinases responsible of
activation of immune cells and as such show utility in the treatment of inflammatory
and non-infectious autoimmune diseases wherein these kinases are involved.


Compounds of the present invention may have improved pharmacokinetic properties such as improved solubility and absorption, reduced adverse side effects and increased or decreased metabolic stability in comparison to known structurally related
5 compounds.

A particular advantage of some of the compounds of the present invention is that they show high systemic clearance.

10 An advantage of some of the compounds of the present invention is that they show low systemic clearance.

Some compounds of the present invention show improved JAK kinase inhibitory activity in comparison to known structurally related compounds.
15

Accordingly, the invention relates to compounds of general formula I:



20

wherein

25 m is 0, 1 or 2;

n is 2 or 4;

R_1 is selected from the group consisting of hydrogen, halogen, cyano, $-NH_2$, $-SO_2NH_2$, $-SONH_2$, and $-CONH_2$;

or R_1 is selected from the group consisting of alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, $R_{1a}O-$, $R_{1a}S-$, $(R_{1a})_2N-$, $R_{1b}-C(=O)N(R_{1c})-$, $R_{1b}O-C(=O)N(R_{1c})-$, $R_{1b}O-C(=O)-$, $(R_{1b})_2N-C(=O)N(R_{1c})-$, $R_{1b}-S(=O)_2N(R_{1c})-$ and $(R_{1b})_2N-S(=O)_2N(R_{1c})-$ either of which may be optionally substituted with one or more R_{1d} ;

R_{1a} is hydrogen;

or R_{1a} independently at each occurrence is selected from the group consisting of alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl- either of which may be optionally substituted with one or more R_{1e} ;

or in the case where two R_{1a} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more R_{1e} ;

R_{1b} and R_{1c} independently at each occurrence are selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl- either of which may be optionally substituted with one or more R_{1e} ;

or in the case where two R_{1b} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more R_{1e} ;

R_{1d} and R_{1e} independently at each occurrence are selected from the group consisting of halogen, cyano, hydroxy, oxo, $-NH_2$, $-SO_2NH_2$, $-CONH_2$, alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, $R_{1f}O-$, $R_{1f}S-$, $(R_{1f})_2N-$, $R_{1f}O-C(=O)-$, $(R_{1f})_2N-C(=O)-$, $R_{1f}-C(=O)N(R_{1f})-$, $R_{1f}O-C(=O)N(R_{1f})-$, $(R_{1f})_2N-C(=O)N(R_{1f})-$, $R_{1f}-C(=O)O-$, $(R_{1f})_2N-C(=O)O-$, $(R_{1f})_2N-S(=O)_2-$ and $R_{1f}-S(=O)_2N(R_{1f})-$;

R_{1f} independently at each occurrence is selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl-;

or in the case where two R_{1f} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle;

R_2 is independently at each occurrence a covalent bond or alkyl- or heteroalkyl- group, where any two R_2 s are attached to the same C ring atom, and together with this C ring

atom said two R_2 s form a carbocycle or heterocycle, hence always forming a spirocyclic piperazine;

R_3 independently at each occurrence is selected from the group consisting of halogen,
 5 cyano, hydroxy, oxo, alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, $R_{3a}O$ -, $R_{3a}S$ -,
 $(R_{3a})_2N$ -, $R_{3a}-C(=O)$ -, $R_{3a}O-C(=O)$ -, $(R_{3a})_2N-C(=O)$ -, $R_{3a}-C(=O)N(R_{3b})$ -, $R_{3a}O$ -
 $C(=O)N(R_{3b})$ -, $R_{3a}-C(=O)O$ -, $(R_{3a})_2N-C(=O)O$ -, $R_{3a}-S(=O)$ -, $R_{3a}-S(=O)_2$ -, $(R_{3a})_2N$ -
 $S(=O)_2$ - and $R_{3a}-S(=O)_2N(R_{3b})$ -;

10 R_{3a} and R_{3b} independently at each occurrence are selected from the group consisting of
 hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl-

or in the case where two R_{3a} s are attached to the same N, they may together with the
 N atom to which they are attached form a heterocycle;

15

R_4 and R_5 independently at each occurrence is selected from the group consisting of
 alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, cycloalkenyl-, cycloalkynyl-,
 heterocyclyl-, cycloalkylalkyl-, heterocyclylalkyl, alkylcycloalkyl-, alkylheterocyclyl-,
 aryl-, heteroaryl-, arylalkyl-, aryloxyalkyl-, heteroarylalkyl-, heteroaryloxyalkyl-, R_6O-L -
 20 , R_6S-L -, $(R_6)_2N-L$ -, $R_6-C(=O)-L$ -, $R_6O-C(=O)-L$ -, $(R_6)_2N-C(=O)-L$ -, $R_6-C(=O)N(R_6)-L$ -,
 $R_6O-C(=O)N(R_6)-L$ -, $(R_6)_2N-C(=O)N(R_6)-L$ -, $R_6-C(=O)O-L$ -, $(R_6)_2N-C(=O)O-L$ -, R_6 -
 $S(=O)_2-L$ -, $(R_6)_2N-S(=O)_2-L$ -, $R_6-S(=O)_2N(R_6)-L$ - and $(R_6)_2N-S(=O)_2N(R_6)-L$ either of
 which may be optionally substituted with one or more R_7 ;

25 or R_4 and R_5 can together with the N atom to which they are attached form a
 heterocyclic ring which may be optionally substituted with one or more R_7 ;

or R_4 and R_5 independently can be hydrogen;

30 L is independently at each occurrence selected from the group consisting of alkyl-,
 heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-,
 cycloalkylalkyl-, heterocyclylalkyl, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-,
 arylalkyl-, aryloxyalkyl-, heteroarylalkyl- and heteroaryloxyalkyl-;

or when R_4 or R_5 is selected from R_6O-L -, L can also be a bond;

35 R_6 independently at each occurrence is selected from the group consisting of
 hydrogen, alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, heterocyclyl-, aryl-,
 arylalkyl- and heteroaryl-, cycloalkylalkyl- either of which may be optionally substituted

with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂, -CONH₂ and -O(C₁-C₄);

or in the case where two R₆ are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

R₇ independently at each occurrence is selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂, -CONH₂ and =CH₂, or R₇ is selected from the group consisting of alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-, arylalkyl-, alkoxy-, aryloxyalkyl-, heteroarylalkyl-, heteroaryloxyalkyl-, R₈O-L-, R₈S-L-, (R₈)₂N-L-, R₈-C(=O)-L-, R₈O-C(=O)-L-, (R₈)₂N-C(=O)-L-, R₈-C(=O)N(R₈)-L-, R₈O-C(=O)N(R₈)-L-, (R₈)₂N-C(=O)N(R₈)-L-, R₈-C(=O)O-L-, (R₈)₂N-C(=O)O-L-, R₈-S(=O)₂-L-, (R₈)₂N-S(=O)₂-L-, R₈-S(=O)₂N(R₈)-L- and (R₈)₂N-S(=O)₂N(R₈)-L

either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

R₈ independently at each occurrence is selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl-, aryl-, arylalkyl-, heteroaryl-, and heteroarylalkyl- either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

or in the case where two R₈ are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof;

with the proviso that when R₁ is hydrogen, and m is 0, and n is 2, and the two R₂'s form a cyclopropyl ring together with the carbon atom to which they are attached, and R₄ is methyl, R₅ is not selected from the group consisting of cyanoethyl or cyclohexyl;

and with the proviso that when R_1 is hydrogen, and m is 0, and n is 2, and the two R_2 's form a cyclopropyl ring together with the carbon atom to which they are attached, and R_5 is methyl, R_4 is not selected from the group consisting of cyanoethyl or cyclohexyl;

5

and with the proviso that when R_1 is hydrogen, and m is 0, and n is 2, and the two R_2 's form a cyclopropyl ring together with the carbon atom to which they are attached, and R_4 is ethyl, R_5 is not ethyl.

10

DETAILED DESCRIPTION OF THE INVENTION

Definitions

The term "hydrocarbon radical" is intended to indicate a radical containing only hydrogen and carbon atoms, it may contain one or more double and/or triple carbon-carbon bonds, and it may comprise cyclic moieties in combination with branched or linear moieties. Said hydrocarbon comprises 1-20 carbon atoms, and preferably comprises 1-12 or 1-10 e.g. 1-6, e.g. 1-4, e.g. 1-3, e.g. 1-2 carbon atoms. The term includes alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkynyl and aryl, as indicated below.

20

In the present context, the term "alkyl" is intended to indicate the radical obtained when one hydrogen atom is removed from a hydrocarbon. Said alkyl may be branched or straight-chained and comprises 1-20, preferably 1-10, such as 2-6, such as 3-4, such as 1-2, such as 1-3, such as 1-4, such as 1-5 such as 2-3, such as 2-4, such as 2-5, such as 3-5, such as 3-6 carbon atoms. The term includes the subclasses normal alkyl (*n*-alkyl), secondary and tertiary alkyl, such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, isopentyl, hexyl and isohexyl.

25

In the present context, the term "(C_a - C_b)alkyl" wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms, e.g. 1-5 or 1-4, such as 1-4 or 1-3 carbon atoms. Thus when a is 1 and b is 5, for example, the term includes methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl and isopentyl.

30

The term "alkylene" is intended to indicate a divalent saturated aliphatic hydrocarbyl group preferably having from 1 to 6 and more preferably 1 to 3 carbon atoms that are either straight-chained or branched. This term is exemplified by groups such as

35

methylene (-CH₂-), ethylene (-CH₂CH₂-), n-propylene (-CH₂CH₂CH₂-), iso-propylene (-CH₂CH(CH₃)-) or (-CH(CH₃)CH₂-), and the like.

5 The term "cycloalkyl" is intended to indicate a saturated cycloalkane radical, including polycyclic radicals, such as bicyclic or tricyclic radicals, comprising 3-20 carbon atoms, preferably 3-10 carbon atoms, in particular 3-8 carbon atoms, such as 3-6 carbon atoms, such as 4-5 carbon atoms, such as 3-5 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and cubanyl.

10 The term "cycloalkylene" is intended to indicate a divalent cycloalkyl group as defined herein.

The term "alkenyl" is intended to indicate a hydrocarbon radical comprising 2-20 carbon atoms, preferably 2-10, in particular 2-6 carbon atoms, such as 2-4 carbon atoms, and
15 having at least 1 and preferably from 1 to 2 sites of double bond unsaturation, e.g. ethenyl, allyl, propenyl, butenyl, pentenyl, nonenyl, or hexenyl. Included within this term are the *cis* and *trans* isomers or mixtures of these isomers.

The term "alkenylene" is intended to indicate a divalent aliphatic hydrocarbyl group
20 preferably having from 2 to 6 and more preferably 2 to 4 carbon atoms that are either straight-chained or branched and having at least 1 and preferably from 1 to 2 sites of double bond unsaturation. This term is exemplified by groups such as ethenylene (-CH=CH-), propenylene (-CH=CHCH₂-), 1-butenylene (-CH=CHCH₂CH₂-) or 2-butenylene (-CH₂CH=CHCH₂-), and the like.

25 The term "cycloalkenyl" is intended to indicate mono-, di- tri- or tetraunsaturated non-aromatic cyclic hydrocarbon radicals, including polycyclic radicals, comprising 3-20 carbon atoms, typically comprising 3-10 carbon atoms, such as 3-8 carbon atoms, such as 4-6 carbon atoms, e.g. cyclopropenyl, cyclobutenyl, cyclopentenyl or
30 cyclohexenyl.

The term "cycloalkenylene" is intended to indicate a divalent cycloalkenyl group as defined herein.

35 The term "alkynyl" is intended to indicate an hydrocarbon radical comprising 1-5 C-C triple bonds and 2-20 carbon atoms, the alkane chain typically comprising 2-10 carbon atoms, in particular 2-6 carbon atoms, such as 2-4 carbon atoms, e.g. ethynyl, propynyl, butynyl, pentynyl or hexynyl.

The term "alkynylene" is intended to indicate a divalent aliphatic hydrocarbyl group preferably having from 2 to 6 and more preferably 2 to 4 carbon atoms that are either straight-chained or branched and having at least 1 and preferably from 1 to 2 sites of triple bond unsaturation. This term is exemplified by groups such as ethynylene (-CC-), propynylene (-CCCH₂-), 1-butyne (-CCCH₂CH₂-) or 2-butyne (-CH₂CCCH₂-), and the like.

The term "cycloalkynyl" is intended to indicate mono-, di-, tri- or tetra-unsaturated non-aromatic cyclic hydrocarbon radicals, including polycyclic radicals, comprising 3-20 carbon atoms, typically comprising 3-10 carbon atoms, such as 3-8 carbon atoms, such as 4-6 carbon atoms, and at least 1 and preferably from 1 to 2 sites of triple bond unsaturation, e.g. cyclopropynyl, cyclobutynyl, cyclopentynyl or cyclohexynyl.

The term "cycloalkynylene" is intended to indicate a divalent cycloalkynyl group as defined herein.

The term "heterocyclic" and "heterocyclyl" is intended to indicate a saturated or unsaturated group having a single ring or multiple condensed rings, including fused bridged and spiro ring systems, and having from 3 to 15 ring atoms, including 1 to 4 hetero atoms, such as 1-5 carbon atoms and 1-3 heteroatoms, such as 1-4 carbon atoms and 1-3 heteroatoms, such as 1-5 carbon atoms and 1-2 heteroatoms, such as 1-5 carbon atoms and 1 heteroatom. These ring atoms are selected from the group consisting of nitrogen, sulphur and oxygen, wherein, in fused ring systems, one or more of the rings can be cycloalkyl, aryl, or heteroaryl, provided that the point of attachment is through the non-aromatic ring. In one embodiment, the nitrogen and/or sulphur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, -S(O)-, or -SO₂- moieties. Examples include tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, morpholinyl, piperidinyl, tetrahydropyranyl, dioxothiolanyl, dioxothianyl, oxetanyl, or azetidiny.

The term "heterocycloalkenyl" is intended to indicate a cycloalkenyl radical as defined above, including polycyclic radicals, optionally fused with carbocyclic rings, comprising 1-6 heteroatoms, preferably 1-3 heteroatoms, selected from O, N, or S, e.g. tetrahydropyranol.

The term "heterocyclylalkyl" is intended to indicate a heterocyclyl group as defined

herein connected via an alkyl group as defined herein.

The term "aryl" is intended to indicate a radical of aromatic carbocyclic rings comprising 6-20 carbon atoms, such as 6-14 carbon atoms, preferably 6-12, such as 6-10 carbon
5 atoms, in particular 5- or 6-membered rings, optionally fused carbocyclic rings with at least one aromatic ring, such as phenyl, naphthyl, biphenyl, anthracenyl, indenyl or indanyl.

The terms "arylalkyl" and "arylcycloalkyl" are intended to indicate an aryl group as
10 defined herein connected via an alkyl or a cycloalkyl group as defined herein, respectively.

The term "heteroaryl" is intended to include radicals of heterocyclic aromatic rings, optionally fused with carbocyclic rings or heterocyclic rings, comprising 1-6
15 heteroatoms (selected from O, S and N) and 1-20 carbon atoms, such as 1-5 heteroatoms and 1-10 carbon atoms, such as 1-5 heteroatoms and 1-6 carbon atoms, such as 1-5 heteroatoms and 1-3 carbon atoms, in particular 5- or 6-membered rings with 1-4 heteroatoms or 1-2 heteroatoms selected from O, S and N, or optionally fused bicyclic rings with 1-4 heteroatoms, and wherein at least one ring is aromatic.
20 Examples of heteroaryl include, but are not limited to, pyridyl, quinolyl, isoquinolyl, indolyl, tetrazolyl, furyl, thiazolyl, imidazolyl, imidazo[1,2-a]pyrimidinyl, pyrazolyl, oxazolyl, oxadiazolyl, thiophenyl, 1,2,4-triazolyl, isoxazolyl, thienyl, pyrazinyl, pyrimidinyl, [1,2,3]triazolyl, isothiazolyl, imidazo[2,1-b]thiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl or pyrrolyl.

25

The term "aryloxy" is intended to indicate groups -O-aryl, wherein aryl is as defined herein, including, by way of example, phenoxy, naphthoxy, and the like.

The term "alkyloxy" is intended to indicate the groups -O-alkyl, -O-alkenyl-, and -O-
30 alkynyl-, wherein alkyl, alkenyl and alkynyl are as defined herein.

The term "halogen" is intended to indicate a substituent from the 7th main group of the periodic table, preferably fluoro, chloro and bromo.

35 The term "amino" refers to the group -NH₂.

The term "aminoalkyl" is intended to indicate a radical of the formula -alkyl-NH_2 , wherein alkyl represents alkylene, cycloalkylene as indicated above, e.g. aminoalkylene, aminocycloethylene etc.

- 5 The term "arylamino" is intended to indicate a radical of the formula -NR_2 , wherein R is aryl as indicated above e.g. phenylamino.

The term "arylaminoalkyl" is intended to indicate an arylamino group as defined herein connected via an alkyl group as defined herein.

10


The term "alkylthio" is intended to indicate a radical of the formula -S-R , wherein R is alkyl as indicated above.

15

The term "oxo" is intended to indicate an oxygen atom which is connected via a double bond:




The term "dioxothiolanyl" is intended to indicate radicals of the structures:



20

The term "dioxothianyl" is intended to indicate radicals of the structures:



- 25 The term "pharmaceutically acceptable salt" is intended to indicate salts prepared by reacting a compound of formula I, which comprises a basic moiety, with a suitable inorganic or organic acid, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric, phosphoric, formic, acetic, 2,2-dichloroacetic, adipic, ascorbic, L-aspartic, L-glutamic, galactaric, lactic, maleic, L-malic, phthalic, citric, propionic, benzoic, glutaric, gluconic, D-glucuronic, methanesulfonic, salicylic, succinic, malonic, tartaric, benzenesulfonic, ethane-1,2-disulfonic, 2-hydroxy ethanesulfonic acid, toluenesulfonic, sulfamic or fumaric acid. Pharmaceutically acceptable salts of compounds of formula I comprising
- 30

an acidic moiety may also be prepared by reaction with a suitable base such as sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, silver hydroxide, ammonia or the like.

5 The term "solvate" is intended to indicate a species formed by interaction between a compound, e.g. a compound of formula I, and a solvent, e.g. alcohol, glycerol or water, wherein said species are in a solid form. When water is the solvent, said species is referred to as a hydrate.

10 Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality towards the point of attachment. For example, the group "arylalkyloxycarbonyl" refers to the group (aryl)-(alkyl)-O-C(O)-.

15 The term "JAK1" is used to indicate a protein tyrosine kinase of the JAK (Janus protein tyrosine kinase) family highly expressed in immune cells where it is essential for signalling by members of the IL-2 receptor family (IL-2, IL-4, IL-7R, IL-9R, IL-15R and IL-21R), the IL-4 receptor family (IL-4R, IL-13R), the gp130 receptor family and class II cytokine receptors.

20

The term "JAK2" is used to indicate a protein tyrosine kinase of the JAK (Janus protein tyrosine kinase) family highly expressed in immune cells where it is essential for signalling downstream of many cytokines and growth factors including the proinflammatory cytokines Epo, IFN- γ , IL-3, IL-5, and GM-CSF.

25

The term "JAK3" is used to indicate a protein tyrosine kinase of the JAK (Janus protein tyrosine kinase) family highly expressed in immune cells where it is essential for signalling downstream of many cytokines and growth factors including the proinflammatory cytokines IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21.

30

The term "TYK2" is used to indicate a protein tyrosine kinase of the JAK (Janus protein tyrosine kinase) family, and TYK2 is implicated in type I interferons, IL-6, IL-10, IL-12 and IL-23 signaling.

35 Embodiments of compounds of formula I:

An embodiment of the invention provides a compound of formula I wherein

m is 0, 1 or 2;

n is 2 or 4;

5

R_1 is selected from the group consisting of hydrogen, halogen, cyano, $-NH_2$, $-SO_2NH_2$, $-SONH_2$, and $-CONH_2$;

or R_1 is selected from the group consisting of alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, $R_{1a}O-$, $R_{1a}S-$, $(R_{1a})_2N-$, $R_{1b}-C(=O)N(R_{1c})-$, $R_{1b}O-C(=O)N(R_{1c})-$, $R_{1b}O-C(=O)-$, $(R_{1b})_2N-C(=O)N(R_{1c})-$, $R_{1b}-S(=O)_2N(R_{1c})-$ and $(R_{1b})_2N-S(=O)_2N(R_{1c})-$ either of which may be optionally substituted with one or more R_{1d} ;

10

R_{1a} is hydrogen;

or R_{1a} independently at each occurrence is selected from the group consisting of alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl- either of which may be optionally substituted with one or more R_{1e} ;

15

or in the case where two R_{1a} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more R_{1e} ;

20

R_{1b} and R_{1c} independently at each occurrence are selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl- either of which may be optionally substituted with one or more R_{1e} ;

25

or in the case where two R_{1b} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more R_{1e} ;

30

R_{1d} and R_{1e} independently at each occurrence are selected from the group consisting of halogen, cyano, hydroxy, oxo, $-NH_2$, $-SO_2NH_2$, $-CONH_2$, alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, $R_{1f}O-$, $R_{1f}S-$, $(R_{1f})_2N-$, $R_{1f}O-C(=O)-$, $(R_{1f})_2N-C(=O)-$, $R_{1f}-C(=O)N(R_{1f})-$, $R_{1f}O-C(=O)N(R_{1f})-$, $(R_{1f})_2N-C(=O)N(R_{1f})-$, $R_{1f}-C(=O)O-$, $(R_{1f})_2N-C(=O)O-$, $(R_{1f})_2N-S(=O)_2-$ and $R_{1f}-S(=O)_2N(R_{1f})-$;

35

R_{1f} independently at each occurrence is selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl-;

or in the case where two R_{1f} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle;

R_2 is independently at each occurrence a covalent bond or alkyl- or heteroalkyl- group, where any two R_2 s are attached to the same C ring atom, and together with this C ring atom said two R_2 s form a carbocycle or heterocycle, hence always forming a spirocyclic piperazine;

R_3 independently at each occurrence is selected from the group consisting of halogen, cyano, hydroxy, oxo, alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, $R_{3a}O$ -, $R_{3a}S$ -, $(R_{3a})_2N$ -, $R_{3a}-C(=O)$ -, $R_{3a}O-C(=O)$ -, $(R_{3a})_2N-C(=O)$ -, $R_{3a}-C(=O)N(R_{3b})$ -, $R_{3a}O-C(=O)N(R_{3b})$ -, $R_{3a}-C(=O)O$ -, $(R_{3a})_2N-C(=O)O$ -, $R_{3a}-S(=O)$ -, $R_{3a}-S(=O)_2$ -, $(R_{3a})_2N-S(=O)_2$ - and $R_{3a}-S(=O)_2N(R_{3b})$ -;

R_{3a} and R_{3b} independently at each occurrence are selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl-

or in the case where two R_{3a} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle;

20

R_4 and R_5 independently at each occurrence is selected from the group consisting of alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclylalkyl, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-, arylalkyl-, aryloxyalkyl-, heteroarylalkyl-, heteroaryloxyalkyl-, R_6O -L-, R_6S -L-, $(R_6)_2N$ -L-, $R_6-C(=O)$ -L-, $R_6O-C(=O)$ -L-, $(R_6)_2N-C(=O)$ -L-, $R_6-C(=O)N(R_6)$ -L-, $R_6O-C(=O)N(R_6)$ -L-, $(R_6)_2N-C(=O)N(R_6)$ -L-, $R_6-C(=O)O$ -L-, $(R_6)_2N-C(=O)O$ -L-, $R_6-S(=O)_2$ -L-, $(R_6)_2N-S(=O)_2$ -L-, $R_6-S(=O)_2N(R_6)$ -L- and $(R_6)_2N-S(=O)_2N(R_6)$ -L either of which may be optionally substituted with one or more R_7 ;

30 or R_4 and R_5 can together with the N atom to which they are attached form a heterocyclic ring which may be optionally substituted with one or more R_7 ;

or R_4 and R_5 independently can be hydrogen;

35 L is independently at each occurrence selected from the group consisting of alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclylalkyl, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-, arylalkyl-, aryloxyalkyl-, heteroarylalkyl- and heteroaryloxyalkyl-;

R₆ independently at each occurrence is selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, heterocyclyl-, aryl-, arylalkyl- and heteroaryl- either of which may be optionally substituted with one or
 5 more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

or in the case where two R₆ are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally
 10 substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

R₇ independently at each occurrence is selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂
 15

or R₇ is selected from the group consisting of alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclylalkyl, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-, arylalkyl-, alkoxy-, aryloxyalkyl-, heteroarylalkyl-, heteroaryloxyalkyl-, R₈O-L-, R₈S-L-, (R₈)₂N-L-,
 20 R₈-C(=O)-L-, R₈O-C(=O)-L-, (R₈)₂N-C(=O)-L-, R₈-C(=O)N(R₈)-L-, R₈O-C(=O)N(R₈)-L-, (R₈)₂N-C(=O)N(R₈)-L-, R₈-C(=O)O-L-, (R₈)₂N-C(=O)O-L-, R₈-S(=O)₂-L-, (R₈)₂N-S(=O)₂-L-, R₈-S(=O)₂N(R₈)-L- and (R₈)₂N-S(=O)₂N(R₈)-L

either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -
 25 SO₂NH₂, -SONH₂ and -CONH₂;

R₈ independently at each occurrence is selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclylalkyl-, aryl-, arylalkyl-, heteroaryl-, and heteroarylalkyl- either of which
 30 may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

or in the case where two R₈ are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally
 35 substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof.

Another embodiment of the invention provides a compound of formula I wherein

5 m is 0, 1 or 2;

n is 2 or 4;

10 R_1 is selected from the group consisting of hydrogen, halogen, cyano, $-NH_2$, $-SO_2NH_2$, $-SONH_2$, and $-CONH_2$;

or R_1 is selected from the group consisting of $(C_1-C_4)alkyl-$, heteroalkyl-, $(C_3-C_6)cycloalkyl-$, heterocyclyl-, $R_{1a}O-$, $R_{1a}S-$, $(R_{1a})_2N-$, $R_{1b}-C(=O)N(R_{1c})-$, $R_{1b}O-C(=O)N(R_{1c})-$, $R_{1b}O-C(=O)-$, $(R_{1b})_2N-C(=O)N(R_{1c})-$, $R_{1b}-S(=O)_2N(R_{1c})-$ and $(R_{1b})_2N-S(=O)_2N(R_{1c})-$ either of which may be optionally substituted with one or more R_{1d} ;

15

R_{1a} is hydrogen;

or R_{1a} independently at each occurrence is selected from the group consisting of $(C_1-C_4)alkyl-$, heteroalkyl-, $(C_3-C_6)cycloalkyl-$ and heterocyclyl- either of which may be optionally substituted with one or more R_{1e} ;

20

or in the case where two R_{1a} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more R_{1e} ;

25 R_{1b} and R_{1c} independently at each occurrence are selected from the group consisting of hydrogen, $(C_1-C_4)alkyl-$, heteroalkyl-, $(C_3-C_6)cycloalkyl-$ and heterocyclyl- either of which may be optionally substituted with one or more R_{1e} ;

or in the case where two R_{1b} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more R_{1e} ;

30

R_{1d} and R_{1e} independently at each occurrence are selected from the group consisting of halogen, cyano, hydroxy, oxo, $-NH_2$, $-SO_2NH_2$, $-CONH_2$, $(C_1-C_4)alkyl-$, heteroalkyl-, $(C_3-C_6)cycloalkyl-$, heterocyclyl-, $R_{1f}O-$, $R_{1f}S-$, $(R_{1f})_2N-$, $R_{1f}O-C(=O)-$, $(R_{1f})_2N-C(=O)-$, $R_{1f}-C(=O)N(R_{1f})-$, $R_{1f}O-C(=O)N(R_{1f})-$, $(R_{1f})_2N-C(=O)N(R_{1f})-$, $R_{1f}-C(=O)O-$, $(R_{1f})_2N-C(=O)O-$, $(R_{1f})_2N-S(=O)_2-$ and $R_{1f}-S(=O)_2N(R_{1f})-$;

35

R_{1f} independently at each occurrence is selected from the group consisting of hydrogen, (C₁-C₄)alkyl-, heteroalkyl-, (C₃-C₆)cycloalkyl- and heterocyclyl-;

or in the case where two R_{1f} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle;

R_2 is independently at each occurrence a covalent bond or (C₁-C₄)alkyl- or heteroalkyl-group, where any two R_2 s are attached to the same C ring atom, and together with this C ring atom said two R_2 s form a carbocycle or heterocycle, hence always forming a spirocyclic piperazine;

R_3 independently at each occurrence is selected from the group consisting of halogen, cyano, hydroxy, oxo, (C₁-C₄)alkyl-, heteroalkyl-, (C₃-C₆)cycloalkyl-, heterocyclyl-, $R_{3a}O-$, $R_{3a}S-$, $(R_{3a})_2N-$, $R_{3a}-C(=O)-$, $R_{3a}O-C(=O)-$, $(R_{3a})_2N-C(=O)-$, $R_{3a}-C(=O)N(R_{3b})-$, $R_{3a}O-C(=O)N(R_{3b})-$, $R_{3a}-C(=O)O-$, $(R_{3a})_2N-C(=O)O-$, $R_{3a}-S(=O)-$, $R_{3a}-S(=O)_2-$, $(R_{3a})_2N-S(=O)_2-$ and $R_{3a}-S(=O)_2N(R_{3b})-$;

R_{3a} and R_{3b} independently at each occurrence are selected from the group consisting of hydrogen, (C₁-C₄)alkyl-, heteroalkyl-, (C₃-C₆)cycloalkyl- and heterocyclyl-

or in the case where two R_{3a} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle;

R_4 and R_5 independently at each occurrence is selected from the group consisting of (C₁-C₅)alkyl-, heteroalkyl-, (C₂-C₄)alkenyl-, (C₂-C₄)alkynyl-, (C₃-C₈)cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkyl(C₁-C₄)alkyl-, heterocyclyl(C₁-C₄)alkyl, (C₁-C₄)alkyl(C₃-C₈)cycloalkyl-, (C₁-C₄)alkylheterocyclyl-, aryl-, heteroaryl-, aryl(C₁-C₄)alkyl-, aryloxy(C₁-C₄)alkyl-, heteroaryl(C₁-C₄)alkyl-, heteroaryloxy(C₁-C₄)alkyl-, R_6O-L- , R_6S-L- , $(R_6)_2N-L-$, $R_6-C(=O)-L-$, $R_6O-C(=O)-L-$, $(R_6)_2N-C(=O)-L-$, $R_6-C(=O)N(R_6)-L-$, $R_6O-C(=O)N(R_6)-L-$, $(R_6)_2N-C(=O)N(R_6)-L-$, $R_6-C(=O)O-L-$, $(R_6)_2N-C(=O)O-L-$, $R_6-S(=O)_2-L-$, $(R_6)_2N-S(=O)_2-L-$, $R_6-S(=O)_2N(R_6)-L-$ and $(R_6)_2N-S(=O)_2N(R_6)-L$ either of which may be optionally substituted with one or more R_7 ;

or R_4 and R_5 can together with the N atom to which they are attached form a heterocyclic ring which may be optionally substituted with one or more R_7 ;

or R_4 and R_5 independently can be hydrogen;

L is independently at each occurrence selected from the group consisting of (C₁-C₄)alkyl-, heteroalkyl-, (C₂-C₄)alkenyl-, (C₂-C₄)alkynyl-, (C₃-C₈)cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, (C₃-C₈)cycloalkyl(C₁-C₄)alkyl-, heterocyclylalkyl, (C₁-C₄)alkyl(C₃-C₈)cycloalkyl-, (C₁-C₄)alkylheterocyclyl-, aryl-,
 5 heteroaryl-, aryl(C₁-C₄)alkyl-, aryloxy(C₁-C₄)alkyl-, heteroaryl(C₁-C₄)alkyl- and heteroaryloxy(C₁-C₄)alkyl-;

or when R₄ or R₅ is selected from R₆O-L-, L can also be a bond;

R₆ independently at each occurrence is selected from the group consisting of hydrogen, (C₁-C₄)alkyl-, heteroalkyl-, (C₂-C₄)alkenyl-, (C₂-C₄)alkynyl-, (C₃-C₆)cycloalkyl-, heterocyclyl-, aryl-, aryl(C₁-C₄)alkyl- and heteroaryl-, (C₃-C₆)cycloalkyl(C₁-C₄)alkyl- either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂, -CONH₂ and -O(C₁-C₄);
 10

15 or in the case where two R₆ are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

20 R₇ independently at each occurrence is selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂, -CONH₂ and =CH₂, or R₇ is selected from the group consisting of (C₁-C₄)alkyl-, heteroalkyl-, (C₂-C₄)alkenyl-, (C₂-C₄)alkynyl-, (C₃-C₈)cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, (C₃-C₈)cycloalkylalkyl-, heterocyclyl(C₁-C₄)alkyl, (C₁-C₄)alkyl(C₃-C₈)cycloalkyl-, (C₁-C₄)alkylheterocyclyl-, aryl-, heteroaryl-, aryl(C₁-C₄)alkyl-, alkoxy-, aryloxy(C₁-C₄)alkyl-, heteroaryl(C₁-C₄)alkyl-, heteroaryloxy(C₁-C₄)alkyl-, R₈O-L-, R₈S-L-, (R₈)₂N-L-, R₈-C(=O)-L-, R₈O-C(=O)-L-, (R₈)₂N-C(=O)-L-, R₈-C(=O)N(R₈)-L-, R₈O-C(=O)N(R₈)-L-, (R₈)₂N-C(=O)N(R₈)-L-, R₈-C(=O)O-L-, (R₈)₂N-C(=O)O-L-, R₈-S(=O)₂-L-, (R₈)₂N-S(=O)₂-L-, R₈-S(=O)₂N(R₈)-L- and (R₈)₂N-S(=O)₂N(R₈)-L
 25

30 either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

R₈ independently at each occurrence is selected from the group consisting of hydrogen, (C₁-C₄)alkyl-, heteroalkyl-, (C₂-C₄)alkenyl-, (C₂-C₄)alkynyl-, (C₃-C₆)cycloalkyl-, heterocyclyl-, (C₃-C₆)cycloalkyl(C₁-C₄)alkyl-, heterocyclyl(C₁-C₄)alkyl-, aryl-, aryl(C₁-C₄)alkyl-, heteroaryl-, and heteroaryl(C₁-C₄)alkyl- either of which may be optionally
 35

substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

5 or in the case where two R₈ are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof;

10

with the proviso that when R₁ is hydrogen, and m is 0, and n is 2, and the two R₂'s form a cyclopropyl ring together with the carbon atom to which they are attached, and R₄ is methyl, R₅ is not selected from the group consisting of cyanoethyl or cyclohexyl;

15 and with the proviso that when R₁ is hydrogen, and m is 0, and n is 2, and the two R₂'s form a cyclopropyl ring together with the carbon atom to which they are attached, and R₅ is methyl, R₄ is not selected from the group consisting of cyanoethyl or cyclohexyl;

20 and with the proviso that when R₁ is hydrogen, and m is 0, and n is 2, and the two R₂'s form a cyclopropyl ring together with the carbon atom to which they are attached, and R₄ is ethyl, R₅ is not ethyl.

An embodiment of the invention provides a compound of formula I wherein m is 0 or 1.

25

An embodiment of the invention provides a compound of formula I wherein m is 0.

An embodiment of the invention provides a compound of formula I wherein n is 2.

30 An embodiment of the invention provides a compound of formula I wherein R₁ is selected from the group consisting of hydrogen, -NH₂, -SO₂NH₂, -SONH₂, and -CONH₂.

An embodiment of the invention provides a compound of formula I wherein R₁ is hydrogen.


35

An embodiment of the invention provides a compound of formula I wherein R₁ is selected from the group consisting (R_{1a})₂N-, R_{1b}-C(=O)N(R_{1c})-, R_{1b}O-C(=O)N(R_{1c})-,


$R_{1b}O-C(=O)-$, $(R_{1b})_2N-C(=O)N(R_{1c})-$, $R_{1b}-S(=O)_2N(R_{1c})-$ and $(R_{1b})_2N-S(=O)_2N(R_{1c})-$ either of which may be optionally substituted with one or more R_{1d} .

An embodiment of the invention provides a compound of formula I wherein R_{1a} is
5 hydrogen.

An embodiment of the invention provides a compound of formula I wherein each R_2 independently at each occurrence is selected from the group consisting of



An embodiment of the invention provides a compound of formula I wherein R_2 is



An embodiment of the invention provides a compound of formula I wherein $m = 0$ and wherein R_1 is hydrogen.

20 An embodiment of the invention provides a compound of formula I wherein R_3 independently at each occurrence is selected from the group consisting of cyano, hydroxy, oxo, alkyl-, heteroalkyl-, and $R_{3a}O-$.

An embodiment of the invention provides a compound of formula I wherein R_3 independently at each occurrence is selected from the group consisting of cyano, hydroxy, oxo, (C_1-C_4) alkyl-, heteroalkyl-, and $R_{3a}O$ -.

5

An embodiment of the invention provides a compound of formula I wherein R_4 and R_5 independently at each occurrence is selected from the group consisting of alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl-, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-, arylalkyl-, aryloxyalkyl-,
 10 heteroarylalkyl-, heteroaryloxyalkyl-, R_6O-L -, R_6S-L -, $(R_6)_2N-L$ -, $R_6O-C(=O)-L$ -, $(R_6)_2N-C(=O)-L$ -, $R_6-C(=O)N(R_6)-L$ -, $R_6O-C(=O)N(R_6)-L$ -, $(R_6)_2N-C(=O)N(R_6)-L$ -, $R_6-C(=O)O-L$ -,
 , $(R_6)_2N-C(=O)O-L$ -, $R_6-S(=O)_2-L$ -, $(R_6)_2N-S(=O)_2-L$ -, $R_6-S(=O)_2N(R_6)-L$ - and $(R_6)_2N-S(=O)_2N(R_6)-L$ either of which may be optionally substituted with one or more R_7 .

15 An embodiment of the invention provides a compound of formula I wherein R_4 and R_5 independently at each occurrence is selected from the group consisting of (C_1-C_5) alkyl-, heteroalkyl-, (C_3-C_8) cycloalkyl-, heterocyclyl-, (C_3-C_8) cycloalkyl (C_1-C_4) alkyl-, heterocyclyl (C_1-C_4) alkyl, (C_1-C_4) alkyl (C_3-C_8) cycloalkyl-, (C_1-C_4) alkylheterocyclyl-, aryl-, heteroaryl-, aryl (C_1-C_4) alkyl-, aryloxy (C_1-C_4) alkyl-, heteroaryl (C_1-C_4) alkyl-,
 20 heteroaryloxy (C_1-C_4) alkyl-, R_6O-L -, R_6S-L -, $(R_6)_2N-L$ -, $R_6O-C(=O)-L$ -, $(R_6)_2N-C(=O)-L$ -, $R_6-C(=O)N(R_6)-L$ -, $R_6O-C(=O)N(R_6)-L$ -, $(R_6)_2N-C(=O)N(R_6)-L$ -, $R_6-C(=O)O-L$ -, $(R_6)_2N-C(=O)O-L$ -, $R_6-S(=O)_2-L$ -, $(R_6)_2N-S(=O)_2-L$ -, $R_6-S(=O)_2N(R_6)-L$ - and $(R_6)_2N-S(=O)_2N(R_6)-L$ either of which may be optionally substituted with one or more R_7 .

25 An embodiment of the invention provides a compound of formula I wherein R_4 and R_5 together with the N atom to which they are attached form a heterocyclic ring which may be optionally substituted with one or more R_7 .

30 An embodiment of the invention provides a compound of formula I wherein R_4 is hydrogen.

An embodiment of the invention provides a compound of formula I wherein R_5 is hydrogen.

35 An embodiment of the invention provides a compound of formula I wherein L is independently at each occurrence selected from the group consisting of alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl-, alkylcycloalkyl-, alkylheterocyclyl-.

An embodiment of the invention provides a compound of formula I wherein L is independently at each occurrence selected from the group consisting of (C₁-C₄)alkyl-, heteroalkyl-, (C₃-C₈)cycloalkyl-, heterocyclyl-, (C₃-C₈)cycloalkyl(C₁-C₄)alkyl-,
 5 heterocyclyl(C₁-C₄)alkyl, alkyl(C₃-C₈)cycloalkyl-, (C₁-C₄)alkylheterocyclyl-, aryl(C₁-C₄)alkyl- and heteroaryl(C₁-C₄)alkyl-.

An embodiment of the invention provides a compound of formula I wherein R₄ and R₅ independently are selected from the group consisting of hydrogen, methyl, ethyl,
 10 propyl, butyl, isopropyl, isobutyl, isoamyl, pentyl, benzyl, butynyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, phenyl, phenylpropyl, phenethyl, pyridylmethyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cubanylmethyl, tetrahydrofuranylmethyl, tetrahydropyranylmethyl, morpholinylethyl,
 15 dioxothiolanylmethyl, dioxothiolanylethyl, dioxothianyl, dioxothianylmethyl, dioxothianylethyl, azetidiny, pyrrolidinylmethyl, piperidinylmethyl, pyrazolylmethyl, pyrazolylethyl, pyrrolylethyl, isoxazolylmethyl, isoxazolylethyl, imidazolylethyl, R₆O-C(=O)-L-, R₆-C(=O)N(R₆)-L-, R₆O-L-, (R₆)₂N-C(=O)-L-, (R₆)₂N-L-, (R₆)₂N-S(=O)₂-L-, R₆-S(=O)₂-L-, R₆-C(=O)-L-, either of which may be optionally substituted with one or
 20 more R₇; and wherein L is selected from the group consisting of methyl, ethyl, propyl, furanylmethyl, benzyl, azetidiny, pyrrolidinylmethyl, piperidinylmethyl;
 and wherein R₆ is independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isobutyl, tert-butyl, phenyl, benzyl, trifluoromethyl, cyclopropylmethyl, either of which R₆ may be optionally substituted with one or more
 25 substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂, -O(C₁-C₄).

An embodiment of the invention provides a compound of formula I wherein R₄ and R₅ independently are selected from the group consisting of hydrogen, methyl, propyl,
 30 butyl, isopropyl, isobutyl, isoamyl, pentyl, benzyl, butynyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, phenyl, phenylpropyl, phenethyl, pyridylmethyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cubanylmethyl, tetrahydrofuranylmethyl, tetrahydropyranylmethyl, morpholinylethyl,
 35 dioxothiolanylmethyl, dioxothiolanylethyl, dioxothianyl, dioxothianylmethyl, dioxothianylethyl, azetidiny, pyrrolidinylmethyl, piperidinylmethyl, pyrazolylmethyl, pyrazolylethyl, pyrrolylethyl, isoxazolylmethyl, isoxazolylethyl, imidazolylethyl, R₆O-C(=O)-L-, R₆-C(=O)N(R₆)-L-, R₆O-L-, (R₆)₂N-C(=O)-L-, (R₆)₂N-L-, (R₆)₂N-S(=O)₂-L-,

$R_6-S(=O)_2-L-$, $R_6-C(=O)-L-$, either of which may be optionally substituted with one or more R_7 ; and wherein L is selected from the group consisting of methyl, ethyl, propyl, furanylmethyl, benzyl, azetidiny, pyrrolidinylmethyl, piperidinylmethyl; and wherein R_6 is independently selected from the group consisting of hydrogen,
 5 methyl, ethyl, propyl, isobutyl, tert-butyl, phenyl, benzyl, trifluoromethyl, cyclopropylmethyl, either of which R_6 may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$, $-O(C_1-C_4)$.

10 An embodiment of the invention provides a compound of formula I wherein R_7 independently at each occurrence is selected from the group consisting of fluoro, chloro, cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$, $-CONH_2$, and $=CH_2$.

15 An embodiment of the invention provides a compound of formula I wherein R_7 is selected from the group consisting of alkyl-, heteroalkyl-, alkynyl-, cycloalkyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl, alkylcycloalkyl-, alkylheterocyclyl-, arylalkyl-, R_8O- , R_8S- , $(R_8)_2N-$, $R_8O-C(=O)-$, $(R_8)_2N-C(=O)-$, $R_8-C(=O)N(R_8)-$, $R_8O-C(=O)N(R_8)-$, $(R_8)_2N-C(=O)N(R_8)-$, $R_8-C(=O)O-$, $(R_8)_2N-C(=O)O-$, $R_8-S(=O)_2-$, $(R_8)_2N-S(=O)_2-$, $R_8-S(=O)_2N(R_8)-$ and $(R_8)_2N-S(=O)_2N(R_8)-$ either of which may be optionally
 20 substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$.

An embodiment of the invention provides a compound of formula I wherein R_7 is
 25 selected from the group consisting of methyl, tert-butyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxothiolanyl, dioxothianyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, pyridyl, imidazolyl, benzyl, $R_8O-C(=O)-$, R_8O- , $(R_8)_2N-C(=O)-$ and $(R_8)_2N-$, either of which may be optionally substituted with one or more substituents selected from the group
 30 consisting of fluoro, chloro, cyano, hydroxy, trifluoromethyl and oxo; and wherein R_8 is selected from the group consisting of methyl, ethyl and phenyl.

An embodiment of the invention provides a compound of formula I wherein R_7 independently at each occurrence is selected from the group consisting of halogen,
 35 cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$.

An embodiment of the invention provides a compound of formula I wherein R_7 is selected from the group consisting of alkyl-, heteroalkyl-, alkynyl-, cycloalkyl-,

heterocyclyl-, cycloalkylalkyl-, heterocyclylalkyl, alkylcycloalkyl-, alkylheterocyclyl-,
 R_8O- , R_8S- , $(R_8)_2N-$, $R_8O-C(=O)-$, $(R_8)_2N-C(=O)-$, $R_8-C(=O)N(R_8)-$, $R_8O-C(=O)N(R_8)-$,
 $(R_8)_2N-C(=O)N(R_8)-$, $R_8-C(=O)O-$, $(R_8)_2N-C(=O)O-$, $R_8-S(=O)_2-$, $(R_8)_2N-S(=O)_2-$, R_8-
 $S(=O)_2N(R_8)-$ and $(R_8)_2N-S(=O)_2N(R_8)-$ either of which may be optionally substituted
 5 with one or more substituents selected from the group consisting of halogen, cyano,
 hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$;

An embodiment of the invention provides a compound of formula I wherein R_7 is
 selected from the group consisting of $(C_1-C_4)alkyl-$, heteroalkyl-, $(C_2-C_4)alkynyl-$, $(C_3-$
 10 $C_8)cycloalkyl-$, heterocyclyl-, $(C_3-C_8)cycloalkyl(C_1-C_4)alkyl-$, heterocyclyl $(C_1-C_4)alkyl$,
 $(C_1-C_4)alkyl(C_3-C_8)cycloalkyl-$, $(C_1-C_4)alkylheterocyclyl-$, aryl $(C_1-C_4)alkyl-$, R_8O- , R_8S- ,
 $(R_8)_2N-$, $R_8O-C(=O)-$, $(R_8)_2N-C(=O)-$, $R_8-C(=O)N(R_8)-$, $R_8O-C(=O)N(R_8)-$, $(R_8)_2N-$
 $C(=O)N(R_8)-$, $R_8-C(=O)O-$, $(R_8)_2N-C(=O)O-$, $R_8-S(=O)_2-$, $(R_8)_2N-S(=O)_2-$, R_8-
 $S(=O)_2N(R_8)-$ and $(R_8)_2N-S(=O)_2N(R_8)-$ either of which may be optionally substituted
 15 with one or more substituents selected from the group consisting of halogen, cyano,
 hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$.

An embodiment of the invention provides a compound of formula I wherein R_8
 independently at each occurrence is selected from the group consisting of hydrogen,
 20 alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, cyclolalkylalkyl-, heterocyclylalkyl-, aryl-,
 arylalkyl-, heteroaryl-, and heteroarylalkyl- either of which may be optionally
 substituted with one or more substituents selected from the group consisting of
 halogen, cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$.

25 An embodiment of the invention provides a compound of formula I wherein R_8
 independently at each occurrence is selected from the group consisting of hydrogen,
 $(C_1-C_4)alkyl-$, heteroalkyl-, $(C_3-C_6)cycloalkyl-$, heterocyclyl-, $(C_3-C_6)cyclolalkyl(C_1-$
 $C_4)alkyl-$, heterocyclyl $(C_1-C_4)alkyl-$, aryl-, aryl $(C_1-C_4)alkyl-$, heteroaryl-, and
 heteroaryl $(C_1-C_4)alkyl-$ either of which may be optionally substituted with one or more
 30 substituents selected from the group consisting of halogen, cyano, hydroxy,
 trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$.

An embodiment of the invention provides a compound of formula wherein one of R_4
 and R_5 is selected from the group consisting of $(C_1-C_2)alkyl-$, heteroalkyl-, $(C_2-$
 35 $C_4)alkenyl-$, $(C_2-C_4)alkynyl-$, $(C_3-C_8)cycloalkyl-$, cycloalkenyl-, cycloalkynyl-,
 heterocyclyl-, cycloalkyl $(C_1-C_4)alkyl-$, heterocyclyl $(C_1-C_4)alkyl$, $(C_1-C_4)alkyl(C_3-$
 $C_8)cycloalkyl-$, $(C_1-C_4)alkylheterocyclyl-$, aryl-, heteroaryl-, aryl $(C_1-C_4)alkyl-$,
 aryloxy $(C_1-C_4)alkyl-$, heteroaryl $(C_1-C_4)alkyl-$, heteroaryloxy $(C_1-C_4)alkyl-$, R_6O-L- , R_6S-L-

, $(R_6)_2N-L-$, $R_6-C(=O)-L-$, $R_6O-C(=O)-L-$, $(R_6)_2N-C(=O)-L-$, $R_6-C(=O)N(R_6)-L-$, $R_6O-C(=O)N(R_6)-L-$, $(R_6)_2N-C(=O)N(R_6)-L-$, $R_6-C(=O)O-L-$, $(R_6)_2N-C(=O)O-L-$, $R_6-S(=O)_2-L-$, $(R_6)_2N-S(=O)_2-L-$, $R_6-S(=O)_2N(R_6)-L-$ and $(R_6)_2N-S(=O)_2N(R_6)-L$ either of which may be optionally substituted with one or more R_7 ;

5 and wherein the other R_4 or R_5 is selected from the group consisting of (C_3-C_5) alkyl-, heteroalkyl-, (C_2-C_4) alkenyl-, (C_2-C_4) alkynyl-, (C_3-C_5) cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkyl(C_1-C_4)alkyl-, heterocyclyl(C_1-C_4)alkyl, (C_1-C_4) alkyl(C_3-C_8)cycloalkyl-, (C_1-C_4) alkylheterocyclyl-, aryl-, heteroaryl-, aryl(C_1-C_4)alkyl-, aryloxy(C_1-C_4)alkyl-, heteroaryl(C_1-C_4)alkyl-, heteroaryloxy(C_1-C_4)alkyl-, R_6O-L- , R_6S-
 10 $L-$, $(R_6)_2N-L-$, $R_6-C(=O)-L-$, $R_6O-C(=O)-L-$, $(R_6)_2N-C(=O)-L-$, $R_6-C(=O)N(R_6)-L-$, $R_6O-C(=O)N(R_6)-L-$, $(R_6)_2N-C(=O)N(R_6)-L-$, $R_6-C(=O)O-L-$, $(R_6)_2N-C(=O)O-L-$, $R_6-S(=O)_2-L-$, $(R_6)_2N-S(=O)_2-L-$, $R_6-S(=O)_2N(R_6)-L-$ and $(R_6)_2N-S(=O)_2N(R_6)-L$ either of which may be optionally substituted with one or more R_7 ;

15

or R_4 and R_5 can together with the N atom to which they are attached form a heterocyclic ring which may be optionally substituted with one or more R_7 ;

or R_4 and R_5 independently can be hydrogen;

20

An embodiment of the invention provides a compound of formula wherein at least one of R_4 and R_5 is selected from the group consisting of heteroalkyl-, heterocyclyl(C_1-C_4)alkyl, aryl(C_1-C_4)alkyl-, and heteroaryl(C_1-C_4)alkyl-, wherein said heteroalkyl-, heterocyclyl(C_1-C_4)alkyl, aryl(C_1-C_4)alkyl- and heteroaryl(C_1-C_4)alkyl- is substituted
 25 with one or more R_7 ;

An embodiment of the invention provides a compound of formula I wherein at least one of R_4 and R_5 is benzyl which is substituted with one or more R_7 .

30

An embodiment of the invention provides a compound of formula I wherein at least one of R_4 and R_5 is selected from the group consisting of R_6O-L- , R_6S-L- , $(R_6)_2N-L-$, $R_6-C(=O)-L-$, $R_6O-C(=O)-L-$, $(R_6)_2N-C(=O)-L-$, $R_6-C(=O)N(R_6)-L-$, $R_6O-C(=O)N(R_6)-L-$, $(R_6)_2N-C(=O)N(R_6)-L-$, $R_6-C(=O)O-L-$, $(R_6)_2N-C(=O)O-L-$, $R_6-S(=O)_2-L-$, $(R_6)_2N-S(=O)_2-L-$, $R_6-S(=O)_2N(R_6)-L-$ and $(R_6)_2N-S(=O)_2N(R_6)-L-$, either of which may be optionally
 35 substituted with one or more R_7 ; wherein L independently at each occurrence is selected from the group consisting of heterocyclyl-, heterocyclyl(C_1-C_4)alkyl, (C_1-C_4) alkylheterocyclyl-, aryl(C_1-C_4)alkyl- and heteroaryl(C_1-C_4)alkyl-.

An embodiment of the invention provides a compound of formula I wherein one of R₄ and R₅ is selected from the group consisting of dioxothiolanylmethyl, dioxothiolanylethyl, dioxothianylmethyl and dioxothianylethyl.

- 5 An embodiment of the invention provides a compound of formula I wherein one of R₄ and R₅ is dioxothiolanylmethyl.

An embodiment of the invention provides a compound of formula I wherein one of R₄ and R₅ is dioxothianylmethyl.

10

An embodiment of the invention provides a compound of formula I wherein at least one of R₄ and R₅ is selected from R₆-C(=O)-L-, R₆-S(=O)₂-L- or (R₆)₂N-S(=O)₂-L-, which may be optionally substituted with one or more R₇; wherein L is selected from the group consisting of heterocyclyl-, heterocyclyl(C₁-C₄)alkyl, (C₁-C₄)alkylheterocyclyl-,
15 aryl(C₁-C₄)alkyl- and heteroaryl(C₁-C₄)alkyl-.

An embodiment of the invention provides a compound of formula I wherein at least one of R₄ and R₅ is selected from R₆-C(=O)-L-, R₆-S(=O)₂-L- or (R₆)₂N-S(=O)₂-L-, which may be optionally substituted with one or more R₇; wherein L is selected from the
20 group consisting of piperidinylmethyl, pyrrolidinylmethyl, benzyl and azetidyl; and wherein R₆ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, cyclopropylmethyl, hydroxymethyl, hydroxyethyl, cyanoethyl, cyanopropyl.

An embodiment of the invention provides a compound of formula I wherein R₆-C(=O)-L-, R₆-S(=O)₂-L- or (R₆)₂N-S(=O)₂-L- is substituted by at least two fluoro; and wherein L is selected from the group consisting of piperidinylmethyl, pyrrolidinylmethyl, benzyl and azetidyl; and wherein R₆ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, cyclopropylmethyl, hydroxymethyl, hydroxyethyl, cyanoethyl, cyanopropyl.
25

30

An embodiment of the invention provides a compound of formula I wherein one of R₄ and R₅ is selected from the group consisting of heterocyclyl(C₁-C₄)alkyl and (C₃-C₆)cycloalkyl(C₁-C₄)alkyl and wherein said heterocyclyl(C₁-C₄)alkyl and (C₃-C₆)cycloalkyl(C₁-C₄)alkyl is substituted with two or more R₇; wherein at least two R₇ are
35 fluoro.

An embodiment of the invention provides a compound of formula I wherein one of R₄ and R₅ is selected from the group consisting of cyclopropylmethyl, cyclobutylmethyl,

cyclohexylmethyl and pyrrolidinylmethyl and wherein said cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl and pyrrolidinylmethyl is substituted with two or more R₇; wherein at least two R₇ are fluoro.

- 5 An embodiment of the invention provides a compound of formula I wherein R₄ is methyl.

An embodiment of the invention provides a compound of formula I wherein R₅ is methyl.

10

An embodiment of the invention provides a compound of formula I which is selected from

- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid amide,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 15 methylamide,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 phenethyl-amide,
 4-[4-(Imidazole-1-sulfonyl)-4,7-diaza-spiro[2.5]oct-7-yl]-7H-pyrrolo[2,3-d]pyrimidine ,
 N-methyl-N-(pyrrolidin-3-ylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
 20 diazaspiro[2.5]octane-8-sulfonamide,
 N-methyl-N-(4-piperidylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
 diazaspiro[2.5]octane-8-sulfonamide as formoc acid salt,
 N-methyl-N-(3-piperidylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
 diazaspiro[2.5]octane-8-sulfonamide as formic acid salt,
 25 N-[(2S)-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-
 4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formic acid salt,
 N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-
 sulfonamide,
 N-[(1,1-dioxothiolan-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
 30 diazaspiro[2.5]octane-8-sulfonamide,
 N-[(1,1-dioxothian-4-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
 diazaspiro[2.5]octane-8-sulfonamide,
 N-(2-cyanoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-
 sulfonamide,
 35 N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-
 sulfonamide,
 N-benzyloxy-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-
 sulfonamide,

- (NZ)-N-[(4-methoxyphenyl)methylene]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
 N-(azetidin-3-yl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
 5 N-methyl-N-[[[(2R)-pyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
 N-methyl-N-[[[(2S)-pyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formic acid salt,
 tert-butyl N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]carbamate,
 10 4-{4-[Phenethyl-(3-phenyl-propyl)-sulfamoyl]-4,7-diaza-spiro[2.5]oct-7-yl}-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid cyclopropylmethyl-phenethyl-amide ,
 15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid cyclobutylmethyl-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-oxo-butyl)-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-hydroxy-propyl)-phenethyl-amide ,
 20 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid isobutyl-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-propyl-amide ,
 25 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid cyclohexylmethyl-phenethyl-amide,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid diphenethylamide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid cyanomethyl-phenethyl-amide ,
 30 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (4-cyano-butyl)-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-(tetrahydro-pyran-2-ylmethyl)-amide ,
 35 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-methoxy-ethyl)-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid but-2-ynyl-phenethyl-amide ,

- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
phenethyl-(2-pyrazol-1-yl-ethyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-
hydroxy-ethyl)-phenethyl-amide ,
- 5 {Phenethyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-
sulfonyl]-amino}-acetic acid ethyl ester ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(4-
fluoro-phenyl)-ethyl]-phenethyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3-
10 fluoro-phenyl)-ethyl]-phenethyl-amide ,
- N-Benzyl-2-{phenethyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-
spiro[2.5]octane-4-sulfonyl]-amino}-acetamide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-
(3-phenyl-propyl)-amide ,
- 15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-
cyclohexyl-ethyl)-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-
(2-oxo-2-phenyl-ethyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-
20 cyano-benzyl)-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-
cyano-benzyl)-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
cyclohexylmethyl-methyl-amide,
- 25 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(4-
fluoro-phenyl)-ethyl]-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3-
fluoro-phenyl)-ethyl]-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-
30 (2-pyrrol-1-yl-ethyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-
(3-methyl-butyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-
pyridin-2-ylmethyl-amide ,
- 35 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [3-(4-
cyano-phenyl)-propyl]-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [3-(3-
cyano-phenyl)-propyl]-methyl-amide ,

- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(2-phenoxy-ethyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3,5-dimethyl-isoxazol-4-yl)-ethyl]-methyl-amide ,
- 5 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-phenethyl-amide ,
- {Methyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetic acid methyl ester ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-
- 10 cyano-propyl)-methyl-amide ,
- N,N-Dimethyl-2-{methyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetamide,
- N-(cyclopropylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 15 N-(cyclobutylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-cyclopentyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[(4,4-difluorocyclohexyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
- 20 diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-(2-phenylpropyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydropyran-2-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 25 N-[[5-(dimethylsulfamoyl)-2-furyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-(2-pyrazol-1-ylethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-[(3-methylisoxazol-5-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
- 30 diazaspiro[2.5]octane-8-sulfonamide,
- N-(isoxazol-5-ylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[2-(4-chlorophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 35 N-[2-(2-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[2-(3-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N-[2-(4-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(cyclopentylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
5 N-(2-cyclopentylethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[2-(1,1-dioxothiolan-3-yl)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(1,1-dioxothian-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
10 diazaspiro[2.5]octane-8-sulfonamide,
N-[(2-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(3-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
15 N-[(4-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[[4-(trifluoromethyl)phenyl]methyl]-
20 5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(2-cyclopropylethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[(4-methylsulfonylphenyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
25 N-[(4-tert-butylcyclohexyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(3,3-difluorocyclobutyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(2,2-difluorocyclopropyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
30 diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[(4-methylenecyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[(3-oxocyclobutyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
35 N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydropyran-4-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[(3-sulfamoylphenyl)methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[(4-sulfamoylphenyl)methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[1-(difluoromethyl)-3H-pyrazol-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 5 N-[[1-(2,2-difluoroethyl)-3H-pyrazol-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (4-cyano-benzyl)-methyl-amide ,
- 4-[4-(Piperidine-1-sulfonyl)-4,7-diaza-spiro[2.5]oct-7-yl]-7H-pyrrolo[2,3-d]pyrimidine,
- 10 1-[7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-piperidine-4-carbonitrile,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-phenyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-cyano-ethyl)-cyclopropyl-amide ,
- 15 1-[7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-piperidine-3-carbonitrile ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amide,
- 20 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid benzyl-methyl-amide,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid dimethylamide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid isopropylamide ,
- 25 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-(3-phenyl-propyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-hydroxy-ethyl)-amide ,
- 30 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid bis-(2-hydroxy-ethyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-amide,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid bis-(3-cyano-propyl)-amide,
- 35 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-(3-phenyl-propyl)-amide,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-phenethyl-amide,

N-isopropyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

5 N-ethyl-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-(cyanomethyl)-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

10 N-(2-hydroxyethyl)-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-ethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

15 N-(cyanomethyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

20 N-(3-cyanopropyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-(2-methoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-(2-imidazol-1-ylethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

25 N-cyclobutyl-N-[3-(dimethylamino)propyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-(2-morpholinoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

30 N-(1-cyanoethyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-(cyanomethyl)-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-(2-hydroxyethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

35 N-(3-cyanopropyl)-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-(2-hydroxyethyl)-N-(2-phenoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N-methyl-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(cyanomethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
5 N-(3-cyanopropyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(oxetan-3-yl)-N-(2-phenoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(2-hydroxyethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
10 N-(1-cyanoethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[(1-propylsulfonylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
15 N-methyl-N-[(1-methylsulfonylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[1-(2-methoxyethylsulfonyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[1-(3-cyanopropylsulfonyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
20 N-[[1-(cyclopropylmethylsulfonyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[1-(3-hydroxypropanoyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
25 N-[[1-(3-hydroxybutanoyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[(1-propanoylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[1-(3-cyanopropanoyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
30 N-[[1-(2,3-dihydroxypropanoyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(1-formylpyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
35 3,3,3-trifluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]propanamide,
4,4-difluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]cyclohexanecarboxamide,

- 4,4,4-trifluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]butanamide,
N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiolane-3-carboxamide,
5 2-(1,1-dioxothian-4-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
3-(1,1-dioxothiolo-3-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]propanamide,
2-(1,1-dioxothiolo-3-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
10 N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiane-4-carboxamide,
N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiane-3-carboxamide,
15 N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]cyclopentanecarboxamide,
2-cyclopentyl-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
3-cyclopentyl-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]propanamide,
20 N-cyclopropyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(2-cyanoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydrofuran-2-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
25 N-(1-methylbutyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-cyclopentyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N,N-bis(cyanomethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
30 N,N-dibenzyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-benzyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
35 N-[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(4,4-difluorocyclohexyl)methyl]-N-ethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N,N-bis[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[1-(3-hydroxypropanoyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 5 N-[[1-(3-cyanopropanoyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[1-(3-cyanopropanoyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[1-(3-hydroxypropanoyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 10 N-[[[(2S)-4,4-difluoro-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[[(2S)-1-(3-cyanopropanoyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 15 N-[[[(2S)-4,4-difluoro-1-formyl-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-[(1-methylsulfonyl-4-piperidyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[1-(3-cyanopropylsulfonyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 20 N-methyl-N-[(1-methylsulfonyl-3-piperidyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[1-(3-cyanopropylsulfonyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 25 N-[[[(2S)-4,4-difluoro-1-methylsulfonyl-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[[(2S)-1-(3-cyanopropylsulfonyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[[(2S)-1-(cyclopropylmethylsulfonyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 30 N-[(1,1-dioxothiolan-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-(cyanomethyl)-N-[(1,1-dioxothiolan-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 35 N-[(1,1-dioxothiolan-3-yl)methyl]-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[(1,1-dioxothian-4-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N-(cyanomethyl)-N-[(1,1-dioxothian-4-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[(1,1-dioxothian-4-yl)methyl]-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 5 N-(2-cyanoethyl)-N-(cyanomethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[(1,1-dioxothiolo-3-yl)methyl]-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
- N-[(1,1-dioxothian-4-yl)methyl]-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
- 10 diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
- N-benzyloxy-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[(2S)-1-benzylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 15 N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]formamide,
- N-[(4-cyanocuban-1-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[1-(2-hydroxyacetyl)azetidin-3-yl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-
- 20 5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[1-(3-hydroxypropanoyl)azetidin-3-yl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-(1-methylsulfonylazetidin-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 25 N-methyl-N-[(2R)-1-methylsulfonylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[(2R)-1-(3-cyanopropylsulfonyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-[(2S)-5-oxopyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-
- 30 5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-[(2R)-5-oxopyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[(2R)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 35 N-[(2R)-1-(2,3-dihydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[(2R)-1-(3-cyanopropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2R)-1-formylpyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2R)-1-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

5 N-[[[(2R)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2S)-1-formylpyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

10 N-[[[(2S)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2S)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-methyl-N-[[[(2S)-1-methylsulfonylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

15 N-[(4-methoxyphenyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide or

tert-butyl N-(3-methylsulfonylpropyl)-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]carbamate

20

An embodiment of the invention provides a compound of formula I, wherein the compound is 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid cyanomethyl-phenethyl-amide.

25 An embodiment of the invention provides a compound of formula I, wherein the compound is 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-phenethyl-amide.

30 An embodiment of the invention provides a compound of formula I, wherein the compound is N-(cyanomethyl)-N-phenethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

35 An embodiment of the invention provides a compound of formula I, wherein the compound is N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[(4-sulfamoylphenyl)methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[(4,4-difluorocyclohexyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]

pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-1-(cyclopropylmethylsulfonyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-methyl-N-phenethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is 4,4-difluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]cyclohexanecarboxamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide;formic acid.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-4,4-difluoro-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[(1,1-dioxothiolan-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-methyl-N-(1-methylsulfonylazetidin-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-methyl-N-[[[(2R)-1-methylsulfonylpyrrolidin-2-yl]methyl]-5-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-methyl-N-[[[(2R)-5-oxopyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

5

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-4,4-difluoro-1-methylsulfonyl-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

10 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[(1,1-dioxothian-4-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

15 An embodiment of the invention provides a compound of formula I, wherein the compound is N-(2-hydroxyethyl)-N-phenethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

20 An embodiment of the invention provides a compound of formula I, wherein the compound is N-(cyclobutylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

25 An embodiment of the invention provides a compound of formula I, wherein the compound is N-methyl-N-[[[(2S)-5-oxopyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

30 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2R)-1-(3-cyanopropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

35 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-1-(3-cyanopropylsulfonyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

40 An embodiment of the invention provides a compound of formula I, wherein the compound is N-(cyanomethyl)-N-[(1,1-dioxothiolan-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[2-(4-fluorophenyl)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

- 5 An embodiment of the invention provides a compound of formula I, wherein the compound is N-(cyclopentylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

- 10 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2R)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

- 15 An embodiment of the invention provides a compound of formula I, wherein the compound is N-methyl-N-[[[(2S)-1-methylsulfonylpyrrolidin-2-yl]methyl]-5-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

- 20 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2R)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

- 25 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-4,4-difluoro-1-formyl-pyrrolidin-2-yl]methyl]-N-methyl-5-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

- 30 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2R)-1-formylpyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

- 35 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2R)-1-(2,3-dihydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

- 40 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-1-formylpyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[[[(2S)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-

(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-(cyanomethyl)-N-[(1,1-dioxothian-4-yl)methyl]-5-(7H-pyrrolo[2,3-d]
5 pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[(3,3-difluorocyclobutyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]
pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

10

An embodiment of the invention provides a compound of formula I, wherein the compound is N-[(4-cyanocuban-1-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]
pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

15 An embodiment of the invention provides a compound of formula I, wherein the compound is N-[(2R)-1-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7Hpyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-Sulfonamide.

An embodiment of the invention provides a compound of formula I, wherein the
20 compound is N-[(2S)-1-(3-cyanopropanoyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-Nmethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide.

The compounds of formula I may be obtained in crystalline form either directly by concentration from an organic solvent or by crystallisation or recrystallisation from an
25 organic solvent or mixture of said solvent and a cosolvent that may be organic or inorganic, such as water. The crystals may be isolated in essentially solvent-free form or as a solvate, such as a hydrate. The invention covers all crystalline modifications and forms and also mixtures thereof.

30 Compounds of formula I may comprise asymmetrically substituted (chiral) carbon atoms and carbon-carbon double bonds which may give rise to the existence of isomeric forms, e.g. enantiomers, diastereomers and geometric isomers. The present invention relates to all such isomers, either in pure form or as mixtures thereof. The invention also relates to all possible tautomers of the compounds of formula I.

35

An embodiment of the invention a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt, hydrate, or solvate thereof together with a pharmaceutically acceptable vehicle or excipient.

An embodiment of the invention a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt, hydrate, or solvate thereof together with a pharmaceutically acceptable vehicle or excipient, and further comprising another
5 therapeutically active compound.

In an embodiment of the invention the compounds of formula I according to the invention may be used in therapy.

10 In an embodiment of the invention the compounds of formula I according to the invention may be useful in therapy, such as for the use in the treatment of dermal diseases or conditions or acute or chronic cutaneous wound disorders.

In an embodiment of the invention the dermal disease or condition is selected from the
15 group consisting of proliferative and inflammatory skin disorders, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis, and eczema.

20 In an embodiment of the invention the compounds of formula I according to the invention may be used in the prophylaxis, treatment and/or amelioration of diseases of the immune system, in particular autoimmune diseases.

In an embodiment of the invention the compounds of formula I according to the
25 invention may be used in the prophylaxis, treatment and/or amelioration of diseases, such as psoriasis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes and complications from diabetes, asthma, atopic dermatitis, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well
30 as other autoimmune diseases.

In an embodiment of the invention the compounds of formula I according to the invention may be used for the manufacture of a medicament for the prophylaxis, treatment and/or amelioration of diseases of the immune system, such as autoimmune
35 diseases.

In an embodiment of the invention the compounds of formula I according to the invention may be used for the manufacture of a medicament for the prophylaxis,

treatment and/or amelioration of skin diseases, such as psoriasis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes and complications from diabetes, asthma, atopic dermatitis, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic
5 retinopathy and macular degeneration as well as other autoimmune diseases.

In an embodiment of the invention the compounds of formula I according to the invention may be used for the manufacture of a medicament for the prophylaxis, treatment and/or amelioration of diseases of the immune system, such as autoimmune
10 diseases wherein the medicament further comprises another therapeutically active compound.

In an embodiment of the invention the compounds of formula I according to the invention may be used for the manufacture of a medicament for the prophylaxis, treatment and/or amelioration of skin diseases, such as psoriasis, rosacea, lupus,
15 multiple sclerosis, rheumatoid arthritis, Type I diabetes and complications from diabetes, asthma, atopic dermatitis, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases wherein
20 the medicament further comprises another therapeutically active compound.

In an embodiment of the invention the compounds of formula I according to the invention may be used as an anti-inflammatory agent capable of modulating the activity of a protein tyrosin kinase of the JAK family of protein tyrosine kinases.
25

In an embodiment of the invention the compounds of formula I according to the invention may be used as an anti-inflammatory agent capable of modulating the activity of JAK1, JAK2, JAK3 or TYK2 protein tyrosine kinases.

30 In an embodiment of the invention the compounds of formula I according to the invention may be used in the treatment, amelioration or prophylaxis of non-infectious anti-inflammatory or autoimmune diseases or conditions wherein the non-infectious inflammatory diseases or conditions are selected from the group consisting of acute inflammatory diseases such as acute lung injury, acute respiratory distress syndrome,
35 allergy, anaphylaxis, sepsis or graft-versus-host disease, or chronic inflammatory diseases such as osteoarthritis, gout, psoriatic arthritis, hepatic cirrhosis, multiple sclerosis, or ocular diseases or conditions such as non-infectious (e.g. allergic) conjunctivitis, uveitis, iritis, keratitis, scleritis, episcleritis, sympathetic ophthalmitis,

blepharitis, keratoconjunctivitis sicca, or immunological cornea graft rejection, and the autoimmune diseases or conditions are selected from the group consisting of autoimmune gastritis, Addison's disease, autoimmune hemolytic anemia, autoimmune thyroiditis, chronic idiopathic urticaria, chronic immune polyneuropathy, diabetes, diabetic nephropathy, myasthenia gravis, pemphigus vulgaris, pernicious anemia, primary biliary cirrhosis, systemic lupus erythematosus and thyroid eye disease.

An embodiment of the invention provides a method of preventing, treating or ameliorating diseases of the immune system, such as autoimmune diseases, the method comprising administering to a patient in need thereof an effective amount of a compound of formula I.

An embodiment of the invention provides a method of preventing, treating or ameliorating skin diseases, such as psoriasis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes and complications from diabetes, asthma, atopic dermatitis, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases, the method comprising administering to a patient in need thereof an effective amount of a compound of formula I.

Besides being useful for human treatment, the compounds of the present invention may also be useful for veterinary treatment of animals including mammals such as horses, cattle, sheep, pigs, dogs, and cats.

For use in therapy, compounds of the present invention are typically in the form of a pharmaceutical composition or pharmaceutical formulation. The invention therefore relates to a pharmaceutical composition comprising a compound of formula I, optionally together with one or more other therapeutically active compounds, such as differentiating agents such as vitamin D derivatives and all-trans retinoid acid; corticosteroids, such as dexamethasone and prednisone, chemotherapeutic agents, anticancer agents, cytotoxic agents, together with a pharmaceutically acceptable excipient or vehicle. The excipient must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

If the treatment involves administration of another therapeutically active compound it is recommended to consult *Goodman & Gilman's The Pharmacological Basis of*

Therapeutics, 9th Ed., J.G. Hardman and L.E. Limbird (Eds.), McGraw-Hill 1995, for useful dosages of said compounds.

Conveniently, the active ingredient comprises from 0.1-99.9% by weight of the composition.

By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers. In the form of a dosage unit, the compound may be administered one or more times a day at appropriate intervals, always depending, however, on the condition of the patient, and in accordance with the prescription made by the medical practitioner. It is also envisaged that in certain treatment regimes, administration with longer intervals e.g. every other day, every week, or even with longer intervals may be beneficial.

Conveniently, dosage unit of a formulation contains between 0.01 mg and 1000 mg, preferably between 1 mg and 500 mg, such as between 5 mg and 100 mg of a compound of formula I.

The formulations include e.g. those in a form suitable for ophthalmic (including sustained or time-released), oral (including sustained or timed release), rectal, parenteral (including subcutaneous, intraperitoneal, intramuscular, intraarticular and intravenous), transdermal, topical, nasal or buccal administration.

The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy, e.g. as disclosed in Remington, The Science and Practice of Pharmacy, 20th ed., 2000. All methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

Formulations suitable for ophthalmic administration may be in the form of a sterile aqueous preparation of the active ingredients, which may be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formula-

tions or biodegradable polymer systems e.g. as disclosed in Encyclopedia of Pharmaceutical Technology, vol.2, 1989, may also be used to present the active ingredient for ophthalmic administration.

5 Formulations suitable for topical or ophthalmic administration include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops, intravitreal injection and time-released drug systems.

10 For topical administration, the compound of formula I may typically be present in an amount of from 0.01 to 20% by weight of the composition, such as 0.1% to about 10 %, but may also be present in an amount of up to about 50% of the composition.

Formulations of the present invention suitable for oral administration may be in the
15 form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid, such as ethanol or glycerol; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. Such oils may be edible oils, such as e.g. cottonseed oil, sesame oil, coconut
20 oil or peanut oil. Suitable dispersing or suspending agents for aqueous suspensions include synthetic or natural gums such as tragacanth, alginate, acacia, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carbomers and polyvinylpyrrolidone. The active ingredients may also be administered in the form of a bolus, electuary or paste.

25

A tablet may be made by compressing or moulding the active ingredient optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient(s) in a free-flowing form such as a powder or granules, optionally mixed by a binder, such as e.g. lactose, glucose,
30 starch, gelatine, acacia gum, tragacanth gum, sodium alginate, carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, polyethylene glycol, waxes or the like; a lubricant such as e.g. sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride or the like; a disintegrating agent such as e.g. starch, methylcellulose, agar, bentonite, croscarmellose sodium, sodium starch glycollate, crospovidone or the like or a dispersing agent, such as polysorbate 80.
35 Moulded tablets may be made by moulding, in a suitable machine, a mixture of the powdered active ingredient and suitable carrier moistened with an inert liquid diluent.

Formulations for rectal administration may be in the form of suppositories in which the compound of the present invention is admixed with low melting water soluble or insoluble solids such as cocoa butter, hydrogenated vegetable oils, polyethylene glycol or fatty acids esters of polyethylene glycols, while elixirs may be prepared using
5 myristyl palmitate.

Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredients, which is preferably isotonic with the blood of the recipient, e.g. isotonic saline, isotonic glucose solution or buffer solution.
10 The formulation may be conveniently sterilised by for instance filtration through a bacteria retaining filter, addition of sterilising agent to the formulation, irradiation of the formulation or heating of the formulation. Liposomal formulations as disclosed in e.g. Encyclopedia of Pharmaceutical Technology, vol.9, 1994, are also suitable for parenteral administration.

15 Alternatively, the compound of formula I may be presented as a sterile, solid preparation, e.g. a freeze-dried powder, which is readily dissolved in a sterile solvent immediately prior to use.

20 Transdermal formulations may be in the form of a plaster or a patch.

Formulations suitable for nasal or buccal administration include powder, self-propelling and spray formulations, such as aerosols and atomisers. Such formulations are disclosed in greater detail in e.g. Modern Pharmaceutics, 2nd ed., G.S. Banker and C.T. Rhodes (Eds.), page 427-432, Marcel Dekker, New York; Modern Pharmaceutics, 3th
25 ed., G.S. Banker and C.T. Rhodes (Eds.), page 618-619 and 718-721, Marcel Dekker, New York and Encyclopedia of Pharmaceutical Technology vol. 10, J Swarbrick and J.C. Boylan (Eds), page 191-221, Marcel Dekker, New York.

30 In addition to the aforementioned ingredients, the formulations of a compound of formula I may include one or more additional ingredients such as diluents, buffers, flavouring agents, colourant, surface active agents, thickeners, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.

35 When the active ingredient is administered in the form of salts with pharmaceutically acceptable non-toxic acids or bases, preferred salts are for instance easily water-soluble or slightly soluble in water, in order to obtain a particular and appropriate rate of absorption.

EXAMPLES

METHODS OF PREPARATION

5 The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of synthesis. The compounds of formula I may for example be prepared using the reactions and techniques outlined below together with methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are carried out in solvents appropriate to the reagents and materials employed and suitable for the transformations being effected. Also, in the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment and work-up procedures, are chosen to be conditions of standard for that reaction, which should be readily recognized by one skilled in the art of organic synthesis. Not all compounds falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternative methods can be used.

Starting materials are either known or commercially available compounds or can be prepared by routine synthetic methods well known to a person skilled in the art.

25 GENERAL PROCEDURES, PREPARATIONS AND EXAMPLES

¹H nuclear magnetic resonance (NMR) spectra were recorded at 300 MHz or 600 MHz. Chemical shift values (δ , in ppm) are quoted in the specified solvent relative to internal tetramethylsilane ($\delta = 0.00$) or chloroform ($\delta = 7.25$) standards. DMSO-d₆ is simply referred to as DMSO in the lists containing the NMR data. The value of a multiplet, either defined (doublet (d), double doublet (dd), triplet (t), quartet (q)) or not (m) at the approximate mid point is given unless a range is quoted. (br) indicates a broad peak. The organic solvents used were usually anhydrous. Chromatography was performed on Merck silica gel 60 (0.040 - 0.063 mm). The solvent ratios indicated refer to v:v unless otherwise noted.

35

The following abbreviations have been used throughout:

BOC	tert-butoxycarbonyl
DCM	dichloromethane

	DMF	N,N'-Dimethylformamide
	DMSO	dimethyl sulfoxide
	Et	ethyl
	EtOAc	ethylacetate
5	EtOH	ethanole
	L	litre
	LG	leaving group
	m	milli
	Me	methyl
10	NMR	nuclear magnetic resonance
	Ms	mesylate
	PG	protecting group
	Ph	phenyl
	Pybrop	bromotripyrrolidinophosphonium hexafluorophosphate
15	THF	tetrahydrofuran
	v	volume

Preparative HPLC/MS

Preparative HPLC/MS was performed on a Dionex APS-system with two Shimadzu
 20 PP150 prep. pumps and a Thermo MSQ Plus mass spectrometer. Column: Waters
 XTerra C-18, 150 mm x 19 mm, 5 μ m; solvents system: A = water (0.1 % formic acid)
 and B = acetonitrile (0.1 % formic acid); flow rate = 18 mL/min; method (10 min):
 Linear gradient method going from 10 % B to 100 % B in 6 minutes and staying at 100
 % B for another 2 minutes. The fractions were collected based on ion traces of relevant
 25 ions and PDA signal (240-400 nm).

Analytical HPLC/MS

Analytical HPLC/MS was performed on a system consisting of a Waters Acquity UPLC,
 Waters Micromass LCT Premier XE mass spectrometer, Waters Acquity PDA. Column:
 30 Acquity UPLC HSS T3 1.8 μ m; 2.1 x 50mm; solvents system: A = 10mM Ammonium
 acetate + 0.1% HCOOH and B = CH₃CN + 0.1% HCOOH; flow rate = 0.7 mL/min;
 method (4.8 min): Linear gradient method going from 1 % B to 95 % B in 2.6 minutes
 and staying at 95 % B for 1.2 minute.

General procedure of preparation:


The compounds of the invention can for example be prepared by the general methods
 outlined in Schemes 1a and 1b, wherein R₁, R₂, R₃, R₄, R₅, m and n are defined as
 described herein.

PG represents a suitable protecting group ("Protective Groups in Organic Synthesis", 3rd ed., Greene T.W. and Wuts P.G.M., John Wiley & Sons Inc.), such as, but not restricted to BOC, SEM and Ts.

5

LG represents a suitable leaving group, such as, but not restricted to: fluorine, chlorine, bromide, iodide, methoxy, N-imidazolyl-, -OMs or -OTs.

Scheme 1a



Compounds of general formula II can be reacted with sulfamide or a substituted sulfamide to give compounds of general formula I, IIIa and IV. Such substitutions with

5 sulfamide and sulfamide derivatives are known in the literature (Synthesis, 1983, 192-194; Organic preparations and procedures international, 1984, 16, 49-77).

Compounds of general formula IIIa and IV can optionally be protected with a suitable protecting group, such as the BOC group, to give compounds of general formula IIIb and V, respectively.


- 5 Compounds of general formula IIIa and IIIb can be derivatized to compounds of general formula IV and V, respectively, using general route A. Compounds of general formula IIIa can furthermore be reacted with a suitable aldehyde to give compounds of general structure VII.
- 10 Compounds of general formula IV and V can be derivatized to compounds of general formula I and VI, respectively, using general route A.

- General route A is a route where a sulfamide derivative of e.g. general formula I, IIIa, IIIb, IV and V is derivatized at the NH or the NH₂ nitrogen of the sulfamide moiety by
- 15 reacting said sulfamide with an appropriate derivative of R₄ or R₅ incorporating a suitable leaving group, like halide, mesylate or tosylate. The reaction is performed in a suitable solvent such as dioxane at an appropriate temperature such as from 0 °C to 180 °C.

- 20 Compounds of general formula V and VI can be deprotected to compounds of general formula I, using standard procedures known to a chemist skilled in the art of organic synthesis (e.g. *"Protective Groups in Organic Synthesis"*, 3rd ed., Greene T.W. and Wuts P.G.M., John Wiley & Sons Inc.).
- 25 Compounds of general formula VII can be reduced to compounds of general formula IV, using standard procedures known to a chemist skilled in the art of organic synthesis.

56

Scheme 1b



Compounds of general formula II can furthermore be reacted with substituted sulfamoyl derivatives, i.e. $R_4R_5NSO_2LG$ in Scheme 1b where LG for example could be Cl, to give compounds of general formula I and IV. Such reactions between e.g. substituted sulfamoyl chlorides and amines are known in the literature (Organic preparations and procedures international, 1984, 16, 49-77; J. Med. Chem. 1999, 42, 1178-1192; Bio. Org. Med. Chem. Lett. 2008, 18, 1312-1317).

Compounds of general formula II can furthermore be reacted with substituted sulfamoyl imidazole derivatives, i.e. $R_4R_5NSO_2LG$ in Scheme 1b where LG is imidazol-N-yl, to give compounds of general formula I and IV. Such reactions between substituted sulfamoyl imidazoles derivatives and amines are known in the literature (Organic preparations and procedures international, 1984, 16, 49-77; J. Org. Chem. 2003, 68, 115-119).

Alternatively, compounds of general structure II can be reacted with $R_7\text{HNSO}_2\text{LG}$ in Scheme 1b where R_7 is an alkoxy-carbonyl, such as BOC or methoxy-carbonyl and where LG for example could be Cl, to give compounds of general formula VIII.


- 5 Compounds of general structure VIII can either be further derivatised using general route A or alternatively be transformed into compounds of general structure IX using Route B being standard Mitsunobu procedures known to a chemist skilled in the art of organic synthesis (O. Mitsunobu et al., Bull. Chem. Soc. Japan 40, 935 (1967); David L. Hughes, Progress in the Mitsunobu reaction. A review, Organic Preparations and
10 Procedures International, Vol. 28, Iss. 2, 1996).

Compounds of general structure IX can be reduced using standard procedures known to a chemist skilled in the art of organic synthesis, to give compounds of general formula XII (US2007/191293 A1, 2007).

15

Compounds of the general formula II can be prepared by the general method outlined in Scheme 2.

Scheme 2



20

The reaction between X and XI to form II can be performed in the presence or absence of an acid (such as HCl) or a base (such as Et_3N or K_2CO_3), in a suitable solvent (such as DMF, EtOH or water) at a suitable temperature such as from room temperature to
25 200 °C by conventional heating or microwave induced heating.

Alternatively, the reaction between X and XI to form II can be performed in the presence of a transition metal based catalysis with a suitable ligand and a suitable base and in a suitable solvent, at a suitable temperature such as from room temperature to 200 °C by conventional heating or microwave induced heating. Typical transition metals
30 includes Pd and Cu, suitable ligands includes P-based ligands like 2,2'-bis(diphenylphosphino)1,1'-binaphthyl and 4,5-bis-diphenylphosphanyl-9,9-dimethyl-9H-xanthene, and N-based ligands like N,N'-dimethylcyclohexane-1,2-diamine, suitable bases includes Cs_2CO_3 , sodium tert-butoxide and K_3PO_4 , and suitable solvents include dioxane and toluene.

Any protecting group represented by PG, such as but not limited to BOC and benzyl, can in general be introduced and removed by standard procedures known to a chemist skilled in the art of organic synthesis (e.g. *"Protective Groups in Organic Synthesis"*, 3rd ed., Greene T.W. and Wuts P.G.M., John Wiley & Sons Inc.).

Compounds of the general formula X and XI are either commercially available or are prepared from commercially available molecules by synthetic transformations according to standard procedures known to a chemist skilled in the art of organic synthesis.

10


Compounds of the general formula XI can for example be prepared by reduction of monoketopiperazines, either commercially available or prepared by methods known to a chemist skilled in the art of organic synthesis.

15 Compounds of the general formula XI can for example be prepared by derivatisation of monoketopiperazines, either commercially available or prepared by methods known to a chemist skilled in the art of organic synthesis, for example by cyclopropanation of appropriately substituted monoketopiperazines.

INTERMEDIATES

Intermediate 1:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid amide



5

To 4-(4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine (1 g, 4.4 mmol) (intermediate 21) in dry dioxane (20 mL) was added sulfamide (419 mg, 4.4 mmol). The reaction mixture was heated to reflux for 6 hours. After evaporation of the solvent *in vacuo* the crude mixture was purified by flash chromatography on silica using heptane -> EtOAc:MeOH (9:1) as eluent.

10


¹H NMR (600 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (dd, J = 3.3, 1.9 Hz, 1H), 7.10 (s, 2H), 6.59 (d, J = 2.9 Hz, 1H), 4.12 – 4.02 (m, 2H), 3.88 (s, 2H), 3.65 – 3.57 (m, 2H), 1.07 (s, 2H), 0.82 (d, J = 1.6 Hz, 2H).

15

¹³C NMR (151 MHz, DMSO) δ 156.47, 151.83, 150.36, 121.30, 101.92, 100.78, 49.04, 47.14, 42.12, 38.51, 13.13.

Intermediate 2:

4-(4-Sulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester



20

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid amide (intermediate 1) (1.5 g, 4.86 mmol) was dissolved in dry DMF (20 ml), added Cs₂CO₃ (1.59 g, 4.86 mmol) and cooled to 0°C. A solution of BOC₂O (1.06 g, 4.86 mmol) in dry DMF (10 mL) was added and the reaction mixture was allowed to warm up to rt and stirred at rt for 16 h. The crude mixture was treated with water (150 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with H₂O (2x50 mL), brine (2x50 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo*. The product was purified by flash chromatography on silica using EtOAc in heptane as eluent.

10


¹H NMR (300 MHz, CDCl₃) δ 8.47 (s, 1H), 7.37 (d, J = 4.2 Hz, 1H), 6.42 (d, J = 4.2 Hz, 1H), 5.30 (s, 2H), 4.19 – 4.05 (m, 2H), 3.94 (s, 2H), 3.82 – 3.67 (m, 2H), 1.64 (s, 9H), 1.31 – 1.17 (m, 2H), 0.87 (q, J = 5.6 Hz, 2H).

15

¹³C NMR (75 MHz, CDCl₃) δ 157.27, 153.15, 153.08, 147.33, 122.38, 104.97, 103.92, 84.75, 50.59, 47.87, 43.41, 39.16, 28.01, 13.76.

Intermediate 3:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methylamide



To 4-(4,7-Diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine (2g, 8.7 mmol) (intermediate 21) in dry pyridine (100 mL) was cooled to 0°C and dropwise added a solution of commercial available methylsulfonyl chloride (419 mg, 8.7 mmol) in dry Et₂O (5 mL). After complete addition, the reaction mixture was allowed to warm up to rt and was afterwards stirred at rt for 1h. An additional equivalent of methylsulfonyl chloride (419 mg, 8.7 mmol) in dry Et₂O (5 mL) was added and after additional 1h at rt a third equivalent of methylsulfonyl chloride (419 mg, 8.7 mmol) in dry Et₂O (5 mL)


was added. The crude mixture was treated with water (150 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with H₂O (2x50 mL), brine (2x50 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo*. Recrystallised in EtOH:CH₂Cl₂ affording the title compound as white crystals.

5

¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (d, J = 2.9 Hz, 2H), 6.60 (d, J = 3.5 Hz, 1H), 4.13 – 3.98 (m, 2H), 3.85 (s, 2H), 3.63 – 3.47 (m, 2H), 2.41 (d, J = 2.5 Hz, 3H), 1.12 – 0.96 (m, 2H), 0.84 (dd, J = 7.0, 5.1 Hz, 2H).

10 Intermediate 4:

4-(4-Methylsulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester



Prepared in a way similar to intermediate 2, using intermediate 3, instead of intermediate 1.


15

¹H NMR (600 MHz, DMSO) δ 8.31 (s, 1H), 7.53 (d, J = 4.2 Hz, 1H), 7.24 (q, J = 4.9 Hz, 1H), 6.87 (d, J = 4.2 Hz, 1H), 4.08 – 3.97 (m, 2H), 3.83 (s, 2H), 3.63 – 3.47 (m, 2H), 2.40 (d, J = 4.9 Hz, 3H), 1.60 (s, 9H), 1.01 (t, J = 5.9 Hz, 2H), 0.84 (dd, J = 4.4, 2.2 Hz, 2H).

20

Intermediate 5:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-amide




Prepared in a way similar to intermediate 1, using 2-(sulfamoylamino)-ethylbenzene instead of sulfamide.

- 5 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.46 (s, 1H), 7.37 – 7.23 (m, 2H), 7.21 (d, J = 7.2 Hz, 4H), 6.58 (d, J = 3.3 Hz, 1H), 4.03 (dd, J = 6.2, 2.8 Hz, 2H), 3.82 (s, 2H), 3.59 – 3.42 (m, 2H), 3.00 (dd, J = 12.0, 7.2 Hz, 2H), 2.74 (t, J = 7.4 Hz, 2H), 0.98 (t, J = 5.9 Hz, 2H), 0.87 – 0.74 (m, 2H).

10 Intermediate 6:

4-(4-Phenethylsulfamoyl)-4,7-diaza-spiro[2.5]oct-7-yl-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester




Prepared in a way similar to intermediate 4, using intermediate 5, instead of intermediate 3.

¹H NMR (300 MHz, DMSO) δ 8.31 (s, 1H), 7.52 (d, J = 4.2 Hz, 1H), 7.48 (t, J = 5.6 Hz, 1H), 7.36 – 7.25 (m, 2H), 7.25 – 7.13 (m, 3H), 6.85 (d, J = 4.2 Hz, 1H), 4.18 – 3.90 (m, 2H), 3.80 (s, 2H), 3.62 – 3.40 (m, 2H), 3.13 – 2.90 (m, 2H), 2.73 (t, J = 7.4 Hz, 2H), 1.60 (s, 9H), 0.98 (t, J = 5.9 Hz, 2H), 0.81 (q, J = 5.3 Hz, 2H).

Intermediate 7:

10 1-(2H-Imidazole-1-sulfonyl)-piperidine-3-carbonitrile




To commercial available trifluoro-methanesulfonate 3-(2H-imidazole-1-sulfonyl)-1-methyl-3H-imidazol-1-ium (0.28 mmol) in dry CH₃CN (1.5 mL) was added piperidine-3-carbonitrile. The reaction mixture was stirred at rt for 2h. The pure compound were obtained by standard preparative HPLC purification of the reaction mixture.

¹H NMR (300 MHz, CDCl₃) δ 7.95 (s, 1H), 7.26 (s, 1H), 7.19 (s, 1H), 3.56 (dd, J = 12.1, 3.5 Hz, 1H), 3.32 (ddd, J = 19.8, 9.4, 5.9 Hz, 2H), 3.12 (dd, J = 11.4, 8.4 Hz, 1H), 2.88 (td, J = 7.6, 3.7 Hz, 1H), 2.05 – 1.87 (m, 2H), 1.75 (ddt, J = 12.2, 8.8, 5.7 Hz, 2H).

Using this procedure the following compounds were obtained:

Intermediate 8:


25 1-(Imidazole-1-sulfonyl)-piperidine-4-carbonitrile



¹H NMR (300 MHz, CDCl₃) δ 7.91 (s, 1H), 7.24 (t, J = 1.3 Hz, 1H), 7.18 (s, 1H), 3.58 – 3.17 (m, 4H), 2.80 (tt, J = 6.6, 4.6 Hz, 1H), 2.20 – 1.79 (m, 4H).

Intermediate 9:


5 Imidazole-1-sulfonic acid cyanomethyl-cyclopropyl-amide



¹H NMR (300 MHz, CDCl₃) δ 8.20 (s, 1H), 7.41 (s, 1H), 7.27 (s, 1H), 4.31 (s, 2H),
10 2.40 (ddd, J = 10.2, 6.6, 4.0 Hz, 1H), 1.00 (dt, J = 4.2, 2.9 Hz, 4H).

Intermediate 10:

Imidazole-1-sulfonic acid (2-cyano-ethyl)-cyclopropyl-amide




15

¹H NMR (300 MHz, CDCl₃) δ 8.00 (s, 1H), 7.31 (t, J = 1.3 Hz, 1H), 7.19 (s, 1H), 3.58
(t, J = 6.7 Hz, 2H), 2.74 (t, J = 6.7 Hz, 2H), 2.31 (ddd, J = 12.3, 6.8, 3.8 Hz, 1H),
1.08 – 0.76 (m, 4H).

20

Intermediate 11:


Imidazole-1-sulfonic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amide



¹H NMR (300 MHz, DMSO) δ 8.20 (s, 1H), 7.65 (t, J = 1.4 Hz, 1H), 7.15 (d, J = 0.9 Hz, 1H), 6.85 (dd, J = 9.0, 5.0 Hz, 2H), 6.74 (dd, J = 8.1, 1.9 Hz, 1H), 3.73 (d, J = 6.6 Hz, 6H), 3.43 – 3.34 (m, 2H), 2.85 (s, 3H), 2.76 – 2.64 (m, 2H).

5 Intermediate 12:


Imidazole-1-sulfonic acid benzyl-(2-cyano-ethyl)-amide



¹H NMR (300 MHz, CDCl₃) δ 7.99 (s, 1H), 7.42 – 7.34 (m, 3H), 7.28 (d, J = 1.6 Hz, 1H), 7.24 – 7.15 (m, 3H), 4.50 (s, 2H), 3.49 (t, J = 7.1 Hz, 2H), 2.42 (t, J = 7.1 Hz, 2H).

Intermediate 13:


1-(Imidazole-1-sulfonyl)-piperidine



¹H NMR (300 MHz, CDCl₃) δ 7.99 (s, 1H), 7.26 (s, 1H), 7.18 (s, 1H), 3.23 – 3.11 (m, 4H), 1.67 (dt, J = 11.2, 5.7 Hz, 4H), 1.58 – 1.44 (m, 2H).

20 Intermediate 14:


Imidazole-1-sulfonic acid methyl-phenethyl-amide



¹H NMR (300 MHz, DMSO) δ 8.19 (s, 1H), 7.64 (t, J = 1.4 Hz, 1H), 7.38 – 7.17 (m, 5H), 7.14 (d, J = 1.0 Hz, 1H), 3.40 (dd, J = 8.3, 6.8 Hz, 2H), 2.85 (s, 3H), 2.82 – 2.71 (m, 2H).

5 Intermediate 15:

4-[4-(Imidazole-1-sulfonyl)-4,7-diaza-spiro[2.5]oct-7-yl]-7H-pyrrolo[2,3-d]pyrimidine



1H NMR (300 MHz, DMSO) δ 11.76 (s, 1H), 8.30 (t, J = 0.9 Hz, 1H), 8.13 (s, 1H), 7.74 (t, J = 1.4 Hz, 1H), 7.21 (d, J = 3.6 Hz, 1H), 7.15 (dd, J = 1.5, 0.8 Hz, 1H), 6.53 (d, J = 3.7 Hz, 1H), 3.85 (dd, J = 13.4, 5.9 Hz, 4H), 3.36 (s, 2H), 1.19 (q, J = 5.4 Hz, 2H), 0.98 (q, J = 5.5 Hz, 2H).


Intermediate 16:

15 4-{4-[2-(Tetrahydro-pyran-2-yloxy)-ethylsulfamoyl]-4,7-diaza-spiro[2.5]oct-7-yl}-
pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester

and


20 Intermediate 17:

4-(4-{Bis-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-sulfamoyl}-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester




4-(4-Sulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 2) (1 g, 2.45 mmol) was dissolved in dry DMF (20 ml), added K_2CO_3 (1.59 g, 4.86 mmol) and heated to 50°C. A solution of 2-(2-bromo-ethoxy)-tetrahydro-pyran (260 mg, 1.22 mmol) in dry DMF (5 mL) was added and the
 5 reaction mixture was stirred at 50 °C for 1h. Additional 0.5 equivalent (260 mg, 1.22 mmol) 2-(2-bromo-ethoxy)-tetrahydro-pyran was added and after another hour at 50 °C one additional equivalent was added. After being stirred at 50 °C for a total of 3h additional 2-(2-bromo-ethoxy)-tetrahydro-pyran (2 eq, 1.04 g, 4.9 mmol) was added and the reaction mixture was stirred at 50°C for 65h. The crude mixture was treated
 10 with water (100 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with H_2O (2X50 mL), brine (2x50 mL), dried over Na_2SO_4 , filtered and concentrated *in vacuo*. The products were purified by flash chromatography on silica using EtOAc in heptane as eluent.

15 Intermediate 16:



1H NMR (300 MHz, $CDCl_3$) δ 8.49 (s, 1H), 7.64 (s, 1H), 7.45 – 7.35 (m, 1H), 6.48 – 6.39 (m, 1H), 4.52 (s, 2H), 4.19 – 4.09 (m, 2H), 3.89 (s, 2H), 3.84 (m, 2H), 3.57 (m, 4H), 1.66 (s, 9H), 1.48 (d, J = 2.9 Hz, 3H), 1.26 (m, 4H), 0.90 (m, 4H).
 20

Intermediate 17:



25 1H NMR (300 MHz, DMSO) δ 8.32 (s, 1H), 7.53 (d, J = 4.2 Hz, 1H), 6.85 (d, J = 4.2 Hz, 1H), 4.58 (s, 2H), 4.03 (d, J = 4.9 Hz, 2H), 3.84 (s, 2H), 3.75 (dt, J = 8.6, 4.4 Hz,

4H), 3.62 – 3.29 (m, 12H), 1.79 – 1.63 (m, 2H), 1.60 (s, 9H), 1.49 (m, 8H), 1.06 (t, J = 5.7 Hz, 2H), 0.86 (t, J = 6.0 Hz, 2H).


Intermediate 18:

- 5 4-[4-(3-Cyano-propylsulfamoyl)-4,7-diaza-spiro[2.5]oct-7-yl]-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester

and

- 10 Intermediate 19:

4-{4-[Bis-(3-cyano-propyl)-sulfamoyl]-4,7-diaza-spiro[2.5]oct-7-yl}-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester



- 15 4-(4-Sulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 2) (112 mg, 0.27 mmol) was dissolved in dry DMF (2 ml), added K₂CO₃ (38 mg, 0.27 mmol) and cooled to 0°C. A solution of 4-bromobutyronitrile (40 mg, 0.27 mmol) in dry DMF (0.5 mL) was added and the reaction mixture was stirred at rt for 16h. The crude mixture was treated with water (10 mL)
- 20 and extracted with EtOAc (3x10 mL). The combined organic phases were washed with H₂O (2x10 mL), brine (2x10 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo*. The products were purified by flash chromatography on silica using EtOAc in heptane as eluent.

- 25 Intermediate 18:

4-[4-(3-Cyano-propylsulfamoyl)-4,7-diaza-spiro[2.5]oct-7-yl]-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester

- 1H NMR (300 MHz, CDCl₃) δ 8.49 (s, 1H), 7.40 (dd, J = 4.2, 2.0 Hz, 1H), 6.43 (d, J = 4.2 Hz, 1H), 4.97 (t, J = 6.3 Hz, 1H), 4.17 – 4.08 (m, 2H), 3.94 (d, J = 5.2 Hz, 2H),
- 30

3.71 – 3.63 (m, 2H), 3.33 – 3.23 (m, 2H), 2.53 – 2.37 (m, 2H), 2.02 – 1.86 (m, 2H), 1.66 (s, 9H), 1.14 – 1.02 (m, 2H), 0.92 (td, $J = 6.9, 3.9$ Hz, 2H).


Intermediate 19:

5 4-{4-[Bis-(3-cyano-propyl)-sulfamoyl]-4,7-diaza-spiro[2.5]oct-7-yl}-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester

1H NMR (300 MHz, CDCl₃) δ 8.50 (s, 1H), 7.40 (dd, $J = 4.2, 1.9$ Hz, 1H), 6.43 (d, $J = 4.2$ Hz, 1H), 4.20 – 4.08 (m, 2H), 3.94 (s, 2H), 3.65 – 3.57 (m, 2H), 3.34 – 3.22 (m, 10 4H), 2.43 (t, $J = 6.9$ Hz, 4H), 2.02 – 1.90 (m, 4H), 1.66 (s, 9H), 1.06 (t, $J = 6.3$ Hz, 2H), 0.93 (t, $J = 6.4$ Hz, 2H).

Intermediate 20:

15 7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-carboxylic acid tert-butyl ester




To commercially available 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (1.0 g, 6.5 mmol) dissolved in DMF (5 ml) was added Et₃N (1.3 ml, 9.8 mmol) followed by commercially available 4,7-diaza-spiro[2.5]octane-4-carboxylic acid tert-butyl ester (1.5 g, 7.2 20 mmol). The reaction mixture was heated for 16 hours at 110 °C. After evaporation of the solvent in vacuo the crude mixture was treated with water (25 mL) and extracted with EtOAc (4x30 mL) the combined organic phases were washed with brine (2x20 mL), dried over Na₂SO₄, filtered and concentrated in vacuo to provide 1.5 g crude. The product was purified by flash chromatography on silica using EtOAc in heptane as 25 eluent.

¹H NMR (300 MHz, DMSO) δ = 11.70 (s, 1H), 8.15 (s, 1H), 7.18 (m, 1H), 6.59 (m, 1H), 3.90 (m, 2H), 3.73 (m, 2H), 3.62 – 3.53 (m, 2H), 1.68 – 1.11 (m, 9H), 1.01 – 0.57 (m, 5H).

Intermediate 21:

4-(4,7-Diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine



5

To 7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-carboxylic acid tert-butyl ester (intermediate 20) (0.5 g, mmol) dissolved in diethyl ether (20 ml) was added HCl in dioxane (ml, M) and the reaction mixture was stirred for 5 hours at room temperature. The precipitate was isolated by filtration, and washed with diethyl ether (2x5 ml). The precipitate was suspended in THF (50 ml) and stirred vigorously with K₂CO₃ (5 gram) for 3 hours. After filtration and evaporation of the solvent in vacuo, the product was obtained as an off-white compound.


10

¹H NMR (300 MHz, DMSO) δ = 11.64 (s, 1H), 8.09 (s, 1H), 7.21 – 7.08 (m, 1H), 6.53 (m, 1H), 3.92 – 3.79 (m, 2H), 3.71 (s, 2H), 2.94 – 2.81 (m, 2H), 1.29 (br s, 1H), 0.59 – 0.37 (m, 4H).

15

Alternatively synthesis of intermediate 21:


4-(4,7-Diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine



To 4-(4-benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine (intermediate 22) (50 g, 78.36 mmol) in MeOH, was added 10% Pd/C (20 g) and HCOONH₄ (98 g, 783.69 mmol) and the reaction mixture was heated to reflux for 30 min. The reaction mixture was filtered through celite bed and washed with MeOH and concentrated under reduced pressure. The crude compound was treated with 50% NaOH solution (200 ml) and stirred for 15 min and solid was obtained by filtration. And the solid was wash with 50 ml of water and dried under vacuum. The crude compound (33 g) in acetone (10 times) was heated to reflux for 30 min. The reaction mixture was cooled and filtered and the solid was washed with acetone to afford the title compound as a solid (29.78 g, 83%).

Intermediate 22:

15 4-(4-Benzyl-4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine




To a stirred solution of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (29.2 g, 190.98 mmol) in water, was added intermediate 23 (50 g, 210 mmol) and K₂CO₃ (79 g, 572.9 mmol) and the resultant reaction mixture was heated to 100°C for 16 h. The reaction mixture was cooled to RT and filtered. The obtained solid was washed with diethyl ether to afford the title compound. (50 g, 80%).

^1H NMR (300 MHz, DMSO) δ = 11.70 (br, 1H), 8.10 (s, 1H), 7.32 (m, 5H), 7.14 (d, 1H), 6.58 (d, 1H), 3.95 (br, 4H), 3.80 (br, 2H), 2.82 (m, 2H), 0.64 (m, 4H)

Intermediate 23:

5 4-benzyl-4,7-diaza-spiro[2.5]octane




To a stirred solution of intermediate 24 (96 g) in THF (500 mL) was added 4N HCl in dioxane (200 mL) and the resultant reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated under reduced pressure. The crude was washed with
10 n-pentane to afford title compound as a solid (75 g, 100%).

^1H NMR (300 MHz, DMSO) δ = 7.4 (br, 5H), 4.00-4.40 (br, 2H), 3.00-3.80 (br, 6H), 0.81 (br, 4H)

15 Intermediate 24:

4-benzyl-4,7-diaza-spiro[2.5]octane-7-carboxylic acid tert-butyl ester



20 To EtMgBr (344 mL) in THF cooled to -78°C was added $\text{Ti}(\text{O}^i\text{Pr})_4$ (39 g, 137.93 mmol), followed by commercially available 4-benzyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester (40 g, 137.93 mmol) and the resultant reaction mixture was heated to reflux for 1 h. After cooling the reaction mixture to 5°C , another portion of EtMgBr (344 mL) and $\text{Ti}(\text{O}^i\text{Pr})_4$ (39 g, 137.93 mmol) was added. The mixture was stirred for 16
25 h at RT. The reaction mixture was quenched with NH_4Cl solution and stirred for 15 min


and filtered through a celite bed and washed with EtOAc. The aqueous layer was again extracted with EtOAc (3 x). The combined EtOAc layers were washed with water and dried over Na₂SO₄ and concentrated under reduced pressure. Purification by column chromatography to afforded the title compound as a solid (24 g, 58%).

5

¹H NMR (300 MHz, DMSO) δ = 7.20 (m, 5H), 3.80 (s, 2H), 3.40 (m, 2H), 3.22 (m, 2H), 2.63 (m, 2H), 1.38 (s, 9H), 0.58 (br, 4H)

Intermediate 25:

10 N-methyl-N-(pyrrolidin-3-ylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



4-(4-Methylsulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 4) (0.71 mmol) was dissolved in dry DMF (0.5 mL) and added Cs₂CO₃ (1.42 mmol) and tert-butyl 3-(bromomethyl)pyrrolidine-1-carboxylate (0.85 mmol). Stirred at 45°C for 16h and then added H₂O (2 mL). Extracted with EtOAc (3 x 2 mL) and the combined organic phases were concentrated *in vacuo*. The residual oil was treated with a mixture of 1,1,1,3,3,3-hexafluoro-2-propanol: 2,2,2-trifluoroethanol (3:1, 4 mL) at 150°C for 2h. The crude reaction mixture was concentrated on celite *in vacuo* and purified by standard column chromatography using methanol in DCM as eluent. The obtained compound was recrystallized in methanol:EtOAc affording the title compound as solid.


LC-MS: 1.59 min, ES (+), m/z: 406.202

25

Using this procedure the following compounds were obtained:

Intermediate 26:

30 N-methyl-N-(4-piperidylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formoc acid salt




1H NMR (600 MHz, DMSO) δ 11.77 (s, 1H), 8.41 (s, 1H), 8.14 (s, 1H), 7.20 (d, J = 3.5 Hz, 1H), 6.60 (d, J = 3.5 Hz, 1H), 4.05 (t, J = 5.2 Hz, 2H), 3.84 (s, 4H), 3.52 (t, J = 5.1 Hz, 2H), 3.15 (dt, J = 12.4, 3.4 Hz, 2H), 2.96 (d, J = 7.3 Hz, 2H), 2.76 – 2.60 (m, 5H), 1.80 (dq, J = 11.0, 7.3, 3.8 Hz, 1H), 1.71 (dd, J = 13.9, 3.8 Hz, 2H), 1.20 (qd, J = 12.8, 3.9 Hz, 2H), 1.03 – 0.77 (m, 4H).

LC-MS: 1.61 min, ES (+), m/z : 420.211

10 Intermediate 27:

N-methyl-N-(3-piperidylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formic acid salt




1H NMR (600 MHz, DMSO) δ 11.78 (s, 1H), 8.40 (s, 1H), 8.14 (s, 1H), 7.20 (d, J = 3.7 Hz, 1H), 6.60 (d, J = 3.7 Hz, 1H), 4.05 (t, J = 5.3 Hz, 2H), 3.83 (d, J = 1.7 Hz, 2H), 3.53 (t, J = 5.1 Hz, 2H), 3.16 – 3.04 (m, 2H), 2.98 (qd, J = 13.8, 7.4 Hz, 2H), 2.69 (s, 3H), 2.63 (d, J = 2.9 Hz, 1H), 2.42 (t, J = 11.6 Hz, 1H), 1.94 (d, J = 7.7 Hz, 1H), 1.77 – 1.66 (m, 2H), 1.60 – 1.49 (m, 1H), 1.12 (td, J = 12.0, 8.5 Hz, 1H), 1.04 – 0.79 (m, 4H).

LC-MS: 1.60 min, ES (+), m/z : 420.218

Intermediate 28:

N-[[[(2S)-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formic acid salt




1H NMR (600 MHz, DMSO) δ 11.73 (s, 1H), 8.18 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.60 (dd, J = 3.6, 1.9 Hz, 1H), 4.09 – 4.00 (m, 2H), 3.84 (s, 2H), 3.54 (td, J = 4.9, 2.3 Hz, 2H), 3.45 (p, J = 7.2 Hz, 2H), 3.21 – 3.01 (m, 4H), 2.75 (s, 3H), 2.38 – 2.26 (m, 1H), 1.92 (m, 2H), 1.04 – 0.94 (m, 2H), 0.91 – 0.83 (m, 2H).

LC-MS: 1.63 min, ES (+), m/z: 442.174

Intermediate 50:

- 10 N-(azetidin-3-yl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.13 (s, 1H), 7.19 (d, J = 3.5 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.37 (p, J = 7.5 Hz, 1H), 4.10 – 3.92 (m, 2H), 3.81 (s, 2H), 3.61 (m, 2H), 3.50 (dd, J = 6.3, 4.0 Hz, 2H), 2.74 (s, 3H), 1.05 – 0.77 (m, 4H).

LC-MS: 1.56 min, ES (+), m/z: 378.172

Intermediate 51:

- 20 N-methyl-N-[[[(2R)-pyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (d, J = 3.4 Hz, 1H), 6.59 (d, J = 3.5 Hz, 1H), 4.04 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.54 (dd, J = 6.3, 4.0 Hz, 2H), 3.26 – 3.16 (m, 2H), 3.12 – 2.84 (m, 2H), 2.84 – 2.67 (m, 5H), 1.91 – 1.52 (m, 3H), 1.43 – 1.17 (m, 1H), 1.09 – 0.73 (m, 4H).

LC-MS: 1.58 min, ES (+), m/z : 406.204

Intermediate 52:

- 10 N-methyl-N-[[[(2S)-pyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formic acid salt




- 15 1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.29 (s, 1H), 8.14 (s, 1H), 7.19 (d, J = 3.5 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.05 (t, J = 5.2 Hz, 2H), 3.84 (s, 2H), 3.54 (t, J = 5.0 Hz, 2H), 3.22 – 3.01 (m, 2H), 2.96 – 2.85 (m, 1H), 2.75 (s, 3H), 1.94 – 1.61 (m, 3H), 1.50 – 1.36 (m, 1H), 1.09 – 0.83 (m, 4H).

LC-MS: 1.57 min, ES (+), m/z: 406.201

Intermediate 29:

N-cyclobutylsulfamoyl chloride



5

Sulfuryl chloride (104 mmol) was dissolved in dry CH₃CN (25 mL), added cyclobutylamine hydrochloride (31 mmol) and stirred at reflux for 16h. The obtained reaction mixture was cooled to rt and concentrated *in vacuo*. The obtained residue was triturated with Et₂O (2 x 25 mL). The combined Et₂O-phases were concentrated *in vacuo* affording the title compound as oil.


10

¹H NMR (300 MHz, CDCl₃) δ 5.75 (s, 1H), 4.27 – 4.04 (m, 1H), 2.64 – 2.37 (m, 2H), 2.26 – 1.96 (m, 2H), 1.93 – 1.68 (m, 2H).

15

Intermediate 30:

N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



To 4-(4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine (6.55 mmol) (intermediate 21) in dry pyridine (25 mL) was added N-cyclobutylsulfamoyl chloride (7.86 mmol) (Intermediate 29). The reaction mixture was stirred at rt for 16h. After evaporation of the solvent *in vacuo* the crude mixture was purified by flash chromatography on silica using heptane -> MeOH:EtOAc affording the title compound as white crystals.


25

¹H NMR (300 MHz, DMSO) δ 11.76 (s, 1H), 8.15 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.20 (dd, J = 3.5, 1.9 Hz, 1H), 6.61 (dd, J = 3.4, 1.5 Hz, 1H), 4.05 (t, J = 5.1 Hz, 2H), 3.83 (s, 2H), 3.53 (dd, J = 6.7, 4.1 Hz, 3H), 2.23 – 2.03 (m, 2H), 2.00 – 1.76 (m, 2H), 1.55 (ddt, J = 15.9, 6.8, 3.2 Hz, 2H), 1.09 – 0.75 (m, 4H).

LC-MS: 1.96 min, ES (+), m/z: 363.159

Intermediate 31:

- 5 tert-butyl 4-[8-(cyclobutylsulfamoyl)-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate




- N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide (intermediate 30) (4.4 mmol) was dissolved in dry DMF (15 ml), added
 10 K_2CO_3 (5.28 mmol) and cooled to 0°C. A solution of BOC_2O (1.06 g, 4.86 mmol) in dry DMF (5 mL) was added and the reaction mixture was allowed to warm up freely to rt and stirred at rt for 16 h. The crude mixture was treated with water (150 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with H_2O (2X50 mL), brine (2x50 mL), dried over Na_2SO_4 , filtered and concentrated *in vacuo*.
 15 The product was purified by flash chromatography on silica using EtOAc in heptane as eluent.

- ^1H NMR (300 MHz, DMSO) δ 8.31 (s, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 4.1 Hz, 1H), 6.86 (d, J = 4.2 Hz, 1H), 4.10 – 3.96 (m, 2H), 3.81 (s, 2H), 3.53 (dd, J = 6.7, 4.0 Hz, 3H), 2.18 – 2.02 (m, 2H), 1.95 – 1.83 (m, 2H), 1.60 (s, 11H), 1.06 – 0.74 (m, 4H).
 20

Using this procedure the following compounds were obtained:

- 25 Intermediate 32:


Tert-butyl 4-[8-(isopropylsulfamoyl)-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate



1H NMR (300 MHz, DMSO) δ 8.31 (s, 1H), 7.52 (d, J = 4.2 Hz, 1H), 7.29 (d, J = 7.4 Hz, 1H), 6.86 (d, J = 4.2 Hz, 1H), 4.09 – 3.99 (m, 2H), 3.82 (s, 2H), 3.55 (dd, J = 6.4, 3.9 Hz, 2H), 3.27 – 3.07 (m, 1H), 1.60 (s, 9H), 1.06 (d, J = 6.7 Hz, 8H), 0.92 – 0.77 (m, 2H).

Intermediate 42:


tert-butyl 4-[8-[(1,1-dioxothiolan-3-yl)methylsulfamoyl]-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate



1H NMR (300 MHz, DMSO) δ 8.31 (s, 1H), 7.60 (t, J = 6.0 Hz, 1H), 7.53 (d, J = 4.2 Hz, 1H), 6.87 (d, J = 4.2 Hz, 1H), 4.04 (t, J = 5.0 Hz, 2H), 3.83 (s, 2H), 3.56 (d, J = 5.0 Hz, 2H), 3.31 (s, 1H), 3.25 – 2.97 (m, 3H), 2.89 (t, J = 6.4 Hz, 2H), 2.79 (dd, J = 13.2, 9.6 Hz, 1H), 2.27 – 2.13 (m, 1H), 1.88 – 1.72 (m, 1H), 1.60 (s, 9H), 1.08 – 0.78 (m, 4H).

Intermediate 43:


tert-butyl 4-[8-(oxetan-3-ylsulfamoyl)-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate



1H NMR (300 MHz, DMSO) δ 8.31 (s, 2H), 7.53 (d, J = 4.1 Hz, 1H), 6.86 (d, J = 4.2 Hz, 1H), 4.63 (dd, J = 7.4, 6.4 Hz, 2H), 4.44 (t, J = 6.4 Hz, 2H), 4.28 (p, J = 7.1 Hz, 1H), 4.04 (td, J = 4.4, 3.7, 2.0 Hz, 2H), 3.80 (s, 2H), 3.59 – 3.45 (m, 2H), 1.60 (s, 9H), 1.07 – 0.95 (m, 2H), 0.90 – 0.79 (m, 2H).

Intermediate 44:


tert-butyl 4-[8-[(1,1-dioxothian-4-yl)methylsulfamoyl]-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate



1H NMR (300 MHz, DMSO) δ 8.31 (s, 1H), 7.59 – 7.47 (m, 2H), 6.86 (d, J = 4.2 Hz, 1H), 4.04 (m, 2H), 3.83 (s, 2H), 3.55 (t, J = 5.0 Hz, 2H), 3.05 (dt, J = 16.2, 11.3 Hz, 4H), 2.70 (t, J = 6.3 Hz, 2H), 2.09 – 1.92 (m, 2H), 1.81 – 1.65 (m, 1H), 1.60 (s, 9H), 1.08 – 0.76 (m, 4H).

Intermediate 45:


tert-butyl 4-[8-(2-cyanoethylsulfamoyl)-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate



1H NMR (300 MHz, DMSO) δ 8.31 (s, 1H), 7.79 (t, J = 5.9 Hz, 1H), 7.53 (d, J = 4.2 Hz, 1H), 6.87 (d, J = 4.2 Hz, 1H), 4.04 (dd, J = 6.3, 3.9 Hz, 2H), 3.83 (s, 2H), 3.59 – 3.52 (m, 2H), 3.03 (q, J = 6.2 Hz, 2H), 2.63 (t, J = 6.4 Hz, 2H), 1.60 (s, 9H), 1.13 – 0.76 (m, 4H).

Intermediate 33:

3-(Sulfamoylamino)oxetane




- 10 Sulfamide (15.6 mmol) was dissolved in H₂O (8 mL), added oxetan-3-amine (6.85 mmol) and stirred at 70°C for 16h and then at 100°C for another 16h. The obtained reaction mixture was cooled to rt and freeze-dried affording the title compound as white solid. Used without further purification.
- 15 1H NMR (300 MHz, DMSO) δ 7.44 (d, J = 8.0 Hz, 1H), 6.64 (s, 2H), 4.77 – 4.58 (m, 2H), 4.49 (t, J = 6.2 Hz, 2H), 4.45 – 4.33 (m, 1H).

Using this procedure the following compounds were obtained:

20 Intermediate 39:

1-cyano-2-(sulfamoylamino)ethane




Obtained as white solid. Used without further purification.

25 Intermediate 34:

1,1-Dioxo-3-[(sulfamoylamino)methyl]thiolane

82




Sulfamide (2.4 mmol) was dissolved in H₂O (10 mL), added (1,1-dioxothiolan-3-yl)methanamine (2 mmol) and stirred at reflux for 16h. The obtained reaction mixture was cooled to rt and freeze-dried affording the title compound as an oil. Used without
5 further purification.

Using this procedure the following compounds were obtained:

Intermediate 35:


10 1,1-Dioxo-3-[(sulfamoylamino)methyl]thiolane



Obtained as an oil and used without further purification

Intermediate 36:


15 Cyano-(sulfamoylamino)methane



Obtained as a solid and used without further purification

Intermediate 37:

20 N-[(1,1-dioxothiolan-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a way similar to intermediate 1, using intermediate 34 instead of sulfamide.

25 ¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.59 (t, J = 5.9 Hz, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.60 (dd, J = 3.7, 1.8 Hz, 1H), 4.05 (t, J = 5.2 Hz, 2H), 3.84


(s, 2H), 3.55 (t, J = 5.3 Hz, 2H), 3.26 – 2.98 (m, 4H), 2.89 (t, J = 6.3 Hz, 2H), 2.85 – 2.68 (m, 1H), 2.31 – 2.13 (m, 1H), 1.87 – 1.70 (m, 1H), 1.12 – 0.76 (m, 4H).

LC-MS: 1.71 min, ES (+), m/z: 441.123

5

Intermediate 38:

N-[(1,1-dioxothian-4-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



10 Prepared in a way similar to intermediate 1, using intermediate 35 instead of sulfamide.


¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.13 (s, 1H), 7.49 (t, J = 6.1 Hz, 1H), 7.18 (dd, J = 3.6, 2.4 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.05 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.54 (t, J = 5.1 Hz, 2H), 3.18 – 2.92 (m, 4H), 2.70 (t, J = 6.3 Hz, 2H), 2.02 (d, J = 13.0 Hz, 2H), 1.79 – 1.47 (m, 3H), 1.09 – 0.72 (m, 4H).

15

LC-MS: 1.73 min, ES (+), m/z: 455.151

Intermediate 40:

20 N-(2-cyanoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a way similar to intermediate 1, using intermediate 39 instead of sulfamide.

25 ¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.76 (s, 1H), 7.19 (dd, J = 3.5, 2.1 Hz, 1H), 6.60 (dd, J = 3.6, 1.5 Hz, 1H), 4.04 (q, J = 5.1 Hz, 2H), 3.84 (s, 2H),


3.57 (dd, $J = 6.3, 3.9$ Hz, 2H), 3.03 (t, $J = 6.4$ Hz, 2H), 2.63 (t, $J = 6.4$ Hz, 2H), 1.09 – 0.80 (m, 4H).

LC-MS: 1.72 min, ES (+), m/z : 362.129

5

Intermediate 41:

N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



10 Prepared in a way similar to intermediate 1, using intermediate 33 instead of sulfamide.


^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.29 (br, 1H), 8.14 (s, 1H), 7.19 (d, $J = 3.6$ Hz, 1H), 6.60 (d, $J = 3.6$ Hz, 1H), 4.63 (dd, $J = 7.5, 6.4$ Hz, 2H), 4.44 (t, $J = 6.5$ Hz, 2H), 4.29 (p, $J = 7.0$ Hz, 1H), 4.05 (dd, $J = 6.5, 3.8$ Hz, 2H), 3.81 (s, 2H), 3.52 (tt, $J = 7.8, 3.4$ Hz, 2H), 1.07 – 0.79 (m, 4H).

15

LC-MS: 1.69 min, ES (+), m/z : 365.116

Intermediate 46:

20 N-benzyloxy-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



O-benzylhydroxylamine hydrochloride (5.13 mmol) was dissolved in DCM (20 mL) and treated with 1N NaOH (6 mL). The phases were separated and the organic phase was washed with H_2O , dried for 30 min using Na_2SO_4 and filtered. The obtained solution was

25


cooled to 0°C and slowly added a solution of HOSO₂Cl (1.71 mmol) in dry DCM (5 mL). After 1h at 0°C a white precipitate was filtered off. The precipitate was washed with DCM and thereafter Et₂O before being dried (freezedryer). The obtained dry compound was suspended in dry toluene (15 mL), added PCl₅ (2.05 mmol) and stirred at reflux for 1h. After being cooled to rt, the reaction mixture was filtered and the filtrate was concentrated *in vacuo*. The obtained oil was added neat to a solution of 4-(4,7-Diazaspiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine (Intermediate 21) (1.71 mmol) in pyridine (7 mL) and stirred at 40°C for 16h. The pure compound was obtained by standard preparative HPLC purification.

¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 10.11 (s, 1H), 8.12 (s, 1H), 7.43 – 7.27 (m, 5H), 7.22 – 7.15 (m, 1H), 6.54 (dd, J = 3.7, 1.8 Hz, 1H), 4.86 (s, 2H), 4.03 (t, J = 4.9 Hz, 2H), 3.81 (s, 2H), 3.66 – 3.55 (m, 2H), 1.17 – 1.05 (m, 2H), 0.93 – 0.74 (m, 2H).

LC-MS: 2.11 min, ES (+), m/z: 415.151

Intermediate 47:

tert-butyl 4-[8-(tert-butoxycarbonylsulfamoyl)-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate




7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diazaspiro[2.5]octane-4-sulfonic acid amide (intermediate 1) (1.95 mmol) was dissolved in dry DMF (15 mL), added Cs₂CO₃ (4.29 mmol), BOC₂O (4.29 mmol) and stirred at rt for 16 h. The crude mixture was treated with water (150 mL) and extracted with EtOAc (3x100 mL). The combined organic phases were washed with H₂O (2x50 mL), brine (2x50 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo*. The product was purified by flash chromatography on silica using EtOAc in heptane as eluent.

¹H NMR (300 MHz, DMSO) δ 11.24 (s, 1H), 8.32 (s, 1H), 7.54 (d, J = 4.2 Hz, 1H), 6.87 (d, J = 4.3 Hz, 1H), 4.04 (dd, J = 6.8, 3.8 Hz, 2H), 3.78 (s, 2H), 3.68 (dd, J = 6.5, 3.8 Hz, 2H), 1.60 (s, 9H), 1.38 (s, 9H), 0.87 (dt, J = 11.3, 4.4 Hz, 4H).

5 Intermediate 48:

tert-butyl 4-[8-[[[(2S)-1-benzylpyrrolidin-2-yl]methyl-tert-butoxycarbonyl-sulfamoyl]-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate




10 Tert-butyl 4-[8-(tert-butoxycarbonylsulfamoyl)-5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate (intermediate 47) (0.55 mmol) was dissolved in dry THF (3 mL) and added [(2S)-1-benzylpyrrolidin-2-yl]methanol (0.61 mmol) and triphenylphosphine (0.66 mmol). The reaction mixture was cooled to 0°C and slowly added isopropyl (NZ)-N-isopropoxycarbonyliminocarbamate (0.66 mmol). The reaction mixture was allowed to warm up freely to rt and stirred at rt for 16h. The crude mixture was treated with water (50 mL) and extracted with EtOAc (3x50 mL). The combined organic phases were washed with H₂O (2x50 mL), brine (2x50 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo*. The product was purified by flash chromatography on silica using EtOAc in heptane as eluent.

20 ¹H NMR (300 MHz, DMSO) δ 8.32 (s, 1H), 7.54 (d, J = 4.2 Hz, 1H), 7.37 – 7.18 (m, 5H), 6.88 (d, J = 4.2 Hz, 1H), 4.77 (hept, J = 6.2 Hz, 4H), 4.14 – 3.93 (m, 4H), 3.87 – 3.56 (m, 6H), 2.91 – 2.81 (m, 1H), 2.81 – 2.70 (m, 1H), 1.91 – 1.78 (m, 1H), 1.60 (s, 9H), 1.41 (s, 9H), 0.97 – 0.81 (m, 4H).

25 Intermediate 49:

(NZ)-N-[(4-methoxyphenyl)methylene]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid amide (intermediate 1) (0.46 mmol) was suspended in dry toluene (5 ml), added 4-methoxybenzaldehyde (0.46 mmol) and stirred at reflux for 48h. The obtained reaction mixture was concentrated *in vacuo* on silica. The product was purified by flash chromatography on silica using EtOAc in heptane as eluent.

¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.93 (s, 1H), 8.09 (s, 1H), 8.00 – 7.89 (m, 2H), 7.17 (dd, *J* = 3.6, 2.2 Hz, 1H), 7.13 – 7.00 (m, 2H), 6.56 (dd, *J* = 3.4, 1.6 Hz, 1H), 4.07 (t, *J* = 5.1 Hz, 2H), 3.85 (s, 3H), 3.82 (s, 2H), 3.72 (dd, *J* = 6.5, 4.0 Hz, 2H), 1.30 – 1.13 (m, 2H), 0.95 – 0.82 (m, 2H).

LC-MS: 2.23 min, ES (+), *m/z*: 427.135

15 Intermediate 53:

tert-butyl N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]carbamate



N-(oxomethylene)sulfamoyl chloride (13.4 mmol) was dissolved in dry benzene (5 mL) and dropwise added t-BuOH (13.4 mmol) while the temperature was kept below 25°C. The reaction mixture was stirred at 25°C for 2h, added hexane (5 mL) and cooled to 0°C. Precipitate was collected by filtration, washed with hexane affording tert-butyl N-chlorosulfonylcarbamate as white crystals. 4-(4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine (4.6 mmol) (intermediate 21) was suspended in dry DCM (25 mL) and added triethylamine (6.9 mmol). To this suspension was slowly added tert-

butyl N-chlorosulfonylcarbamate (4.6 mmol) at rt. After 15 min all starting material has been consumed. The obtained reaction mixture was concentrated *in vacuo* on celite. The product was purified by flash chromatography on silica using EtOAc:MeOH in heptane as eluent.

5


¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 11.22 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.5, 2.3 Hz, 1H), 6.61 (dd, J = 3.7, 1.7 Hz, 1H), 4.09 – 3.99 (m, 2H), 3.80 (s, 2H), 3.67 (dd, J = 6.5, 3.7 Hz, 2H), 1.38 (s, 9H), 1.17 – 1.06 (m, 2H), 0.96 – 0.81 (m, 2H).

10 LC-MS: 1.98 min, ES (+), m/z: 409.166

EXAMPLES

Example 1:

15 4-{4-[Phenethyl-(3-phenyl-propyl)-sulfamoyl]-4,7-diaza-spiro[2.5]oct-7-yl}-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester




20 4-(4-Phenethylsulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 6) (0.1 mmol) was dissolved in dry DMF (0.5 mL) and added Cs₂CO₃ (0.12 mmol) and bromo-ethane (0.12 mmol). Stirred at rt for 16h and then added H₂O (2 mL). Extracted with EtOAc (3 x 2 mL) and the combined organic phases were concentrated *in vacuo*. The residual oil was treated with TFA (1
25 mL) at rt for 3h. The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

1H NMR (300 MHz, DMSO) δ 12.71 (s, 1H), 8.41 (s, 1H), 7.44 (dd, J = 3.2, 1.7 Hz, 1H), 7.38 – 7.12 (m, 5H), 6.91 (d, J = 3.1 Hz, 1H), 4.26 – 4.07 (m, 2H), 3.94 (s, 2H), 3.60 – 3.43 (m, 2H), 3.42 – 3.27 (m, 2H), 3.23 (q, J = 7.1 Hz, 2H), 2.92 – 2.77 (m, 2H), 1.11 (t, J = 7.1 Hz, 3H), 1.02 (t, J = 5.9 Hz, 2H), 0.93 (t, J = 6.1 Hz, 2H).

Using this procedure the following compounds were obtained:

10 Example 2:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
cyclopropylmethyl-phenethyl-amide



15


1H NMR (300 MHz, DMSO) δ 12.75 (s, 1H), 8.42 (s, 1H), 7.45 (dd, J = 3.3, 2.3 Hz, 1H), 7.37 – 7.27 (m, 2H), 7.27 – 7.15 (m, 3H), 6.93 (d, J = 2.4 Hz, 1H), 4.38 – 4.06 (m, 2H), 3.95 (s, 2H), 3.62 – 3.48 (m, 2H), 3.47 – 3.34 (m, 2H), 3.07 (d, J = 6.9 Hz, 2H), 2.96 – 2.75 (m, 2H), 0.99 (dd, J = 26.3, 4.5 Hz, 5H), 0.63 – 0.44 (m, 2H), 0.26 (dd, J = 4.8, 1.1 Hz, 2H).

20

Example 3:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
cyclobutylmethyl-phenethyl-amide

25




1H NMR (300 MHz, DMSO) δ 12.79 (s, 1H), 8.44 (s, 1H), 7.46 (dd, J = 3.2, 2.1 Hz, 1H), 7.32 (dd, J = 10.2, 4.3 Hz, 2H), 7.27 – 7.15 (m, 3H), 6.94 (d, J = 2.7 Hz, 1H),
 5 4.26 – 4.09 (m, 2H), 3.96 (s, 2H), 3.66 – 3.44 (m, 2H), 3.37 – 3.23 (m, 2H), 3.23 – 3.14 (m, 2H), 2.88 – 2.75 (m, 2H), 2.58 (dt, J = 15.1, 7.6 Hz, 1H), 2.01 (dt, J = 8.4, 5.9 Hz, 2H), 1.79 (ddt, J = 23.8, 17.9, 8.4 Hz, 4H), 1.04 (t, J = 5.9 Hz, 2H), 0.95 (t, J = 6.1 Hz, 2H).

10

Example 4:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-oxo-butyl)-phenethyl-amide




15

1H NMR (300 MHz, DMSO) δ 12.42 (s, 1H), 8.33 (s, 1H), 7.37 (dd, J = 3.3, 1.6 Hz, 1H), 7.34 – 7.25 (m, 2H), 7.21 (dd, J = 6.8, 4.5 Hz, 3H), 6.82 (d, J = 3.2 Hz, 1H),

4.16 (s, 2H), 4.15 – 4.02 (m, 2H), 3.89 (s, 2H), 3.54 – 3.44 (m, 2H), 3.37 – 3.24 (m, 2H), 2.88 – 2.73 (m, 2H), 2.43 (q, J = 7.3 Hz, 2H), 1.08 – 0.85 (m, 7H).

Example 5:


- 5 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-hydroxy-propyl)-phenethyl-amide



- 1H NMR (300 MHz, DMSO) δ 12.23 (s, 1H), 8.28 (s, 1H), 7.36 – 7.27 (m, 3H), 7.27 – 7.17 (m, 3H), 6.78 (s, 1H), 4.09 (s, 2H), 3.88 (s, 2H), 3.45 (m, 2H), 3.41 (t, J = 6.1 Hz, 2H), 3.35 – 3.27 (m, 2H), 3.20 (dd, J = 13.1, 5.3 Hz, 2H), 3.02 – 2.69 (m, 2H), 1.82 – 1.53 (m, 2H), 1.00 (m, 2H), 0.90 (m, 2H).

Example 6:


- 15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid isobutyl-phenethyl-amide



1H NMR (300 MHz, DMSO) δ 12.76 (s, 1H), 8.43 (s, 1H), 7.46 (dd, J = 3.3, 2.3 Hz, 1H), 7.36 – 7.27 (m, 2H), 7.21 (dd, J = 9.9, 4.4 Hz, 3H), 6.94 (d, J = 2.5 Hz, 1H), 4.24 – 4.10 (m, 2H), 3.96 (d, J = 5.5 Hz, 2H), 3.58 – 3.43 (m, 2H), 3.36 – 3.21 (m, 2H), 2.99 (d, J = 7.5 Hz, 2H), 2.91 – 2.74 (m, 2H), 1.90 (dq, J = 13.7, 6.8 Hz, 1H), 1.03 (d, J = 3.9 Hz, 2H), 0.96 (t, J = 6.1 Hz, 2H), 0.88 (d, J = 6.6 Hz, 6H).

Example 7:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 10 phenethyl-propyl-amide




1H NMR (300 MHz, DMSO) δ 12.65 (s, 1H), 8.40 (s, 1H), 7.42 (dd, J = 3.2, 1.5 Hz, 1H), 7.37 – 7.27 (m, 2H), 7.27 – 7.17 (m, 3H), 6.89 (d, J = 3.2 Hz, 1H), 4.27 – 4.05 (m, 2H), 3.94 (s, 2H), 3.58 – 3.40 (m, 2H), 3.40 – 3.20 (m, 2H), 3.19 – 3.03 (m, 2H),

2.89 – 2.68 (m, 2H), 1.67 – 1.42 (m, 2H), 1.02 (t, J = 6.0 Hz, 2H), 0.93 (t, J = 6.1 Hz, 2H), 0.84 (t, J = 7.4 Hz, 3H).

Example 8:


- 5 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
cyclohexylmethyl-phenethyl-amide



- 10 ^1H NMR (300 MHz, DMSO) δ 11.90 (s, 1H), 8.19 (s, 1H), 7.61 – 7.26 (m, 2H), 7.26 – 7.17 (m, 4H), 6.66 (d, J = 2.8 Hz, 1H), 4.22 – 3.94 (m, 2H), 3.86 (s, 2H), 3.50 – 3.37 (m, 2H), 3.34 – 3.20 (m, 2H), 2.98 (d, J = 7.2 Hz, 2H), 2.91 – 2.76 (m, 2H), 1.62 (dd, J = 29.9, 11.2 Hz, 6H), 1.39 – 1.05 (m, 3H), 1.05 – 0.74 (m, 6H).

- 15 Example 18:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
diphenethylamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.36 – 7.27 (m, 4H), 7.26 – 7.14 (m, 7H), 6.58 (dd, J = 3.5, 1.7 Hz, 1H), 4.02 (s, 2H), 3.83 (s, 2H), 3.44 – 3.26 (m, 6H), 2.87 – 2.76 (m, 4H), 1.07 – 0.72 (m, 4H).

Example 19:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
cyanomethyl-phenethyl-amide

10




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.13 (s, 1H), 7.39 – 7.07 (m, 6H), 6.57 (s, 1H), 4.40 (s, 2H), 4.15 – 3.90 (m, 2H), 3.80 (s, 2H), 3.48 – 3.30 (m, 4H), 2.89 (t, J = 7.5 Hz, 2H), 1.04 – 0.77 (m, 4H).

15

Example 20:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (4-cyano-butyl)-phenethyl-amide



- 5 ^1H NMR (300 MHz, DMSO) δ 11.82 (s, 1H), 8.16 (s, 1H), 7.36 – 7.18 (m, 6H), 6.62 (dd, J = 3.5, 1.7 Hz, 1H), 4.09 – 3.97 (m, 2H), 3.84 (s, 2H), 3.43 (dd, J = 5.2, 4.6 Hz, 4H), 3.33 – 3.25 (m, 2H), 3.17 (t, J = 7.0 Hz, 2H), 2.87 – 2.78 (m, 2H), 1.76 – 1.44 (m, 4H), 1.08 – 0.81 (m, 4H).

10 Example 21:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-(tetrahydro-pyran-2-ylmethyl)-amide




- 15 ^1H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.14 (s, 1H), 7.37 – 7.26 (m, 2H), 7.26 – 7.17 (m, 4H), 6.59 (dd, J = 3.6, 1.7 Hz, 1H), 4.07 – 3.99 (m, 2H), 3.83 (s, 2H), 3.46 –

3.39 (m, 2H), 3.32 – 3.26 (m, 5H), 3.11 (t, J = 7.1 Hz, 2H), 2.88 – 2.76 (m, 2H), 2.44 (t, J = 6.8 Hz, 2H), 1.56 – 1.33 (m, 4H), 0.99 – 0.80 (m, 4H).

Example 22:


- 5 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-methoxy-ethyl)-phenethyl-amide



- 10 ¹H NMR (300 MHz, DMSO) δ 11.85 (s, 1H), 8.17 (s, 1H), 7.58 – 7.08 (m, 6H), 6.64 (dd, J = 3.5, 1.6 Hz, 1H), 4.14 – 3.96 (m, 2H), 3.85 (s, 2H), 3.46 (dd, J = 10.3, 4.6 Hz, 4H), 3.41 – 3.28 (m, 4H), 3.27 (s, 3H), 2.94 – 2.75 (m, 2H), 1.14 – 0.80 (m, 4H).

Example 23:

- 15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid but-2-ynyl-phenethyl-amide




1H NMR (300 MHz, DMSO) δ 11.80 (s, 1H), 8.16 (s, 1H), 7.42 – 7.26 (m, 2H), 7.26 – 7.17 (m, 4H), 6.61 (dd, J = 3.6, 1.7 Hz, 1H), 4.08 – 3.99 (m, 2H), 3.96 (d, J = 2.4 Hz, 2H), 3.82 (s, 2H), 3.39 (m, 4H), 2.94 – 2.76 (m, 2H), 1.81 (t, J = 2.3 Hz, 3H), 0.98 (t, J = 5.9 Hz, 2H), 0.84 (t, J = 6.1 Hz, 2H).

Example 24:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
phenethyl-(2-pyrazol-1-yl-ethyl)-amide

10




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.75 (d, J = 2.2 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.30 (t, J = 7.2 Hz, 2H), 7.24 – 7.09 (m, 4H), 6.58 (dd, J = 3.5, 1.8 Hz, 1H), 6.26 (t, J = 2.0 Hz, 1H), 4.27 (t, J = 6.2 Hz, 2H), 4.09 – 3.93 (m, 2H), 3.82 (s, 2H), 3.58 (t, J = 6.3 Hz, 2H), 3.34 (m, 2H), 3.21 – 3.09 (m, 2H), 2.73 – 2.63 (m, 2H), 1.07 – 0.73 (m, 4H).

Example 25:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-hydroxy-ethyl)-phenethyl-amide

20




¹H NMR (600 MHz, DMSO) δ 11.73 (s, 1H), 8.13 (s, 1H), 7.38 – 7.28 (m, 2H), 7.25 – 7.17 (m, 4H), 6.59 (d, J = 3.6 Hz, 1H), 4.80 (t, J = 5.3 Hz, 1H), 4.04 (s, 2H), 3.84 (s, 2H), 3.54 (q, J = 6.1 Hz, 2H), 3.46 (t, J = 5.1 Hz, 2H), 3.40 – 3.34 (m, 2H), 3.21 (t, J = 6.3 Hz, 2H), 2.87 – 2.82 (m, 2H), 1.00 (t, J = 5.6 Hz, 2H), 0.90 – 0.80 (m, 2H).

Example 46:

{Phenethyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetic acid ethyl ester

10




¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.13 (s, 1H), 7.35 – 7.13 (m, 6H), 6.58 (s, 1H), 4.13 (q, J = 7.1 Hz, 2H), 4.03 (m, 4H), 3.81 (s, 2H), 3.48 – 3.34 (m, 4H), 2.89 – 2.73 (m, 2H), 1.21 (t, J = 7.1 Hz, 3H), 0.99 – 0.80 (m, 4H).

15

Example 47:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(4-fluoro-phenyl)-ethyl]-phenethyl-amide




- 5 ¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.13 (s, 1H), 7.44 – 6.96 (m, 10H), 6.57 (dd, J = 3.6, 1.8 Hz, 1H), 4.11 – 3.96 (m, 2H), 3.82 (s, 2H), 3.41 – 3.33 (m, 6H), 2.84 (dd, J = 15.5, 8.0 Hz, 4H), 0.95 (t, J = 5.9 Hz, 2H), 0.85 (t, J = 6.0 Hz, 2H).

LC-MS (MSX13330): 2.61 min, ES (+), m/z : 535.215

10

Example 48:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3-fluoro-phenyl)-ethyl]-phenethyl-amide




15

¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.13 (s, 1H), 7.36 – 7.05 (m, 10H), 6.57 (dd, J = 3.6, 1.8 Hz, 1H), 4.02 (s, 2H), 3.83 (s, 2H), 3.41 – 3.32 (m, 4H), 2.95 – 2.72 (m, 4H), 0.95 (t, J = 5.4 Hz, 2H), 0.85 (t, J = 6.1 Hz, 2H).

5 Example 49:


N-Benzyl-2-{phenethyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetamide



- 10 ¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.45 (t, J = 5.9 Hz, 1H), 7.40 – 7.06 (m, 12H), 6.57 (dd, J = 3.6, 1.8 Hz, 1H), 4.30 (d, J = 5.9 Hz, 2H), 4.02 (m, 2H), 3.87 (s, 2H), 3.81 (s, 2H), 3.55 – 3.37 (m, 4H), 2.90 – 2.79 (m, 2H), 0.99 (t, J = 5.8 Hz, 2H), 0.81 (t, J = 5.9 Hz, 2H).

15 Example 10:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(3-phenyl-propyl)-amide




4-(4-Methylsulfonyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 4) (0.71 mmol) was dissolved in dry DMF (0.5 mL) and added Cs_2CO_3 (0.85 mmol) and (3-bromo-propyl)-benzene (0.085 mmol). Stirred at 35°C for 1.5h and then added H_2O (2 mL). Extracted with EtOAc (3 x 2 mL) and the combined organic phases were concentrated *in vacuo*. The residual oil was treated with TFA (2 mL) at rt $\rightarrow$ 45°C for 1.5h. The crude reaction mixture was concentrated *in vacuo* and redissolved in DMSO (0.5 mL). The pure compounds were obtained by standard preparative HPLC purification of the reaction mixture.

^1H NMR (300 MHz, DMSO) δ 12.28 (s, 1H), 8.30 (s, 1H), 7.56 – 7.07 (m, 6H), 6.79 (d, J = 2.0 Hz, 1H), 4.22 – 3.94 (m, 2H), 3.88 (s, 2H), 3.62 – 3.40 (m, 2H), 3.20 – 2.95 (m, 2H), 2.71 (s, 3H), 2.63 – 2.52 (m, 2H), 1.89 – 1.70 (m, 2H), 0.94 (dd, J = 21.9, 4.3 Hz, 4H).

Using this procedure the following compounds were obtained:

Example 11:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-cyclohexyl-ethyl)-methyl-amide



1H NMR (300 MHz, DMSO) δ 12.07 (s, 1H), 8.24 (s, 1H), 7.29 (dd, J = 3.4, 2.4 Hz, 1H), 6.72 (dd, J = 3.5, 1.6 Hz, 1H), 4.23 – 3.99 (m, 2H), 3.87 (s, 2H), 3.59 – 3.46 (m, 2H), 3.16 – 2.96 (m, 2H), 2.67 (s, 3H), 1.77 – 1.53 (m, 5H), 1.40 (dd, J = 14.7, 6.9 Hz, 2H), 1.30 – 1.10 (m, 4H), 1.07 – 0.76 (m, 6H).

Example 12:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-
10 (2-oxo-2-phenyl-ethyl)-amide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 8.03 – 7.93 (m, 2H), 7.68 (t, J = 7.3 Hz, 1H), 7.56 (t, J = 7.6 Hz, 2H), 7.31 – 7.11 (m, 1H), 6.74 – 6.53 (m, 1H), 4.77 (s, 2H), 4.25 – 3.93 (m, 2H), 3.85 (s, 2H), 3.65 – 3.45 (m, 2H), 2.81 (s, 3H), 1.06 (t, J = 5.8 Hz, 2H), 0.87 (t, J = 6.0 Hz, 2H).

Example 13:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-benzyl)-methyl-amide

5




¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.85 – 7.73 (m, 2H), 7.71 – 7.51 (m, 2H), 7.20 (dd, J = 3.5, 2.5 Hz, 1H), 6.60 (dd, J = 3.6, 1.8 Hz, 1H), 4.35 (s, 2H), 4.15 – 3.96 (m, 2H), 3.87 (s, 2H), 3.73 – 3.50 (m, 2H), 2.64 (s, 3H), 1.03 (t, J = 5.9 Hz, 2H), 0.91 (s, 2H).

10

Example 14:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-cyano-benzyl)-methyl-amide

15




¹H NMR (300 MHz, DMSO) δ 11.83 (s, 1H), 8.17 (s, 1H), 7.87 (d, J = 7.7 Hz, 1H), 7.77 (t, J = 7.6 Hz, 1H), 7.66 – 7.46 (m, 2H), 7.22 (s, 1H), 6.64 (s, 1H), 4.49 (s, 2H), 4.08 (s, 2H), 3.87 (s, 2H), 3.72 – 3.53 (m, 2H), 2.71 (s, 3H), 1.05 – 0.96 (m, 2H), 0.96 – 0.85 (m, 2H).

5

Example 15:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
cyclohexylmethyl-methyl-amide




10

¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.23 – 7.11 (m, 1H), 6.59 (dd, J = 3.5, 1.7 Hz, 1H), 4.12 – 3.94 (m, 2H), 3.83 (s, 2H), 3.58 – 3.40 (m, 2H), 2.89 (d, J = 7.2 Hz, 2H), 2.65 (s, 3H), 1.60 (ddd, J = 13.7, 11.1, 7.8 Hz, 5H), 1.32 – 1.06 (m, 4H), 1.08 – 0.74 (m, 6H).

15

Example 16:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(4-fluoro-phenyl)-ethyl]-methyl-amide



1H NMR (300 MHz, DMSO) δ 11.88 (s, 1H), 8.17 (s, 1H), 7.34 – 7.19 (m, 3H), 7.18 – 7.03 (m, 2H), 6.63 (dd, J = 3.5, 1.7 Hz, 1H), 4.18 – 3.88 (m, 2H), 3.82 (s, 2H), 3.48 – 3.38 (m, 2H), 3.35 – 3.21 (m, 2H), 2.87 – 2.77 (m, 2H), 2.71 (s, 3H), 1.02 – 0.89 (m, 2H), 0.89 – 0.79 (m, 2H).

Example 17:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3-fluoro-phenyl)-ethyl]-methyl-amide



1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.35 (td, J = 8.0, 6.3 Hz, 1H), 7.18 (dd, J = 3.5, 2.5 Hz, 1H), 7.14 – 7.00 (m, 3H), 6.57 (dd, J = 3.6, 1.8 Hz, 1H), 4.06 – 3.93 (m, 2H), 3.81 (s, 2H), 3.50 – 3.36 (m, 2H), 3.37 – 3.17 (m, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.71 (s, 3H), 0.97 – 0.88 (m, 2H), 0.88 – 0.79 (m, 2H).

Example 26:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(2-pyrrol-1-yl-ethyl)-amide




5

^1H NMR (300 MHz, DMSO) δ 11.82 (s, 1H), 8.16 (s, 1), 7.22 (dd, J = 3.4, 2.5 Hz, 1H), 6.77 (t, J = 2.1 Hz, 2H), 6.61 (dd, J = 3.5, 1.6 Hz, 1H), 6.01 (t, J = 2.1 Hz, 2H), 4.17 – 3.94 (m, 4H), 3.82 (s, 2H), 3.46 – 3.31 (m, 4H), 2.55 (s, 3H), 1.01 – 0.78 (m, 4H).

10

Example 27:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(3-methyl-butyl)-amide




15

^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.5, 2.6 Hz, 1H), 6.59 (dd, J = 3.6, 1.8 Hz, 1H), 4.10 – 3.97 (m, 2H), 3.83 (s, 2H), 3.58 – 3.47 (m, 2H), 3.12 – 3.00 (m, 2H), 2.67 (s, 3H), 1.64 – 1.47 (m, 1H), 1.39 (dd, J = 14.6, 7.1 Hz, 2H), 0.99 (t, J = 6.0 Hz, 2H), 0.88 (d, J = 6.6 Hz, 8H).

Example 28:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-pyridin-2-ylmethyl-amide




5

¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.54 (d, J = 4.9 Hz, 1H), 8.26 (s, 1H), 7.83 (td, J = 7.7, 1.8 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.36 – 7.27 (m, 1H), 7.24 – 7.15 (m, 1H), 6.60 (dd, J = 3.6, 1.8 Hz, 1H), 4.37 (s, 2H), 4.14 – 4.00 (m, 2H), 3.86 (s, 2H), 3.63 – 3.54 (m, 2H), 2.73 (s, 3H), 1.05 – 1.00 (m, 2H), 0.94 – 0.82 (m, 2H).

10

Example 29:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [3-(4-cyano-phenyl)-propyl]-methyl-amide



¹H NMR (300 MHz, DMSO) δ 11.93 (s, 1H), 8.20 (s, 1H), 7.83 – 7.67 (m, 2H), 7.45 (d, J = 8.3 Hz, 2H), 7.32 – 7.16 (m, 1H), 6.67 (d, J = 1.9 Hz, 1H), 4.21 – 3.97 (m, 2H), 3.84 (s, 2H), 3.59 – 3.45 (m, 2H), 3.15 – 3.00 (m, 2H), 2.76 – 2.61 (m, 5H), 1.91 – 1.74 (m, 2H), 0.92 (dt, J = 11.8, 7.6 Hz, 4H).

Example 30:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [3-(3-cyano-phenyl)-propyl]-methyl-amide



1H NMR (300 MHz, DMSO) δ 11.96 (s, 1H), 8.21 (s, 1H), 7.73 (s, 1H), 7.65 (ddd, J = 19.4, 10.4, 4.6 Hz, 2H), 7.50 (t, J = 7.7 Hz, 1H), 7.26 (dd, J = 3.4, 2.5 Hz, 1H), 6.68 (dd, J = 3.5, 1.6 Hz, 1H), 4.20 – 3.99 (m, 2H), 3.85 (s, 2H), 3.60 – 3.41 (m, 2H), 3.21 – 2.97 (m, 2H), 2.71 (s, 3H), 2.69 – 2.57 (m, 2H), 1.97 – 1.73 (m, 2H), 0.92 (dt, J = 12.1, 7.7 Hz, 4H).

Example 31:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(2-phenoxy-ethyl)-amide




10

1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.36 – 7.24 (m, 2H), 7.19 (dd, J = 3.5, 2.5 Hz, 1H), 7.02 – 6.89 (m, 3H), 6.59 (dd, J = 3.6, 1.8 Hz, 1H), 4.12 (t, J = 5.5 Hz, 2H), 4.09 – 4.00 (m, 2H), 3.85 (s, 2H), 3.61 – 3.52 (m, 2H), 3.46 (t, J = 5.5 Hz, 2H), 2.82 (s, 3H), 1.03 (t, J = 5.9 Hz, 2H), 0.86 (q, J = 5.2 Hz, 2H).

15

Example 32:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3,5-dimethyl-isoxazol-4-yl)-ethyl]-methyl-amide



1H NMR (300 MHz, DMSO) δ 11.91 (s, 1H), 8.19 (s, 1H), 7.30 – 7.22 (m, 1H), 6.73 – 6.61 (m, 1H), 4.12 – 3.97 (m, 2H), 3.84 (s, 2H), 3.53 – 3.43 (m, 2H), 3.16 (t, J = 7.3 Hz, 2H), 2.74 (s, 3H), 2.57 (t, J = 7.3 Hz, 2H), 2.31 (s, 3H), 2.16 (s, 3H), 1.08 – 0.76 (m, 4H).

Example 33:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-phenethyl-amide



1H NMR (600 MHz, DMSO) δ 11.73 (s, 1H), 8.13 (s, 1H), 7.31 (dd, J = 10.4, 4.6 Hz, 2H), 7.23 (dd, J = 16.0, 7.4 Hz, 3H), 7.19 (dd, J = 3.4, 2.6 Hz, 1H), 6.59 (dd, J = 3.6, 1.9 Hz, 1H), 4.04 (dd, J = 8.4, 5.7 Hz, 2H), 3.83 (s, 2H), 3.42 (t, J = 5.1 Hz, 2H), 3.36 – 3.30 (m, 2H), 3.26 – 3.15 (m, 2H), 2.86 – 2.79 (m, 2H), 2.47 (t, J = 7.1 Hz, 2H), 1.86 – 1.76 (m, 2H), 0.98 (t, J = 5.5 Hz, 2H), 0.85 (d, J = 15.3 Hz, 2H).

Example 34:

{Methyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetic acid methyl ester



5

4-(4-Methylsulfonyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-

carboxylic acid tert-butyl ester (intermediate 4) (0.047 mmol) was dissolved in dry DMF (0.5 mL) and added Cs₂CO₃ (0.071 mmol) and chloroacetic acid methyl ester (0.071

10

mmol). Stirred at 40°C for 2h and then added H₂O (1.5 mL). Extracted with EtOAc (3 x 1 mL) and the combined organic phases were washed with brine (1 mL) and concentrated *in vacuo*. The residual oil was treated with TFA (1 mL) at rt for 1h. The crude reaction mixture was concentrated *in vacuo* and redissolved in DMSO (0.5 mL).

The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

15

¹H NMR (300 MHz, DMSO) δ 12.24 (s, 1H), 8.29 (s, 1H), 7.41 – 7.28 (m, 1H), 6.83 – 6.74 (m, 1H), 4.13 – 4.05 (m, 2H), 4.01 (s, 2H), 3.88 (s, 2H), 3.68 (s, 3H), 3.62 – 3.54 (m, 2H), 2.81 (s, 3H), 1.07 (dd, J = 8.9, 2.9 Hz, 2H), 0.96 – 0.82 (m, 2H).


20

Using this procedure the following compounds were obtained:

Example 35:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-methyl-amide


25



1H NMR (300 MHz, DMSO) δ 12.06 (s, 1H), 8.24 (s, 1H), 7.47 – 7.14 (m, 1H), 6.72 (dd, J = 3.4, 1.6 Hz, 1H), 4.17 – 4.03 (m, 2H), 3.87 (s, 2H), 3.60 – 3.50 (m, 2H), 3.21 – 3.08 (m, 2H), 2.71 (s, 3H), 2.55 – 2.40 (m, 2H), 1.82 (p, J = 7.2 Hz, 2H), 1.13 – 0.77 (m, 4H).

Example 36:

N,N-Dimethyl-2-{methyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetamide




1H NMR (300 MHz, DMSO) δ 11.98 (s, 1H), 8.21 (s, 1H), 7.38 – 7.10 (m, 1H), 6.80 – 6.57 (m, 1H), 4.07 (m, 2H), 4.02 (s, 2H), 3.86 (s, 2H), 2.93 (s, 3H), 2.89 (s, 2H), 2.83 (s, 3H), 2.73 (s, 3H), 1.13 – 1.05 (m, 2H), 0.90 – 0.80 (m, 2H).

LC-MS (MSX13351): 1.74 min, ES (+), m/z: 408.177

Example 59:

N-(cyclopropylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




5 ^1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.2 Hz, 1H), 6.59 (dd, J = 3.7, 1.6 Hz, 1H), 4.04 (dd, J = 6.1, 4.2 Hz, 2H), 3.84 (s, 2H), 3.54 (dd, J = 6.5, 3.8 Hz, 2H), 2.95 (d, J = 6.9 Hz, 2H), 2.77 (s, 3H), 1.10 – 0.78 (m, 5H), 0.55 – 0.43 (m, 2H), 0.26 – 0.12 (m, 2H).

10 LC-MS: 2.10 min, ES (+), m/z : 377.170

Example 60:

N-(cyclobutylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



15

^1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.2 Hz, 1H), 6.59 (dd, J = 3.7, 1.7 Hz, 1H), 4.15 – 3.96 (m, 2H), 3.84 (s, 2H), 3.53 (dd, J = 6.4, 4.0 Hz, 2H), 3.08 (d, J = 7.4 Hz, 2H), 2.64 (s, 3H), 2.12 – 1.93 (m, 2H), 1.77 (m, 4H), 1.05 – 0.76 (m, 4H).


20

LC-MS: 2.24 min, ES (+), m/z : 391.193

Example 61:

N-cyclopentyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

25



¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.39 – 7.03 (m, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.04 (t, J = 5.2 Hz, 2H), 3.83 (s, 2H), 3.51 (dd, J = 6.3, 4.0 Hz, 2H), 2.61 (s, 3H), 1.86 – 1.42 (m, 8H), 1.07 – 0.75 (m, 4H).


5

LC-MS: 2.21 min, ES (+), m/z : 391.190

Example 62:

N-[(4,4-difluorocyclohexyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

10



¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.7 Hz, 1H), 4.05 (dd, J = 6.5, 3.8 Hz, 2H), 3.84 (s, 2H), 3.53 (dd, J = 6.3, 3.9 Hz, 2H), 2.98 (d, J = 6.9 Hz, 2H), 2.68 (s, 3H), 2.16 – 1.64 (m, 7H), 1.29 – 1.06 (m, 2H), 1.04 – 0.81 (m, 4H).


15

LC-MS: 2.24 min, ES (+), m/z : 455.199

Example 63:

N-methyl-N-(2-phenylpropyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide


20



LC-MS: 2.33 min, ES (+), m/z: 441.206

Example 64:


- 5 N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydropyran-2-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



LC-MS: 2.11 min, ES (+), m/z: 421.194

10 Example 65:

- N-[[5-(dimethylsulfamoyl)-2-furyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 15 ¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.4 Hz, 1H), 7.16 (d, J = 3.5 Hz, 1H), 6.66 (d, J = 3.5 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.38 (s, 2H), 4.09 – 3.99 (m, 2H), 3.85 (s, 2H), 3.57 (d, J = 5.1 Hz, 2H), 2.73 (s, 6H), 2.70 (s, 3H), 1.14 – 0.77 (m, 4H).

LC-MS: 2.08 min, ES (+), m/z: 510.156

Example 66:

N-methyl-N-(2-pyrazol-1-ylethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 5 ^1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.19 (dd, J = 3.7, 2.3 Hz, 1H), 6.57 (dd, J = 3.7, 1.7 Hz, 1H), 6.25 (t, J = 2.1 Hz, 1H), 4.29 (t, J = 6.1 Hz, 2H), 4.07 – 3.94 (m, 2H), 3.81 (s, 2H), 3.47 (t, J = 6.1 Hz, 3H), 3.41 (s, 3H), 2.58 (s, 3H), 1.10 – 0.75 (m, 4H).

- 10 LC-MS: 1.86 min, ES (+), m/z : 417.184

Example 67:

N-methyl-N-[(3-methylisoxazol-5-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 15 ^1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.6, 2.3 Hz, 1H), 6.60 (dd, J = 3.6, 1.7 Hz, 1H), 6.33 (s, 1H), 4.41 (s, 2H), 4.12 – 3.99 (m, 2H), 3.84 (s, 2H), 3.61 – 3.47 (m, 2H), 2.73 (s, 3H), 2.23 (s, 3H), 1.08 – 0.81 (m, 4H).

- 20 LC-MS: 1.96 min, ES (+), m/z : 418.145

Example 68:

N-(isoxazol-5-ylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.55 (d, J = 1.9 Hz, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.4 Hz, 1H), 6.60 (dd, J = 3.7, 1.8 Hz, 1H), 6.48 (d, J = 1.8 Hz, 1H), 4.49 (s, 2H), 4.04 (d, J = 5.2 Hz, 2H), 3.84 (s, 2H), 3.58 – 3.51 (m, 2H), 2.74 (s, 3H), 1.10 – 0.77 (m, 4H).

LC-MS: 1.91 min, ES (+), m/z : 404.146

Example 69:

- 10 N-[2-(4-chlorophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.49 – 7.27 (m, 2H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 7.08 – 6.86 (m, 2H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.12 (t, J = 5.4 Hz, 2H), 4.03 (d, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.57 (d, J = 5.5 Hz, 2H), 3.45 (d, J = 5.7 Hz, 2H), 2.80 (s, 3H), 1.12 – 0.77 (m, 4H).

LC-MS: 2.36 min, ES (+), m/z : 477.142

- 20 Example 70:

N-[2-(2-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.75 (dd, J = 7.6, 1.7 Hz, 1H), 7.73 – 7.63 (m, 1H), 7.29 (d, J = 8.5 Hz, 1H), 7.19 (dd, J = 3.6, 2.2 Hz, 1H), 7.17 – 7.08 (m, 1H), 6.58 (dd, J = 3.4, 1.9 Hz, 1H), 4.30 (t, J = 5.1 Hz, 2H), 4.05 (t, J = 5.1 Hz, 2H), 3.85 (s, 2H), 3.56 (d, J = 5.0 Hz, 4H), 2.89 (s, 3H), 1.19 – 0.77 (m, 4H).

LC-MS: 2.15 min, ES (+), m/z : 468.179

10 Example 71:

N-[2-(3-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.56 – 7.45 (m, 2H), 7.42 (dt, J = 7.3, 1.2 Hz, 1H), 7.32 (ddd, J = 8.4, 2.6, 1.2 Hz, 1H), 7.19 (dd, J = 3.5, 2.1 Hz, 1H), 6.59 (dd, J = 3.6, 1.6 Hz, 1H), 4.20 (t, J = 5.4 Hz, 2H), 4.05 (t, J = 5.1 Hz, 2H), 3.85 (s, 2H), 3.56 (dd, J = 6.2, 3.8 Hz, 2H), 3.48 (t, J = 5.4 Hz, 2H), 2.81 (s, 3H), 1.10 – 0.81 (m, 4H).

20 LC-MS: 2.18 min, ES (+), m/z : 468.186

Example 72:

N-[2-(4-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.15 (s, 1H), 7.90 – 7.63 (m, 2H), 7.20 (dd, J = 3.6, 2.2 Hz, 1H), 7.18 – 7.11 (m, 2H), 6.59 (dd, J = 3.7, 1.7 Hz, 1H), 4.23 (t, J = 5.2 Hz, 2H), 4.05 (dd, J = 6.3, 3.8 Hz, 2H), 3.85 (s, 2H), 3.56 (dd, J = 6.2, 3.9 Hz, 2H), 3.50 (t, J = 5.4 Hz, 2H), 2.81 (s, 3H), 1.15 – 0.78 (m, 4H).

LC-MS: 2.15 min, ES (+), m/z : 468.172

Example 73:

- 10 N-(cyclopentylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.04 (dd, J = 6.3, 3.9 Hz, 2H), 3.83 (s, 2H), 3.52 (dd, J = 6.3, 3.9 Hz, 2H), 2.96 (d, J = 7.6 Hz, 2H), 2.68 (s, 3H), 2.13 (h, J = 7.5 Hz, 1H), 1.75 – 1.40 (m, 6H), 1.29 – 1.11 (m, 2H), 1.06 – 0.80 (m, 4H).

LC-MS: 2.33 min, ES (+), m/z : 405.184

- 20 Example 74:

N-(2-cyclopentylethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.7, 2.1 Hz, 1H), 6.60 (dd, J = 3.7, 1.5 Hz, 1H), 4.05 (dd, J = 6.1, 3.8 Hz, 2H), 3.84 (s, 2H), 3.53 (dd, J = 6.4, 3.9 Hz, 2H), 3.11 – 2.97 (m, 2H), 2.68 (s, 3H), 1.82 – 1.62 (m, 3H), 1.63 – 1.41 (m, 6H), 1.07 (m, 2H), 1.02 – 0.83 (m, 4H).

LC-MS: 2.45 min, ES (+), m/z : 419.191

Example 75:

- 10 N-[2-(1,1-dioxothiolan-3-yl)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.2 Hz, 1H), 6.59 (dd, J = 3.7, 1.7 Hz, 1H), 4.05 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.54 (dd, J = 6.4, 3.9 Hz, 2H), 3.40 – 2.94 (m, 6H), 2.69 (s, 3H), 2.30 (dq, J = 9.0, 5.5, 4.4 Hz, 2H), 1.82 – 1.58 (m, 3H), 1.10 – 0.76 (m, 4H).

LC-MS: 1.85 min, ES (+), m/z : 469.169

- 20 Example 76:

N-[(1,1-dioxothian-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.7, 2.3 Hz, 1H), 6.60 (dd, J = 3.6, 1.7 Hz, 1H), 4.05 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.53 (t, J = 5.1 Hz, 2H), 3.17 – 2.86 (m, 6H), 2.69 (s, 3H), 2.22 (m, 1H), 2.12 – 1.99 (m, 1H), 1.89 – 1.68 (m, 2H), 1.22 (qd, J = 13.3, 3.5 Hz, 1H), 1.07 – 0.82 (m, 4H).

LC-MS: 1.83 min, ES (+), m/z : 469.138

Example 77:

- 10 N-[(2-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.50 – 7.31 (m, 2H), 7.31 – 7.13 (m, 3H), 6.60 (dd, J = 3.7, 1.7 Hz, 1H), 4.33 (s, 2H), 4.06 (dd, J = 6.4, 3.9 Hz, 2H), 3.86 (s, 2H), 3.56 (dd, J = 6.2, 3.9 Hz, 2H), 2.64 (s, 3H), 1.06 – 0.81 (m, 4H).

LC-MS: 2.24 min, ES (+), m/z : 431.166

Example 78:

- 20 N-[(3-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.15 (s, 1H), 7.44 (ddd, J = 9.0, 7.5, 6.0 Hz, 1H), 7.31 – 7.01 (m, 4H), 6.61 (dd, J = 3.8, 1.8 Hz, 1H), 4.30 (s, 2H), 4.08 (t, J = 5.1 Hz, 2H), 3.87 (s, 2H), 3.59 (dd, J = 6.5, 4.0 Hz, 2H), 2.63 (s, 3H), 1.11 – 0.82 (m, 4H).

LC-MS: 2.25 min, ES (+), m/z : 431.162

Example 79:

- 10 N-[(4-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.15 (s, 1H), 7.37 (dd, J = 8.6, 5.6 Hz, 2H), 7.28 – 7.11 (m, 3H), 6.61 (dd, J = 3.7, 1.7 Hz, 1H), 4.26 (s, 2H), 4.07 (dd, J = 6.5, 3.8 Hz, 2H), 3.87 (s, 2H), 3.59 (dd, J = 6.3, 3.9 Hz, 2H), 2.59 (s, 3H), 1.09 – 0.85 (m, 4H).

LC-MS: 2.24 min, ES (+), m/z : 431.163

- 20 Example 80:

N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.15 (s, 1H), 7.46 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 8.3 Hz, 2H), 7.20 (dd, J = 3.6, 2.3 Hz, 1H), 6.60 (dd, J = 3.7, 1.8 Hz, 1H), 4.31 (s, 2H), 4.08 (t, J = 5.1 Hz, 2H), 3.87 (s, 2H), 3.59 (dd, J = 6.3, 3.9 Hz, 2H), 2.62 (s, 3H), 1.11 – 0.83 (m, 4H).

LC-MS: 2.42 min, ES (+), m/z : 497.153

Example 81:

- 10 N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[[4-(trifluoromethyl)phenyl]methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.15 (s, 1H), 7.76 (d, J = 8.0 Hz, 2H), 7.56 (d, J = 8.0 Hz, 2H), 7.20 (dd, J = 3.6, 2.3 Hz, 1H), 6.61 (dd, J = 3.5, 1.7 Hz, 1H), 4.39 (s, 2H), 4.08 (dd, J = 6.4, 3.8 Hz, 2H), 3.88 (s, 2H), 3.60 (dd, J = 6.2, 3.9 Hz, 2H), 2.64 (s, 3H), 1.10 – 0.86 (m, 4H).

LC-MS: 2.38 min, ES (+), m/z : 481.159

- 20 Example 82:

N-(2-cyclopropylethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.5, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.04 (t, J = 5.3 Hz, 2H), 3.84 (s, 2H), 3.58 – 3.41 (m, 2H), 3.18 – 3.06 (m, 2H), 2.69 (s, 3H), 1.48 – 1.34 (m, 2H), 1.05 – 0.81 (m, 4H),
5 0.70 – 0.56 (m, 1H), 0.47 – 0.35 (m, 2H), 0.09 – 0.02 (m, 2H).

LC-MS: 2.21 min, ES (+), m/z : 391.185

Example 83:

- 10 N-methyl-N-[(4-methylsulfonylphenyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.15 (s, 1H), 7.99 – 7.89 (m, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 3.6 Hz, 1H), 6.61 (d, J = 3.7 Hz, 1H), 4.41 (s, 2H), 4.09
15 (d, J = 5.5 Hz, 2H), 3.87 (s, 2H), 3.60 (t, J = 5.1 Hz, 2H), 3.22 (s, 3H), 2.66 (s, 3H), 1.10 – 0.88 (m, 4H).

LC-MS: 1.98 min, ES (+), m/z : 491.153

- 20 Example 84:

N-[(4-tert-butylcyclohexyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (dd, J = 3.6, 2.4 Hz, 1H), 6.59 (dd, J = 3.6, 1.7 Hz, 1H), 4.04 (t, J = 5.2 Hz, 2H), 3.83 (s, 2H), 3.61 – 3.44 (m, 2H), 2.87 (d, J = 7.2 Hz, 2H), 2.65 (s, 3H), 1.76 (d, J = 9.4 Hz, 4H), 1.54 – 1.40 (m, 1H), 1.14 – 0.68 (m, 18H).

LC-MS: 2.83 min, ES (+), m/z : 475.286

Example 85:

- 10 N-[(3,3-difluorocyclobutyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.75 – 11.69 (m, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.7 Hz, 1H), 4.05 (dd, J = 6.5, 3.9 Hz, 2H), 3.84 (s, 2H), 3.53 (dd, J = 6.3, 3.9 Hz, 2H), 3.20 (d, J = 6.7 Hz, 2H), 2.69 (m, 5H), 2.50 – 2.21 (m, 3H), 1.04 – 0.82 (m, 4H).

LC-MS: 2.14 min, ES (+), m/z : 427.168

- 20 Example 86:

N-[(2,2-difluorocyclopropyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.4, 1.5 Hz, 1H), 6.59 (d, J = 3.5 Hz, 1H), 4.04 (dd, J = 6.7, 3.7 Hz, 2H), 3.84 (s, 2H), 3.55 (dd, J = 6.3, 4.1 Hz, 2H), 3.09 (ddd, J = 14.5, 7.7, 1.4 Hz, 1H), 2.74 (s, 3H), 2.08 – 1.86 (m, 1H), 1.66 (tdd, J = 12.2, 7.8, 4.8 Hz, 1H), 1.30 (dtd, J = 13.7, 7.7, 3.9 Hz, 1H), 1.07 – 0.82 (m, 4H).

LC-MS: 2.10 min, ES (+), m/z : 413.151

10 Example 87:

N-methyl-N-[(4-methylenecyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.7, 2.1 Hz, 1H), 6.59 (dd, J = 3.7, 1.5 Hz, 1H), 4.61 (t, J = 1.6 Hz, 2H), 4.04 (dd, J = 6.3, 3.8 Hz, 2H), 3.83 (s, 2H), 3.52 (dd, J = 6.2, 3.9 Hz, 2H), 2.93 (d, J = 6.8 Hz, 2H), 2.68 (s, 3H), 2.26 (dt, J = 13.4, 3.6 Hz, 2H), 1.99 (td, J = 13.3, 12.7, 3.8 Hz, 2H), 1.76 (ddq, J = 13.4, 10.2, 3.5 Hz, 3H), 1.05 – 0.80 (m, 6H).

20 LC-MS: 2.42 min, ES (+), m/z : 431.226

Example 88:


N-methyl-N-[(3-oxocyclobutyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



LC-MS: 2.13 min, ES (+), m/z: 405.169

Example 89:

- 5 N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydropyran-4-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 10 ¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.7, 2.2 Hz, 1H), 6.59 (dd, J = 3.6, 1.6 Hz, 1H), 4.05 (dd, J = 6.2, 3.8 Hz, 2H), 3.91 – 3.75 (m, 4H), 3.53 (dd, J = 6.1, 3.9 Hz, 2H), 3.31 – 3.19 (m, 2H), 2.95 (d, J = 7.2 Hz, 2H), 2.68 (s, 3H), 1.81 (ddh, J = 15.1, 7.6, 3.7 Hz, 1H), 1.55 (ddd, J = 12.6, 3.7, 1.9 Hz, 2H), 1.24 – 1.04 (m, 2H), 1.03 – 0.79 (m, 4H).

LC-MS: 1.94 min, ES (+), m/z: 421.195

15

Example 90:

- N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[(3-sulfamoylphenyl)methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide



¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.85 – 7.72 (m, 2H), 7.66 – 7.49 (m, 2H), 7.20 (d, J = 3.5 Hz, 1H), 6.60 (d, J = 3.6 Hz, 1H), 4.36 (s, 2H), 4.08 (t, J = 5.1 Hz, 2H), 3.87 (s, 2H), 3.59 (t, J = 5.1 Hz, 2H), 2.65 (s, 3H), 1.18 – 0.79 (m, 4H).


5

LC-MS: 1.91 min, ES (+), m/z : 492.142

Example 91:

N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[(4-sulfamoylphenyl)methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide

10



¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.88 – 7.78 (m, 2H), 7.51 (d, J = 8.1 Hz, 2H), 7.35 (s, 2H), 7.24 – 7.15 (m, 1H), 6.65 – 6.56 (m, 1H), 4.36 (s, 2H), 4.08 (t, J = 5.2 Hz, 2H), 3.87 (s, 2H), 3.60 (t, J = 5.1 Hz, 2H), 2.63 (s, 3H), 1.09 – 0.82 (m, 4H).


15

LC-MS: 1.89 min, ES (+), m/z : 492.153

Example 92:

N-[[1-(difluoromethyl)-3H-pyrazol-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

20




¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.21 (d, J = 2.7 Hz, 1H), 8.14 (s, 1H), 7.78 (t, J = 59.1 Hz, 1H), 7.19 (dd, J = 3.7, 2.3 Hz, 1H), 6.60 (dd, J = 3.6, 1.7 Hz, 1H), 6.48 (d, J = 2.7 Hz, 1H), 4.28 (s, 2H), 4.06 (dd, J = 6.4, 3.8 Hz, 2H), 3.86 (s, 2H), 3.57 (m, 2H), 2.68 (s, 3H), 1.08 – 0.80 (m, 4H).

25

LC-MS: 2.02 min, ES (+), m/z: 453.159

Example 93:

5 N-[[1-(2,2-difluoroethyl)-3H-pyrazol-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.75 (d, J = 2.2 Hz, 1H), 7.19 (dd, J = 3.6, 2.4 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 6.32 (tt, J = 55.0, 3.8 Hz, 1H), 6.27 (d, J = 2.3 Hz, 1H), 4.59 (td, J = 15.1, 3.8 Hz, 2H), 4.19 (s, 2H), 4.05 (t, J = 5.1 Hz, 2H), 3.85 (s, 2H), 3.61 – 3.48 (m, 2H), 2.64 (s, 3H), 1.12 – 0.78 (m, 4H).

LC-MS: 1.97 min, ES (+), m/z: 467.165

Example 177:

15 N-[(4-cyanocuban-1-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




20 1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.7 Hz, 1H), 4.31 – 4.17 (m, 3H), 4.04 (t, J = 5.2 Hz, 2H), 3.98 (dd, J = 5.8, 4.0 Hz, 3H), 3.84 (s, 2H), 3.53 (dd, J = 6.4, 3.9 Hz, 2H), 3.34 (s, 2H), 2.69 (s, 3H), 1.07 – 0.76 (m, 4H).

LC-MS: 2.12 min, ES (+), m/z: 464.180

25 Example 183:

N-methyl-N-[[[(2S)-5-oxopyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.66 (s, 1H), 7.19 (dd, J = 3.7, 2.2 Hz, 1H), 6.59 (dd, J = 3.6, 1.7 Hz, 1H), 4.05 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.77 – 3.67 (m, 1H), 3.54 (t, J = 5.1 Hz, 2H), 3.16 – 2.96 (m, 2H), 2.74 (s, 3H), 2.18 – 2.03 (m, 3H), 1.82 – 1.67 (m, 1H), 1.01 – 0.85 (m, 4H).

LC-MS: 1.70 min, ES (+), m/z: 420.181

Example 184:

- 10 N-methyl-N-[[[(2R)-5-oxopyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.66 (s, 1H), 7.19 (dd, J = 3.7, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.05 (t, J = 5.2 Hz, 2H), 3.84 (s, 2H), 3.77 – 3.68 (m, 1H), 3.54 (t, J = 5.0 Hz, 2H), 3.15 – 2.97 (m, 2H), 2.74 (s, 3H), 2.22 – 2.04 (m, 3H), 1.80 – 1.70 (m, 1H), 1.04 – 0.82 (m, 4H).

LC-MS: 1.70 min, ES (+), m/z: 420.182

- 20 Example 37:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (4-cyano-benzyl)-methyl-amide




4-(4-Methylsulfonyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 4) (0.237 mmol) was dissolved in dry DMF (2 mL) and added Cs_2CO_3 (0.35 mmol) and 4-bromomethyl-benzonitrile (0.35 mmol). Stirred at rt for 16h and then added H_2O (10 mL). Extracted with EtOAc (3 x 10 mL) and the combined organic phases were concentrated *in vacuo*. Purified by flash chromatography on silica using a gradient of heptane to EtOAc as eluent. The obtained compound was treated with TFA (2 mL) at rt for 2h. The crude reaction mixture was added sat. Na_2CO_3 to pH=7 and the extracted with EtOAc (3 x 10 mL). the combined organic phases was washes with brine (10 mL), dried (Na_2SO_4), filtered and concentrated *in vacuo*. The pure compound was obtained by trituration using CH_2Cl_2 .

^1H NMR (600 MHz, DMSO) δ 11.75 (s, 1H), 8.14 (s, 1H), 7.87 (d, $J = 8.3$ Hz, 2H), 7.53 (d, $J = 8.3$ Hz, 2H), 7.20 (dd, $J = 3.4, 2.6$ Hz, 1H), 6.61 (dd, $J = 3.6, 1.9$ Hz, 1H), 4.39 (s, 2H), 4.07 (s, 2H), 3.87 (s, 2H), 3.64 – 3.53 (m, 2H), 2.64 (s, 3H), 1.03 (t, $J = 5.7$ Hz, 2H), 0.91 (q, $J = 5.4$ Hz, 2H).

Example 38:

4-[4-(Piperidine-1-sulfonyl)-4,7-diaza-spiro[2.5]oct-7-yl]-7H-pyrrolo[2,3-d]pyrimidine

132




A solution of 1-(imidazole-1-sulfonyl)-piperidine (intermediate 13) (0.047 mmol) in dry CH_2Cl_2 (1 mL) was cooled to 0°C and added trifluoro-methanesulfonic acid methyl ester (0.047 mmol). The reaction mixture was allowed to warm up freely to rt over a period of 4h and then concentrated *in vacuo*. The residual oil was redissolved in dry CH_3CN (1.5 mL), added a solution of 4-(4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine (intermediate 21) (0.047 mmol) in DMSO (1 mL) and then stirred at 50°C for 3h. The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (d, $J = 1.4$ Hz, 1H), 7.28 – 7.13 (m, 1H), 6.59 (dd, $J = 3.7, 1.9$ Hz, 1H), 4.09 – 3.97 (m, 2H), 3.82 (s, 2H), 3.59 – 3.50 (m, 2H), 3.01 (d, $J = 5.2$ Hz, 4H), 1.65 – 1.41 (m, 6H), 1.03 (t, $J = 5.9$ Hz, 2H), 0.86 (t, $J = 6.1$ Hz, 2H).

Using this procedure the following compounds were obtained:

Example 39:

1-[7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-piperidine-4-carbonitrile




^1H NMR (300 MHz, DMSO) δ 11.75 (s, 1H), 8.14 (s, 1H), 7.20 (dd, $J = 3.5, 2.6$ Hz, 1H), 6.60 (dd, $J = 3.6, 1.8$ Hz, 1H), 4.20 – 3.92 (m, 2H), 3.82 (s, 2H), 3.62 – 3.48 (m,

2H), 3.23 (m, 3H), 2.99 (m, 2H), 1.93 (m, 2H), 1.82 – 1.64 (m, 2H), 1.04 (t, J = 6.0 Hz, 2H), 0.88 (t, J = 6.2 Hz, 2H).

Example 40:

- 5 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-phenyl-amide




- 1H NMR (300 MHz, DMSO) δ 8.12 (s, 1H), 7.50 – 7.24 (m, 5H), 7.18 (d, J = 3.6 Hz, 1H), 6.57 (d, J = 3.6 Hz, 1H), 4.07 – 3.98 (m, 2H), 3.79 (s, 2H), 3.59 – 3.53 (m, 2H),
 10 3.14 (s, 3H), 0.82 – 0.73 (m, 4H). No indole-H observed.

LC-MS (MSX12592): 2.17 min, ES (+), m/z: 399.146

Example 41:

- 15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-cyano-ethyl)-cyclopropyl-amide




LC-MS (MSX12244): 1.97 min, ES (+), m/z: 402.175

20

Example 42:


1-[7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-piperidine-3-carbonitrile



LC-MS (MSX12245): 1.94 min, ES (+), m/z: 402.171

5 Example 51:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amide



1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.19 (s, 1H), 6.86 (dd, J = 8.1, 5.0 Hz, 2H), 6.74 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 2.9 Hz, 1H), 4.03 – 3.97 (m, 2H), 3.82 (s, 2H), 3.74 (s, 3H), 3.72 (s, 3H), 3.47 – 3.40 (m, 2H), 3.17 (d, J = 5.2 Hz, 2H), 2.76 (t, J = 7.5 Hz, 2H), 2.71 (s, 3H), 0.94 (s, 2H), 0.84 (d, J = 4.8 Hz, 2H).

Example 52:


15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid benzyl-methyl-amide



¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 7.46 – 7.24 (m, 6H), 7.20 (d, J = 3.6 Hz, 1H), 6.61 (d, J = 3.6 Hz, 1H), 4.27 (s, 2H), 4.10 – 4.04 (m, 2H), 3.87 (s, 2H), 3.63 – 3.53 (m, 2H), 2.60 (s, 3H), 1.08 – 1.00 (m, 2H), 0.93 – 0.86 (m, 2H).

5 Example 45:


7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid dimethylamide



10 ¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.4, 2.5 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.08 – 3.99 (m, 2H), 3.83 (s, 2H), 3.59 – 3.52 (m, 2H), 2.68 (s, 6H), 1.01 (t, J = 6.0 Hz, 2H), 0.87 (t, J = 6.1 Hz, 2H).

Example 50:


15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic isopropylamide



20 ¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (d, J = 3.6 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.05 (dd, J = 7.5, 2.8 Hz, 2H), 3.83 (s, 2H), 3.54 (dd, J = 5.7, 4.6 Hz, 2H), 1.09 – 1.00 (m, 8H), 0.83 (q, J = 5.2 Hz, 2H).

Example 9:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic phenethyl-(3-phenyl-propyl)-amide




7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-amide (intermediate 5) (0.05 mmol) was dissolved in dry DMF (0.5 mL) and added Cs_2CO_3 (0.05 mmol) and (3-bromo-propyl)-benzene (0.05 mmol). Stirred at rt
 5 for 2h and then filtered through a syringe filter (0.45 μm). The pure compounds were obtained by standard preparative HPLC purification of the reaction mixture.

^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.12 (s, 1H), 7.37 – 7.25 (m, 4H), 7.25 – 7.12 (m, 7H), 6.57 (dd, J = 3.5, 1.8 Hz, 1H), 4.01 (dd, J = 5.2, 4.2 Hz, 2H), 3.80 (s, 2H), 3.40 – 3.33 (m, 4H), 3.22 – 3.04 (m, 2H), 2.86 – 2.72 (m, 2H), 2.55 (t, J = 7.7 Hz, 2H), 1.82 (qd, J = 8.2, 3.5 Hz, 2H), 1.03 – 0.71 (m, 4H).
 10

Example 53:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-hydroxy-ethyl)-amide
 15




4-{4-[2-(Tetrahydro-pyran-2-yloxy)-ethylsulfamoyl]-4,7-diaza-spiro[2.5]oct-7-yl}-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 16) was

treated with TFA (1 mL) at rt for 1h. The crude reaction mixture was concentrated *in vacuo* and redissolved in DMSO (0.5 mL). The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

5 LC-MS (MSX13841): 1.63 min, ES (+), m/z: 353.141

Example 54:

10 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid bis-(2-hydroxy-ethyl)-amide




15 4-(4-{Bis-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-sulfamoyl}-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 17) was treated with a mixture of TFA (0.5 mL), H₂O (0.2 mL) and THF (0.2 mL) at 40 °C for 1h. The crude reaction mixture was neutralised using sat. NaHCO₃ and then extracted with EtOAc (3 x 10 mL). The combined organic phases were dried (Na₂SO₄), filtered and concentrated *in vacuo*. The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

20

¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (dd, J = 3.4, 2.5 Hz, 1H), 6.59 (dd, J = 3.5, 1.6 Hz, 1H), 4.11 – 3.99 (m, 2H), 3.84 (s, 2H), 3.52 (m, 6H), 3.20 (t, J = 6.3 Hz, 4H), 1.03 (t, J = 5.8 Hz, 2H), 0.85 (q, J = 5.2 Hz, 2H).

25 Example 55:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-amide




4-[4-(3-Cyano-propylsulfamoyl)-4,7-diaza-spiro[2.5]oct-7-yl]-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 18) was dissolved in THF (1 mL), added TFA (0.5 mL) and then stirred at rt for 2h.

The crude reaction mixture was concentrated *in vacuo* and redissolved in MeOH (0.5 mL). The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

¹H NMR (300 MHz, DMSO) δ 12.10 (s, 1H), 8.25 (s, 1H), 7.51 (t, J = 5.8 Hz, 1H), 7.30 (dd, J = 3.3, 2.6 Hz, 1H), 6.74 (dd, J = 3.5, 1.5 Hz, 1H), 4.13 – 4.05 (m, 2H), 3.88 (s, 2H), 3.62 – 3.54 (m, 2H), 2.84 (dd, J = 12.7, 6.8 Hz, 2H), 2.57 – 2.51 (m, 2H), 1.72 (p, J = 7.0 Hz, 2H), 1.04 (t, J = 6.0 Hz, 2H), 0.94 – 0.83 (m, 2H).

Example 56:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid bis-(3-cyano-propyl)-amide




4-{4-[Bis-(3-cyano-propyl)-sulfamoyl]-4,7-diaza-spiro[2.5]oct-7-yl}-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 19) was dissolved in THF (1 mL), added TFA (0.5 mL) and then stirred at rt for 2h. The crude reaction mixture was concentrated *in vacuo* and redissolved in MeOH (0.5 mL). The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

1H NMR (300 MHz, DMSO) δ 11.96 (s, 1H), 8.21 (s, 1H), 7.37 – 7.08 (m, 1H), 6.68 (dd, J = 3.5, 1.6 Hz, 1H), 4.14 – 4.06 (m, 2H), 3.86 (s, 2H), 3.59 – 3.46 (m, 6H), 3.26 – 3.08 (m, 4H), 1.90 – 1.70 (m, 4H), 1.05 (dd, J = 6.7, 4.2 Hz, 2H), 0.91 (t, J = 6.2 Hz, 2H).

Example 57:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-(3-phenyl-propyl)-amide



10

4-[4-(3-Cyano-propylsulfamoyl)-4,7-diaza-spiro[2.5]oct-7-yl]-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 18) was dissolved in CH₃CN (0.4 mL), added Cs₂CO₃ and (3-bromo-propyl)-benzene. Stirred at for 16h and then added additional (3-bromo-propyl)-benzene (2 equivalents) before being stirred at rt for 3 days. The crude reaction mixture was filtered through a syringe filter (0.45 μ m) and purified by standard preparative HPLC purification. The residual oil was dissolved in THF (1 mL), added TFA (0.5 mL) and then stirred at rt for 2h. The crude reaction mixture was concentrated *in vacuo* and redissolved in MeOH (0.5 mL). The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

15

20


1H NMR (300 MHz, DMSO) δ 11.79 (s, 1H), 8.15 (s, 1H), 7.36 – 7.10 (m, 6H), 6.61 (dd, J = 3.5, 1.7 Hz, 1H), 4.10 – 4.02 (m, 2H), 3.82 (s, 2H), 3.51 – 3.44 (m, 2H), 3.17 (dd, J = 8.0, 6.9 Hz, 2H), 3.14 – 3.07 (m, 2H), 2.56 (t, J = 7.6 Hz, 2H), 1.89 – 1.70 (m, 4H), 1.02 – 0.78 (m, 4H).

25

LC-MS (MSX13112): 2.30 min, ES (+), m/z: 494.219

Example 58:

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-phenethyl-amide




4-(4-Phenethylsulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 6) (0.78 mmol) was dissolved in dry DMF (5 mL) and added K_2CO_3 (1.56 mmol) and iodomethane (1.17 mmol). Stirred at rt for 3h and then added H_2O (20 mL). Extracted with EtOAc (3 x 20 mL) and the combined organic phases were concentrated *in vacuo*. Purified by flash chromatography on silica using EtOAc in heptane as eluent. The obtained compound was treated with TFA (2 mL) at rt for 1.5h. The crude reaction mixture was added sat. Na_2CO_3 to pH=7 and the extracted with EtOAc (3 x 10 mL). The combined organic phases was washes with brine (10 mL), dried (Na_2SO_4), filtered and concentrated *in vacuo*. The pure compound was obtained by flash chromatography on silica using EtOAc in heptane as eluent.

^1H NMR (600 MHz, DMSO) δ 11.73 (s, 1H), 8.13 (s, 1H), 7.31 (t, $J = 7.5$ Hz, 2H), 7.28 – 7.15 (m, 4H), 6.58 (d, $J = 3.6$ Hz, 1H), 4.00 (s, 2H), 3.81 (s, 2H), 3.43 – 3.40 (m, 2H), 3.32 – 3.26 (m, 2H), 2.87 – 2.79 (m, 2H), 2.72 (s, 3H), 0.93 (t, $J = 5.7$ Hz, 2H), 0.86 – 0.79 (m, 2H).

Example 94:

N-isopropyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 1, using intermediate 32, instead of intermediate 6.

- 5 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (dd, J = 3.5, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.7 Hz, 1H), 4.11 – 3.98 (m, 2H), 3.94 – 3.77 (m, 3H), 3.51 (dd, J = 6.2, 4.0 Hz, 2H), 2.58 (s, 3H), 1.08 (d, J = 6.7 Hz, 6H), 1.04 – 0.79 (m, 4H).


LC-MS: 2.05 min, ES (+), m/z : 365.160

10

Using this procedure the following compounds were obtained:

Example 95:

N-ethyl-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-
15 sulfonamide




- 20 ^1H NMR (300 MHz, DMSO) δ 11.76 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.6, 2.3 Hz, 1H), 6.61 (dd, J = 3.5, 1.8 Hz, 1H), 4.06 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.73 (p, J = 6.7 Hz, 1H), 3.53 – 3.45 (m, 2H), 3.14 (q, J = 7.0 Hz, 2H), 1.23 – 1.06 (m, 9H), 1.04 – 0.80 (m, 4H).

LC-MS: 2.13 min, ES (+), m/z : 379.178

Example 96:

N-(cyanomethyl)-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.6, 2.3 Hz, 1H), 6.60 (dd, J = 3.5, 1.8 Hz, 1H), 4.29 (s, 2H), 4.06 (t, J = 5.1 Hz, 2H), 3.86 (d, J = 15.7 Hz, 3H), 3.54 (t, J = 5.0 Hz, 2H), 1.17 (d, J = 6.7 Hz, 6H), 1.12 – 0.82 (m, 4H).

LC-MS: 2.00 min, ES (+), m/z: 390.165

10 Example 97:

N-(2-hydroxyethyl)-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (dd, J = 3.5, 2.3 Hz, 1H), 6.59 (dd, J = 3.6, 1.7 Hz, 1H), 4.72 (br, 1H), 4.05 (t, J = 5.1 Hz, 2H), 3.83 (s, 2H), 3.71 (p, J = 6.6 Hz, 1H), 3.55 – 3.43 (m, 4H), 3.09 (t, J = 7.2 Hz, 2H), 1.10 (d, J = 6.7 Hz, 6H), 1.05 – 0.80 (m, 4H).

LC-MS: 1.83 min, ES (+), m/z: 395.183

20

Example 98:

N-cyclobutyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 1, using intermediate 31, instead of intermediate 6.


- 5 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.1 Hz, 1H), 6.59 (dd, J = 3.8, 1.5 Hz, 1H), 4.18 – 3.97 (m, 3H), 3.82 (s, 2H), 3.50 (dd, J = 6.5, 3.8 Hz, 2H), 2.67 (s, 3H), 2.24 – 2.06 (m, 2H), 2.06 – 1.90 (m, 2H), 1.65 – 1.45 (m, 2H), 1.02 – 0.78 (m, 4H).

- 10 LC-MS: 2.11 min, ES (+), m/z : 377.179

Using this procedure the following compounds were obtained:

Example 99:

- 15 N-cyclobutyl-N-ethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 20 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.09 – 3.88 (m, 3H), 3.84 (s, 2H), 3.49 (dd, J = 6.3, 4.0 Hz, 2H), 3.23 (q, J = 7.1 Hz, 2H), 2.21 – 1.95 (m, 4H), 1.55 (m, 2H), 1.10 (t, J = 7.0 Hz, 3H), 1.06 – 0.80 (m, 4H).

LC-MS: 2.20 min, ES (+), m/z : 391.189

- 25 Example 100:

N-(cyanomethyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.5, 2.3 Hz, 1H), 6.60 (dd, J = 3.5, 1.8 Hz, 1H), 4.37 (s, 2H), 4.17 – 4.00 (m, 3H), 3.83 (s, 2H), 3.55 (d, J = 5.1 Hz, 2H), 2.32 – 2.13 (m, 2H), 2.07 (m, 2H), 1.68 – 1.48 (m, 2H), 1.12 – 0.84 (m, 4H).

LC-MS: 2.07 min, ES (+), m/z : 402.169

10

Example 101:

N-cyclobutyl-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




15 1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.18 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.77 (s, 1H), 4.09 – 3.89 (m, 3H), 3.83 (s, 2H), 3.54 – 3.40 (m, 4H), 3.20 (t, J = 7.0 Hz, 2H), 2.22 – 1.93 (m, 4H), 1.66 – 1.42 (m, 2H), 1.04 – 0.80 (m, 4H).

20 LC-MS: 1.88 min, ES (+), m/z : 407.161

Example 102:

N-(3-cyanopropyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.2 Hz, 1H), 6.59 (dd, J = 3.5, 1.7 Hz, 1H), 4.10 – 3.89 (m, 3H), 3.84 (s, 2H), 3.49 (dd, J = 6.4, 3.9 Hz, 2H), 3.33 – 3.17 (m, 2H), 2.54 (m, 2H), 2.21 – 1.86 (m, 4H), 1.78 (m, 2H), 1.56 (m, 2H), 1.05 – 0.81 (m, 4H).

LC-MS: 2.09 min, ES (+), m/z : 430.194

Example 103:

- 10 N-cyclobutyl-N-(2-methoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.09 – 3.87 (m, 3H), 3.84 (s, 2H), 3.55 – 3.23 (m, 9H), 2.22 – 1.93 (m, 4H), 1.66 – 1.39 (m, 2H), 1.05 – 0.80 (m, 4H).

LC-MS: 2.13 min, ES (+), m/z : 421.200

Example 104:


- 20 N-cyclobutyl-N-(2-imidazol-1-ylethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



LC-MS: 1.71 min, ES (+), m/z: 457.217

Example 105:


- 5 N-cyclobutyl-N-[3-(dimethylamino)propyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



LC-MS: 1.73 min, ES (+), m/z: 448.247

10 Example 106:

- N-cyclobutyl-N-(2-morpholinoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




LC-MS: 1.73 min, ES (+), m/z: 476.236

15

Example 107:

- N-(1-cyanoethyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.14 (s, 1H), 7.24 – 7.16 (m, 1H), 6.61 (dd, J = 3.7, 1.7 Hz, 1H), 4.90 (q, J = 7.0 Hz, 1H), 4.15 – 3.89 (m, 3H), 3.85 (s, 2H), 3.58 (t, J = 5.1 Hz, 2H), 2.33 (h, J = 10.2 Hz, 2H), 2.21 – 2.03 (m, 2H), 1.73 – 1.44 (m, 5H), 1.19 – 0.79 (m, 4H).

LC-MS: 2.15 min, ES (+), m/z : 416.183

Example 108:

10 N-(cyanomethyl)-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




Prepared in a similar manner as example 1, using intermediate 16, instead of intermediate 6.

15

LC-MS: 1.72 min, ES (+), m/z : 392.153

Example 109:


20 N-(2-hydroxyethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



LC-MS: 1.68 min, ES (+), m/z: 367.154

Example 110:

- 5 N-(3-cyanopropyl)-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 12.00 (s, 1H), 8.22 (s, 1H), 7.27 (t, J = 3.0 Hz, 1H), 6.76 – 6.64 (m, 1H), 4.21 – 4.03 (m, 2H), 3.87 (s, 2H), 3.60 – 3.47 (m, 6H), 3.25 – 3.06 (m, 4H), 1.83 (p, J = 7.3 Hz, 2H), 1.20 – 0.79 (m, 4H).

LC-MS: 1.73 min, ES (+), m/z: 420.180

Example 111:

- 15 N-(2-hydroxyethyl)-N-(2-phenoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.38 – 7.23 (m, 2H), 7.21 – 7.14 (m, 1H), 7.00 – 6.89 (m, 3H), 6.58 (dd, J = 3.7, 1.8 Hz, 1H), 4.78 (br, 1H), 4.11 (t, J = 5.8 Hz, 2H), 4.07 – 4.00 (m, 2H), 3.85 (s, 2H), 3.55 (t, J = 5.4 Hz, 4H), 3.33 – 3.16 (m, 4H), 1.08 – 0.80 (m, 4H).

LC-MS: 2.05 min, ES (+), m/z: 473.194

Example 112:

- 5 N-methyl-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 58, using intermediate 43, instead of intermediate 6.


10

¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.24 – 7.15 (m, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.79 – 4.55 (m, 5H), 4.08 – 3.98 (m, 2H), 3.81 (s, 2H), 3.51 (dd, J = 6.2, 4.0 Hz, 2H), 2.77 (s, 3H), 1.06 – 0.80 (m, 4H).

- 15 LC-MS: 1.80 min, ES (+), m/z: 379.144

Example 113:

N-(cyanomethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



20

Prepared in a similar manner as example 1, using intermediate 43, instead of intermediate 6.


¹H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.15 (s, 1H), 7.25 – 7.16 (m, 1H), 6.60 (dd, J = 3.7, 1.8 Hz, 1H), 4.86 – 4.57 (m, 5H), 4.48 (s, 2H), 4.04 (dd, J = 6.3, 3.8 Hz, 2H), 3.83 (s, 2H), 3.58 (dd, J = 6.2, 3.9 Hz, 2H), 1.14 – 0.81 (m, 4H).

5 LC-MS: 1.84 min, ES (+), m/z : 404.151

Using this procedure the following compounds were obtained:

Example 114:

10 N-(3-cyanopropyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.24 – 7.14 (m, 1H), 6.65 – 6.54 (m, 1H), 4.80 – 4.55 (m, 4H), 4.12 – 4.00 (m, 2H), 3.83 (s, 2H), 3.52 (dd, J = 6.2, 3.9 Hz, 2H), 3.37 – 3.25 (m, 3H), 2.55 (t, J = 7.1 Hz, 2H), 1.84 (p, J = 7.3 Hz, 2H), 1.15 – 0.76 (m, 4H).

LC-MS: 1.84 min, ES (+), m/z : 432.174

20 Example 115:

N-(oxetan-3-yl)-N-(2-phenoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.13 (s, 1H), 7.38 – 7.24 (m, 2H), 7.23 – 7.14 (m, 1H), 7.01 – 6.88 (m, 3H), 6.57 (dd, J = 3.6, 1.8 Hz, 1H), 4.84 – 4.58 (m,


5H), 4.12 (t, J = 5.4 Hz, 2H), 4.04 (t, J = 5.1 Hz, 2H), 3.83 (s, 2H), 3.67 (t, J = 5.5 Hz, 2H), 3.59 – 3.50 (m, 2H), 1.07 – 0.79 (m, 4H).

LC-MS: 2.19 min, ES (+), m/z: 485.183

5

Example 116:

N-(2-hydroxyethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 10 ^1H NMR (300 MHz, DMSO) δ 11.95 (s, 1H), 8.20 (s, 1H), 7.26 (dd, J = 3.5, 2.2 Hz, 1H), 6.68 (dd, J = 3.5, 1.7 Hz, 1H), 4.33 – 3.26 (m, 14H), 3.26 – 2.96 (m, 2H), 1.20 – 1.00 (m, 2H), 0.96 – 0.78 (m, 2H).

LC-MS: 1.69 min, ES (+), m/z: 409.156

15

Example 117:

N-(1-cyanoethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 20 ^1H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.15 (s, 1H), 7.25 – 7.16 (m, 1H), 6.61 (dd, J = 3.5, 1.8 Hz, 1H), 4.97 – 4.56 (m, 6H), 4.06 (t, J = 5.3 Hz, 2H), 3.85 (s, 2H), 3.62 (t, J = 5.0 Hz, 2H), 1.49 (d, J = 7.1 Hz, 3H), 1.16 – 1.03 (m, 2H), 0.94 (d, J = 6.6 Hz, 2H).

- 25 LC-MS: 1.90 min, ES (+), m/z: 418.167

Example 118:

N-methyl-N-[(1-propylsulfonylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



5

N-methyl-N-(pyrrolidin-3-ylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide (intermediate 25) (0.042 mmol) was dissolved in dry DMSO (0.5 mL), added DIPEA (0.25 mL) and propane-1-sulfonyl chloride (0.050 mmol) and then stirred at 40°C for 1h. The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

10

¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.5, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.13 – 3.97 (m, 2H), 3.84 (s, 2H), 3.53 (t, J = 5.0 Hz, 2H), 3.44 – 3.18 (m, 4H), 3.14 – 2.91 (m, 5H), 2.71 (s, 3H), 2.64 – 2.50 (m, 1H), 1.98 (m, 1H), 1.79 – 1.54 (m, 2H), 1.13 – 0.82 (m, 7H).

15


LC-MS: 2.04 min, ES (+), m/z: 512.207

Using this procedure the following compounds were obtained:

20

Example 119:

N-methyl-N-[(1-methylsulfonylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



25


¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.7, 2.4 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.05 (t, J = 5.3 Hz, 2H), 3.84 (s, 2H), 3.54 (t, J =

5.1 Hz, 2H), 3.45 – 3.15 (m, 3H), 3.10 (d, $J = 7.5$ Hz, 2H), 2.94 (dd, $J = 9.9, 7.0$ Hz, 1H), 2.89 (s, 3H), 2.71 (s, 3H), 2.61 – 2.50 (m, 1H), 1.98 (dtd, $J = 12.1, 7.0, 4.8$ Hz, 1H), 1.63 (dq, $J = 12.4, 7.8$ Hz, 1H), 1.05 – 0.82 (m, 4H).

5 LC-MS: 1.89 min, ES (+), m/z : 484.180

Example 120:

N-[[1-(2-methoxyethylsulfonyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



10


^1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, $J = 3.5, 2.3$ Hz, 1H), 6.59 (dd, $J = 3.7, 1.8$ Hz, 1H), 4.05 (t, $J = 5.3$ Hz, 2H), 3.84 (s, 2H), 3.66 (t, $J = 5.9$ Hz, 2H), 3.53 (t, $J = 5.2$ Hz, 2H), 3.43 – 3.18 (m, 8H), 3.10 (d, $J = 7.4$ Hz, 2H), 2.96 (dd, $J = 9.6, 7.0$ Hz, 1H), 2.71 (s, 3H), 2.61 – 2.50 (m, 1H), 1.97 (dtd, $J = 11.7, 6.9, 4.7$ Hz, 1H), 1.62 (dq, $J = 12.4, 7.9$ Hz, 1H), 1.05 – 0.82 (m, 4H).

15

LC-MS: 1.95 min, ES (+), m/z : 528.185

Example 121:

20 N-[[1-(3-cyanopropylsulfonyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, $J = 3.5, 2.3$ Hz, 1H), 6.59 (dd, $J = 3.6, 1.8$ Hz, 1H), 4.05 (t, $J = 5.2$ Hz, 2H), 3.84 (s, 2H), 3.54 (t, $J =$


5.1 Hz, 2H), 3.47 – 3.05 (m, 8H), 2.99 (dd, $J = 9.7, 7.0$ Hz, 1H), 2.71 (s, 3H), 2.65 (t, $J = 7.2$ Hz, 2H), 2.12 – 1.88 (m, 3H), 1.75 – 1.56 (m, 1H), 1.05 – 0.82 (m, 4H).

LC-MS: 1.96 min, ES (+), m/z : 537.204

5

Example 122:

N-[[1-(cyclopropylmethylsulfonyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




10 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, $J = 3.5, 2.4$ Hz, 1H), 6.59 (dd, $J = 3.7, 1.7$ Hz, 1H), 4.05 (t, $J = 5.2$ Hz, 2H), 3.84 (s, 2H), 3.60 – 3.21 (m, 6H), 3.17 – 2.91 (m, 5H), 2.71 (s, 3H), 2.62 – 2.51 (m, 1H), 2.06 – 1.87 (m, 1H), 1.73 – 1.54 (m, 1H), 1.04 – 0.82 (m, 4H), 0.65 – 0.47 (m, 2H), 0.41 – 0.26 (m, 2H).

15 LC-MS: 2.05 min, ES (+), m/z : 524.208

Example 123:

N-[[1-(3-hydroxypropanoyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



20

N-methyl-N-(pyrrolidin-3-ylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide (intermediate 25) (0.042 mmol) was dissolved in dry DMSO (0.5 mL), added DIPEA (0.25 mL), 3-hydroxypropanoic acid (0.050 mmol) and Pybrop (0.050 mmol) then stirred at 40°C for 1h. The pure compound was
25 obtained by standard preparative HPLC purification of the reaction mixture.

¹H NMR (300 MHz, DMSO) δ 11.75 – 11.68 (m, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.2 Hz, 1H), 6.59 (dd, J = 3.5, 1.7 Hz, 1H), 4.48 (s, 1H), 4.05 (t, J = 5.2 Hz, 2H), 3.84 (s, 2H), 3.68 – 3.31 (m, 7H), 3.29 – 2.91 (m, 4H), 2.72 (d, J = 3.7 Hz, 3H), 2.49 – 2.30 (m, 2H), 2.07 – 1.82 (m, 1H), 1.61 (m, 1H), 0.94 (m, 4H).


5

LC-MS: 1.72 min, ES (+), m/z : 478.193

Using this procedure the following compounds were obtained:

10 Example 124:

N-[[1-(3-hydroxybutanoyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




LC-MS: 1.76 min, ES (+), m/z : 492.209

15

Example 125:

N-methyl-N-[(1-propanoylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




20 ¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.5, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.04 (d, J = 5.5 Hz, 2H), 3.84 (s, 2H), 3.52 (s, 2H), 3.49 – 3.35 (m, 2H), 3.27 – 2.91 (m, 4H), 2.71 (d, J = 3.4 Hz, 3H), 2.50 (m, 1H), 2.21 (q, J = 7.4 Hz, 2H), 2.03 – 1.85 (m, 1H), 1.75 – 1.49 (m, 1H), 1.07 – 0.81 (m, 7H).

25

LC-MS: 1.86 min, ES (+), m/z : 462.199

Example 126:

N-[[1-(3-cyanopropanoyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




5 ¹H NMR (300 MHz, DMSO) δ 11.79 (s, 1H), 8.16 (s, 1H), 7.21 (dd, J = 3.5, 2.3 Hz, 1H), 6.66 – 6.58 (m, 1H), 4.06 (t, J = 5.2 Hz, 2H), 3.84 (s, 2H), 3.61 – 3.35 (m, 5H), 3.31 – 2.93 (m, 4H), 2.72 (d, J = 4.6 Hz, 3H), 2.61 (d, J = 1.5 Hz, 3H), 2.58 – 2.39 (m, 1H), 2.09 – 1.84 (m, 1H), 1.62 (m, 1H), 1.05 – 0.82 (m, 4H).

10 LC-MS: 1.83 min, ES (+), m/z : 487.193

Example 127:

N-[[1-(2,3-dihydroxypropanoyl)pyrrolidin-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




15

LC-MS: 1.68 min, ES (+), m/z : 494.213

Example 128:

N-[(1-formylpyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

20



¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.18 – 8.09 (m, 2H), 7.19 (dd, J = 3.6, 2.1 Hz, 1H), 6.59 (dd, J = 3.7, 1.6 Hz, 1H), 4.05 (dd, J = 6.5, 3.8 Hz, 2H), 3.84 (s, 2H), 3.66 – 3.13 (m, 6H), 3.13 – 2.90 (m, 2H), 2.72 (d, J = 1.7 Hz, 3H), 2.59 – 2.39 (m, 1H), 2.05 – 1.86 (m, 1H), 1.60 (m, 1H), 1.04 – 0.81 (m, 4H).


5

LC-MS: 1.76 min, ES (+), m/z: 434.166

Example 129:

3,3,3-trifluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

10



3,3,3-trifluoropropanoic acid (0.24 mmol) was dissolved in dry DCM (0.5 mL) in a 4 mL vial, added oxalyl chloride (0.24 mmol) and a catalytic amount of DMF. Stirred at rt for 1h and added to a mixture of intermediate 4 (0.05 mmol) and Et₃N (0.47 mmol) in dry DCM (0.5 mL). Stirred at rt for 16h. Reaction mixture filtered through a syringe filter, added TFA (1 mL) and stirred at rt for 15 min. Reaction mixture added H₂O (5 mL) and extracted with DCM (3 x 5 mL). The organic phase was dried (Na₂SO₄), filtered, concentrated *in vacuo* and redissolved in DMSO (1 mL). The pure compound was obtained by standard preparative HPLC purification.

20

¹H NMR (300 MHz, DMSO) δ 12.23 (s, 1H), 8.29 (s, 1H), 7.34 (dd, J = 3.5, 2.2 Hz, 1H), 6.77 (dd, J = 3.6, 1.7 Hz, 1H), 4.11 (dd, J = 6.4, 4.0 Hz, 2H), 3.88 (s, 2H), 3.76 (dd, J = 6.5, 3.9 Hz, 2H), 3.24 (s, 3H), 3.10 (m, 2H), 1.10 – 0.93 (m, 4H).

25


LC-MS: 2.11 min, ES (+), m/z: 433.117

Using this procedure the following compounds were obtained:

Example 130:

30


4,4-difluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]cyclohexanecarboxamide



LC-MS: 2.21 min, ES (+), m/z: 469.184

Example 131:

- 5 4,4,4-trifluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]butanamide




- 10 ¹H NMR (300 MHz, DMSO) δ 11.76 (s, 1H), 8.14 (d, J = 5.5 Hz, 1H), 7.20 (q, J = 3.0 Hz, 1H), 6.66 – 6.55 (m, 1H), 4.07 (dd, J = 6.4, 3.9 Hz, 2H), 3.84 (s, 2H), 3.70 (t, J = 5.2 Hz, 2H), 3.22 (s, 3H), 2.90 (t, J = 7.4 Hz, 2H), 2.62 – 2.39 (m, 2H), 1.06 – 0.88 (m, 4H).

LC-MS: 2.17 min, ES (+), m/z: 447.139

- 15 Example 135:

N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiolane-3-carboxamide



159

¹H NMR (300 MHz, DMSO) δ 11.76 (s, 1H), 8.15 (s, 1H), 7.21 (dd, J = 3.6, 2.3 Hz, 1H), 6.61 (dd, J = 3.7, 1.8 Hz, 1H), 4.14 – 4.00 (m, 2H), 3.90 (dd, J = 8.7, 6.7 Hz, 1H), 3.83 (s, 2H), 3.77 – 3.63 (m, 2H), 3.44 – 3.29 (m, 2H), 3.25 (s, 3H), 3.23 – 3.04 (m, 2H), 2.50 – 2.30 (m, 1H), 2.08 (m, 1H), 1.10 – 0.92 (m, 4H).

5


LC-MS: 1.87 min, ES (+), m/z: 469.134

Example 136:

2-(1,1-dioxothian-4-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

10

diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide




LC-MS: 1.88 min, ES (+), m/z: 497.164

15

Example 137:

3-(1,1-dioxothiolan-3-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

diazaspiro[2.5]octan-8-yl]sulfonyl]propanamide



¹H NMR (300 MHz, DMSO) δ 11.76 (s, 1H), 8.14 (s, 1H), 7.21 (dd, J = 3.6, 2.3 Hz, 1H), 6.61 (dd, J = 3.5, 1.8 Hz, 1H), 4.06 (t, J = 5.2 Hz, 2H), 3.83 (s, 2H), 3.71 (t, J = 5.0 Hz, 2H), 3.31 – 3.10 (m, 5H), 3.10 – 2.93 (m, 1H), 2.78 – 2.57 (m, 3H), 2.39 – 2.16 (m, 2H), 1.80 – 1.57 (m, 3H), 1.04 – 0.88 (m, 4H).


20

LC-MS: 1.89 min, ES (+), m/z: 497.162

25

Example 138:


2-(1,1-dioxothiolan-3-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide



5 LC-MS: 1.87 min, ES (+), m/z: 483.148

Example 139:

N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiane-4-carboxamide




10

LC-MS: 1.90 min, ES (+), m/z: 483.150

Example 140:

N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiane-3-carboxamide


15



LC-MS: 1.91 min, ES (+), m/z: 483.148

Example 132:

N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]cyclopentanecarboxamide



- 5 Intermediate 4 (0.071 mmol) was dissolved in dry DCM (1 mL) and added commercial available cyclopentanecarbonyl chloride (0.085 mmol) and Et₃N (0.21 mmol). Stirred at rt for 1h and then at 40°C for 1.5h. More 1,1-dioxothiolane-3-carbonyl chloride was added (2 x 0.107 mmol) with 1h in between each portion. After being stirred at 40°C for 1h the reaction mixture was concentrated *in vacuo*, added 2,2,2-trifluoroethanol (1
10 mL) and stirred at 60°C for 16 h. The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

1H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.5, 2.3 Hz, 1H), 6.61 (dd, J = 3.7, 1.8 Hz, 1H), 4.11 – 3.99 (m, 2H), 3.83 (s, 2H), 3.70 (dd, J =
15 6.5, 3.9 Hz, 2H), 3.23 (s, 3H), 1.89 – 1.67 (m, 3H), 1.58 (m, 6H), 0.97 (s, 4H).


LC-MS: 2.19 min, ES (+), m/z: 419.186

Using this procedure the following compounds were obtained:

20

Example 133:

2-cyclopentyl-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide



¹H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.6, 2.3 Hz, 1H), 6.61 (dd, J = 3.7, 1.8 Hz, 1H), 4.06 (dd, J = 6.4, 3.9 Hz, 2H), 3.83 (s, 2H), 3.74 – 3.64 (m, 2H), 3.19 (s, 3H), 2.60 (d, J = 7.0 Hz, 2H), 2.25 – 2.07 (m, 1H), 1.83 – 1.65 (m, 2H), 1.64 – 1.37 (m, 4H), 1.15 – 0.80 (m, 6H).

5


LC-MS: 2.33 min, ES (+), m/z: 433.199

Example 134:

3-cyclopentyl-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

10

diazaspiro[2.5]octan-8-yl]sulfonyl]propanamide



¹H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.6, 2.4 Hz, 1H), 6.61 (dd, J = 3.5, 1.8 Hz, 1H), 4.06 (dd, J = 6.4, 3.8 Hz, 2H), 3.84 (s, 2H), 3.70 (dd, J = 6.4, 3.9 Hz, 2H), 3.19 (s, 3H), 2.58 (t, J = 7.5 Hz, 2H), 1.83 – 1.36 (m, 8H),

15

1.17 – 0.80 (m, 7H).


LC-MS: 2.43 min, ES (+), m/z: 477.208

Example 141:

N-cyclopropyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

20

diazaspiro[2.5]octane-8-sulfonamide



Sulfonyl chloride (1.44 mmol) was dissolved in dry DCM (3 mL), cooled to 0°C and added a mixture of N-methylcyclopropanamine (0.48 mmol) and Et₃N (1.44 mmol) in dry DCM (1 mL). The reaction mixture was allowed to warm up freely to rt, stirred for

25

16h. The reaction mixture was concentrated *in vacuo* and triturated with Et₂O (2 x 1 mL). Et₂O removed *in vacuo* and the obtained pale oil was dissolved in dry DCM (1 mL) and added to a solution of 4-(4,7-diaza-spiro[2.5]oct-7-yl)-7H-pyrrolo[2,3-d]pyrimidine (0.48 mmol) (intermediate 21) in a mixture of DMSO:DIPEA (2:1, 3 mL). The reaction mixture was stirred at 40°C for 16h. The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.


¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.6, 1.8 Hz, 1H), 4.05 (dd, J = 6.4, 3.7 Hz, 2H), 3.83 (s, 2H), 3.55 (dd, J = 6.2, 4.0 Hz, 2H), 2.70 (d, J = 1.2 Hz, 3H), 2.31 – 2.19 (m, 1H), 1.05 – 0.83 (m, 4H), 0.73 – 0.56 (m, 4H).

LC-MS: 2.02 min, ES (+), m/z: 363.162

Using this procedure the following compounds were obtained:

Example 142:


N-(2-cyanoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydrofuran-2-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



LC-MS: 1.98 min, ES (+), m/z: 446.191

Example 143:

N-(1-methylbutyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



4-(4-Sulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester (intermediate 2) (0.049 mmol) was dissolved in dry DMF (1 mL) and added Cs₂CO₃ (0.147 mmol) and 2-bromopentane (0.074 mmol). Stirred at 60°C for 16h and then filtered through a syringe filter. The obtained filtrate was added 2,2,2-trifluoroethanol (1 mL) and heated to 100°C for 1h. The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.


¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.13 (s, 1H), 7.18 (dd, J = 5.6, 2.2 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.12 – 3.95 (m, 2H), 3.82 (d, J = 1.9 Hz, 2H), 3.52 (d, J = 4.4 Hz, 2H), 1.52 – 1.16 (m, 5H), 1.08 – 0.76 (m, 10H).

LC-MS: 2.13 min, ES (+), m/z: 379.187

Using this procedure the following compounds were obtained:

Example 144:

N-cyclopentyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.13 (s, 1H), 7.35 (d, J = 6.9 Hz, 1H), 7.29 – 7.11 (m, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.05 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.61 – 3.46 (m, 2H), 1.73 (dd, J = 7.3, 4.3 Hz, 2H), 1.67 – 1.51 (m, 2H), 1.51 – 1.38 (m, 4H), 1.11 – 0.74 (m, 4H).

LC-MS: 2.05 min, ES (+), m/z: 377.171

Example 145:

N,N-bis(cyanomethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



¹H NMR (300 MHz, DMSO) δ 11.75 (s, 1H), 8.15 (s, 1H), 7.29 – 7.11 (m, 1H), 6.69 – 6.49 (m, 1H), 4.46 (s, 4H), 4.06 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.62 (d, J = 5.4 Hz, 2H), 1.14 – 0.88 (m, 4H).


5

LC-MS: 1.88 min, ES (+), m/z: 387.136

Example 146:

N,N-dibenzyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

10




¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.39 – 7.15 (m, 11H), 6.59 (d, J = 3.4 Hz, 1H), 4.27 (s, 4H), 4.08 (t, J = 4.9 Hz, 2H), 3.85 (s, 2H), 3.51 – 3.45 (m, 2H), 0.85 (d, J = 9.8 Hz, 4H).

15

LC-MS: 2.50 min, ES (+), m/z: 489.176

Example 147:

N-benzyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



^1H NMR (300 MHz, DMSO) δ 11.69 (s, 1H), 8.12 (s, 1H), 7.89 (t, J = 6.0 Hz, 1H), 7.38 – 7.21 (m, 5H), 7.20 – 7.13 (m, 1H), 6.58 (d, J = 3.9 Hz, 1H), 4.04 (t, J = 5.2 Hz, 2H), 3.98 (d, J = 4.7 Hz, 2H), 3.82 (s, 2H), 0.98 – 0.70 (m, 4H).


5

LC-MS: 2.06 min, ES (+), m/z : 399.134

Example 148:

N-[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide


10



Example 149:

N-[(4,4-difluorocyclohexyl)methyl]-N-ethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide


15



Example 150:

N,N-bis[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

20



4-(4-Sulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid
tert-butyl ester (intermediate 2) (0.049 mmol) was dissolved in dry DMF (1 mL) and
5 added Cs_2CO_3 (0.147 mmol) and 4-(bromomethyl)-1,1-difluoro-cyclohexane (0.044
mmol) and stirred at 45°C for 16h. The obtained reaction mixture was added
bromoethane (0.098 mmol) and stirred at 45°C for 2h before being filtered through a
syringe filter. The obtained filtrate was added 2,2,2-trifluoroethanol (1 mL) and heated
to 100°C for 1h. The pure compounds were obtained by standard preparative HPLC
10 purification of the reaction mixture.

Example 148:

1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.43 (t, J = 6.0 Hz, 1H), 7.18
(dd, J = 3.5, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.05 (t, J = 5.0 Hz, 2H), 3.84
15 (s, 2H), 3.55 (t, J = 5.2 Hz, 2H), 2.66 (t, J = 6.4 Hz, 2H), 2.07 – 1.91 (m, 2H), 1.84 –
1.64 (m, 3H), 1.29 – 1.07 (m, 4H), 1.06 – 0.78 (m, 4H).

LC-MS: 2.12 min, ES (+), m/z: 441.187

20 Example 149:

LC-MS: 2.31 min, ES (+), m/z: 469.220

Example 150:


25 1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.49 (s, 1H), 7.23 – 7.12 (m, 1H), 6.59
(dd, J = 3.7, 1.8 Hz, 1H), 4.11 – 4.02 (m, 2H), 3.82 (s, 2H), 3.49 – 3.44 (m, 2H), 2.99
(d, J = 6.8 Hz, 4H), 2.10 – 1.66 (m, 14H), 1.35 – 1.07 (m, 4H), 1.00 – 0.79 (m, 4H).

LC-MS: 2.49 min, ES (+), m/z: 537.260

30

Example 151:

N-[[1-(3-hydroxypropanoyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 123, using intermediate 26, instead of
5 intermediate 25.


¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.4 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.56 – 4.32 (m, 2H), 4.04 (d, J = 5.2 Hz, 2H), 3.94 – 3.78 (m, 3H), 3.61 (t, J = 6.6 Hz, 2H), 3.52 (t, J = 5.0 Hz, 2H), 3.05 – 2.89 (m, 3H), 2.69 (s, 3H), 2.49 – 2.40 (m, 3H), 1.90 – 1.75 (m, 1H), 1.66 (t, J = 14.1 Hz, 2H), 1.16 – 0.83 (m, 6H).

LC-MS: 1.76 min, ES (+), m/z: 492.218

15 Using this procedure the following compounds were obtained:

Example 152:

N-[[1-(3-cyanopropanoyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



20


¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.36 (d, J = 13.0 Hz, 1H), 4.04 (t, J = 5.1 Hz, 2H), 3.91 – 3.75 (m, 3H), 3.52 (t, J = 5.1 Hz, 2H), 3.04 – 2.88 (m, 3H), 2.77 – 2.64 (m, 5H), 2.59 (dd, J = 7.1, 5.3 Hz, 3H), 1.84 (ddd, J = 11.1, 7.6, 3.9 Hz, 1H), 1.66 (s, 2H), 1.18 – 0.77 (m, 6H).

25

LC-MS: 1.89 min, ES (+), m/z: 501.212

Example 153:

N-[[1-(3-cyanopropanoyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



5

Prepared in a similar manner as example 123, using intermediate 27, instead of intermediate 25.

LC-MS: 1.92 min, ES (+), m/z: 501.215


10

Using this procedure the following compounds were obtained:

Example 154:

N-[[1-(3-hydroxypropanoyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

15



¹H NMR (300 MHz, DMF) δ 11.95 (s, 1H), 8.34 (s, 1H), 7.40 (dd, J = 3.6, 2.4 Hz, 1H), 6.81 (dd, J = 3.6, 1.8 Hz, 1H), 4.46 (d, J = 13.1 Hz, 1H), 4.25 (t, J = 5.3 Hz, 2H), 4.04 (m, 3H), 3.88 – 3.78 (m, 2H), 3.73 (t, J = 5.0 Hz, 2H), 3.28 – 3.07 (m, 3H), 3.03 – 2.79 (m, 5H), 2.63 – 2.50 (m, 2H), 2.09 – 1.76 (m, 3H), 1.66 – 1.31 (m, 2H), 1.30 – 1.03 (m, 4H).


20

LC-MS: 1.79 min, ES (+), m/z: 492.242

25

Example 155:

N-[[[(2S)-4,4-difluoro-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 123, using intermediate 28, instead of intermediate 25.


¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.7, 2.4 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.53 (t, J = 5.3 Hz, 1H), 4.47 – 4.28 (m, 1H), 4.00 (dd, J = 24.5, 9.9 Hz, 4H), 3.83 (d, J = 3.5 Hz, 2H), 3.64 (p, J = 5.6 Hz, 2H), 3.52 (m, 2H), 3.20 (d, J = 5.8 Hz, 2H), 2.77 (d, J = 7.1 Hz, 3H), 2.40 (q, J = 6.6 Hz, 3H), 1.08 – 0.81 (m, 4H).

LC-MS: 1.82 min, ES (+), m/z: 514.208

Using this procedure the following compounds were obtained:

Example 156:

N-[[[(2S)-1-(3-cyanopropanoyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (d, J = 1.4 Hz, 1H), 7.19 (dd, J = 3.5, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.57 – 4.36 (m, 1H), 4.14 – 3.91 (m, 4H),


3.83 (d, $J = 3.9$ Hz, 2H), 3.52 (t, $J = 5.3$ Hz, 2H), 3.23 – 3.09 (m, 3H), 2.78 (d, $J = 4.2$ Hz, 3H), 2.69 – 2.58 (m, 4H), 2.47 – 2.30 (m, 1H), 1.07 – 0.82 (m, 4H).

LC-MS: 1.96 min, ES (+), m/z : 523.202

5

Example 157:

N-[[[(2S)-4,4-difluoro-1-formyl-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




10 ^1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.19 (dd, $J = 3.6, 2.4$ Hz, 1H), 6.59 (dd, $J = 3.7, 1.8$ Hz, 1H), 4.49 – 4.35 (m, 1H), 4.04 (d, $J = 5.5$ Hz, 2H), 3.97 (d, $J = 13.5$ Hz, 1H), 3.83 (d, $J = 1.9$ Hz, 2H), 3.57 – 3.48 (m, 2H), 3.23 – 3.10 (m, 2H), 2.76 (d, $J = 3.0$ Hz, 3H), 1.08 – 0.78 (m, 4H).

15 LC-MS: 1.85 min, ES (+), m/z : 470.180

Example 158:

N-methyl-N-[(1-methylsulfonyl-4-piperidyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



20

Prepared in a similar manner as example 118, using intermediate 26, instead of intermediate 25.

25 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.19 (dd, $J = 3.7, 2.3$ Hz, 1H), 6.59 (dd, $J = 3.7, 1.8$ Hz, 1H), 4.05 (t, $J = 5.1$ Hz, 2H), 3.84 (s, 2H), 3.62 – 3.48

(m, 4H), 2.98 (d, $J = 6.6$ Hz, 2H), 2.84 (s, 3H), 2.78 – 2.63 (m, 5H), 1.83 – 1.63 (m, 3H), 1.26 – 1.08 (m, 2H), 1.06 – 0.83 (m, 4H).


LC-MS: 1.94 min, ES (+), m/z : 498.191

5

Using this procedure the following compounds were obtained:

Example 159:

10 N-[[1-(3-cyanopropylsulfonyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




15 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (s, 1H), 7.19 (dd, $J = 3.6, 2.4$ Hz, 1H), 6.59 (dd, $J = 3.7, 1.7$ Hz, 1H), 4.04 (d, $J = 5.4$ Hz, 2H), 3.84 (s, 2H), 3.61 (d, $J = 12.4$ Hz, 2H), 3.53 (dd, $J = 6.3, 3.7$ Hz, 2H), 3.16 – 3.04 (m, 2H), 2.98 (d, $J = 6.7$ Hz, 2H), 2.81 (td, $J = 12.2, 2.3$ Hz, 2H), 2.69 (s, 3H), 2.65 (t, $J = 7.3$ Hz, 2H), 2.09 – 1.88 (m, 2H), 1.73 (d, $J = 11.7$ Hz, 3H), 1.27 – 1.03 (m, 2H), 1.03 – 0.79 (m, 4H).

LC-MS: 2.01 min, ES (+), m/z : 551.213

20 Example 160:

N-methyl-N-[(1-methylsulfonyl-3-piperidyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



25 Prepared in a similar manner as example 118, using intermediate 27, instead of intermediate 25.

173


1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.09 – 3.96 (m, 2H), 3.84 (s, 2H), 3.53 (t, J = 5.3 Hz, 2H), 3.49 – 3.35 (m, 2H), 3.00 (d, J = 7.2 Hz, 2H), 2.83 (s, 3H), 2.80 – 2.60 (m, 4H), 2.50 – 2.46 (m, 1H), 1.95 – 1.83 (m, 1H), 1.83 – 1.61 (m, 2H), 1.58 – 1.41 (m, 1H), 1.09 (dd, J = 11.3, 9.0 Hz, 1H), 1.02 – 0.81 (m, 4H).

LC-MS: 1.97 min, ES (+), m/z: 498.184

Using this procedure the following compounds were obtained:

Example 161:

N-[[1-(3-cyanopropylsulfonyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.05 (s, 1H), 3.84 (s, 2H), 3.62 – 3.42 (m, 5H), 3.14 – 3.05 (m, 2H), 2.99 (d, J = 7.2 Hz, 2H), 2.89 – 2.77 (m, 1H), 2.69 (s, 3H), 2.65 (t, J = 7.4 Hz, 2H), 2.61 – 2.53 (m, 1H), 1.98 (p, J = 7.3 Hz, 2H), 1.91 – 1.80 (m, 1H), 1.78 – 1.64 (m, 2H), 1.57 – 1.35 (m, 1H), 1.22 – 1.04 (m, 1H), 1.04 – 0.75 (m, 4H).

LC-MS: 2.04 min, ES (+), m/z: 551.215

Example 162:

N-[[[(2S)-4,4-difluoro-1-methylsulfonyl-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 118, using intermediate 28, instead of intermediate 25.


- 5 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.7, 1.8 Hz, 1H), 4.27 – 4.13 (m, 1H), 4.10 – 4.00 (m, 2H), 3.99 – 3.63 (m, 4H), 3.53 (t, J = 5.1 Hz, 2H), 3.29 (d, J = 7.5 Hz, 2H), 3.06 (s, 3H), 2.77 (s, 3H), 2.74 – 2.56 (m, 1H), 2.46 – 2.33 (m, 1H), 1.06 – 0.82 (m, 4H).

- 10 LC-MS: 2.02 min, ES (+), m/z : 520.162

Using this procedure the following compounds were obtained:

Example 163:

- 15 N-[[[(2S)-1-(3-cyanopropylsulfonyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 20 ^1H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.4 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.34 – 4.18 (m, 1H), 4.12 – 4.01 (m, 2H), 4.01 – 3.64 (m, 4H), 3.54 (t, J = 5.1 Hz, 2H), 3.37 – 3.21 (m, 4H), 2.76 (s, 3H), 2.65 (t, J = 7.3 Hz, 2H), 2.51 – 2.32 (m, 1H), 2.10 – 1.92 (m, 2H), 1.04 – 0.82 (m, 4H).

LC-MS: 2.07 min, ES (+), m/z : 573.185

Example 164:


N-[[[(2S)-1-(cyclopropylmethylsulfonyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



LC-MS: 2.19 min, ES (+), m/z: 560.193

Example 165:

10 N-[(1,1-dioxothiolan-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 143, using intermediate 42, instead of intermediate 2.


15 ¹H NMR (300 MHz, DMSO) δ 11.79 (s, 1H), 8.16 (s, 1H), 7.25 – 7.14 (m, 1H), 6.62 (dd, J = 3.7, 1.8 Hz, 1H), 4.06 (t, J = 5.2 Hz, 2H), 3.84 (s, 2H), 3.54 (t, J = 5.2 Hz, 2H), 3.26 – 3.00 (m, 6H), 2.91 – 2.74 (m, 1H), 2.72 (s, 3H), 2.30 – 2.13 (m, 1H), 1.89 – 1.69 (m, 1H), 1.04 – 0.84 (m, 4H).

20 LC-MS: 1.81 min, ES (+), m/z: 455.197

Example 166:

N-(cyanomethyl)-N-[(1,1-dioxothiolan-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

176




1H NMR (300 MHz, DMSO) δ 12.30 (s, 1H), 8.31 (s, 1H), 7.39 – 7.32 (m, 1H), 6.80 (dd, J = 3.7, 1.8 Hz, 1H), 4.39 (s, 2H), 4.13 (d, J = 5.5 Hz, 2H), 3.90 (s, 2H), 3.60 (t, J = 5.2 Hz, 2H), 3.32 (dd, J = 7.1, 1.8 Hz, 2H), 3.28 – 3.15 (m, 2H), 3.15 – 3.01 (m, 1H), 2.92 – 2.70 (m, 2H), 2.30 – 2.18 (m, 1H), 1.82 (m, J = 13.1, 9.1 Hz, 1H), 1.17 – 0.92 (m, 4H).

LC-MS: 1.84 min, ES (+), m/z : 480.133

10 Example 167:

N-[(1,1-dioxothiolan-3-yl)methyl]-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 12.22 (s, 1H), 8.28 (s, 1H), 7.36 – 7.28 (m, 1H), 6.77 (dd, J = 3.6, 1.7 Hz, 1H), 4.11 (t, J = 5.1 Hz, 2H), 3.89 (s, 2H), 3.60 – 3.48 (m, 4H), 3.33 – 3.00 (m, 8H), 2.87 – 2.64 (m, 2H), 2.36 – 2.11 (m, 1H), 1.93 – 1.67 (m, 1H), 1.11 – 0.83 (m, 4H).

LC-MS: 1.70 min, ES (+), m/z : 485.163

20

Example 178:

N-[1-(2-hydroxyacetyl)azetidin-3-yl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 123, using intermediate 50, instead of intermediate 25.


- 5 ^1H NMR (300 MHz, DMSO) δ 11.74 (b, 1H), 8.14 (s, 1H), 7.19 (d, J = 3.5 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.87 (b, 1H), 4.61 – 4.46 (m, 1H), 4.31 (q, J = 7.9, 6.2 Hz, 2H), 4.02 (dt, J = 11.9, 5.4 Hz, 4H), 3.90 (s, 2H), 3.81 (s, 2H), 3.51 (dd, J = 6.2, 3.8 Hz, 2H), 2.77 (s, 3H), 1.08 – 0.82 (m, 4H).

- 10 LC-MS: 1.66 min, ES (+), m/z : 436.176

Using this procedure the following compounds were obtained:

Example 179:

- 15 N-[1-(3-hydroxypropanoyl)azetidin-3-yl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 1 ^1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 1.7 Hz, 1H), 6.59 (d, J = 3.5 Hz, 1H), 4.62 – 4.44 (m, 2H), 4.33 – 4.19 (m, 2H), 4.10 – 4.01 (m, 2H), 4.01 – 3.88 (m, 2H), 3.82 (s, 2H), 3.64 – 3.55 (m, 2H), 3.51 (t, J = 5.0 Hz, 2H), 2.77 (s, 3H), 2.20 (td, J = 6.5, 3.4 Hz, 2H), 1.09 – 0.80 (m, 4H).
- 20

LC-MS: 1.66 min, ES (+), m/z : 450.193

Example 180:

N-methyl-N-(1-methylsulfonylazetidin-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




- 5 Prepared in a similar manner as example 118, using intermediate 50, instead of intermediate 25.

1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.7, 1.8 Hz, 1H), 6.58 (d, J = 3.4 Hz, 1H), 4.57 – 4.41 (m, 1H), 4.12 – 3.92 (m, 6H), 3.81 (s, 2H),
 10 3.52 (t, J = 5.0 Hz, 2H), 3.28 (s, 1H), 3.06 (s, 3H), 2.78 (s, 3H), 1.07 – 0.83 (m, 4H).

LC-MS: 1.85 min, ES (+), m/z : 456.149

Example 181:

- 15 N-methyl-N-[(2R)-1-methylsulfonylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 118, using intermediate 51, instead of intermediate 25.

20

1H NMR (300 MHz, DMSO) δ 11.68 (b, 1H), 8.14 (s, 1H), 7.19 (d, J = 3.6 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.12 – 3.99 (m, 2H), 3.91 – 3.74 (m, 3H), 3.53 (t, J = 5.1 Hz, 2H), 3.31 – 3.04 (m, 4H), 2.93 (s, 3H), 2.74 (s, 3H), 1.87 (m, 4H), 1.08 – 0.80 (m, 4H).


LC-MS: 1.91 min, ES (+), m/z: 484.178

Using this procedure the following compounds were obtained:

5

Example 182:

N-[[[(2R)-1-(3-cyanopropylsulfonyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




10 ¹H NMR (300 MHz, DMSO) δ 11.73 (b, 1H), 8.14 (s, 1H), 7.19 (d, J = 3.6 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.14 – 3.99 (m, 2H), 3.99 – 3.86 (m, 1H), 3.83 (d, J = 2.3 Hz, 2H), 3.53 (t, J = 5.1 Hz, 2H), 3.31 – 3.04 (m, 6H), 2.74 (s, 3H), 2.65 (t, J = 7.2 Hz, 2H), 2.11 – 1.81 (m, 6H), 1.08 – 0.81 (m, 4H).

15 LC-MS: 1.98 min, ES (+), m/z: 537.205

Example 185:

N-[[[(2R)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



20

Prepared in a similar manner as example 123, using intermediate 51, instead of intermediate 25.

180

¹H NMR (300 MHz, DMSO) δ 11.92 (s, 1H), 8.19 (s, 1H), 7.25 (dd, J = 3.7, 2.3 Hz, 1H), 6.67 (dd, J = 3.5, 1.7 Hz, 1H), 4.14 (s, 1H), 4.11 – 4.02 (m, 2H), 3.98 (d, J = 1.8 Hz, 2H), 3.85 (s, 2H), 3.54 (t, J = 5.1 Hz, 2H), 3.42 – 3.24 (m, 3H), 3.23 – 3.00 (m, 2H), 2.76 (s, 3H), 1.85 (td, J = 11.6, 5.2 Hz, 4H), 1.08 – 0.81 (m, 4H).


5

LC-MS: 1.76 min, ES (+), m/z : 464.205

Using this procedure the following compounds were obtained:

10 Example 186:


N-[[[(2R)-1-(2,3-dihydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



15 LC-MS: 1.70 min, ES (+), m/z : 494.218

Example 187:

N-[[[(2R)-1-(3-cyanopropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



20


¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.13 (d, J = 1.3 Hz, 1H), 7.19 (dd, J = 3.4, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.15 (d, J = 6.5 Hz, 1H), 4.04 (q, J = 4.3 Hz, 2H), 3.87 – 3.75 (m, 2H), 3.58 – 3.34 (m, 4H), 3.17 – 3.05 (m, 2H), 2.85 – 2.69 (m, 3H), 2.68 – 2.56 (m, 3H), 1.99 – 1.74 (m, 4H), 1.04 – 0.80 (m, 4H).

25

LC-MS: 1.88 min, ES (+), m/z: 487.227

Example 188:

5 N-[[[(2R)-1-formylpyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.86 (s, 1H), 8.29 – 8.06 (m, 2H), 7.23 (dd, J = 3.6, 1.9 Hz, 1H), 6.65 (d, J = 3.4 Hz, 1H), 4.08 (dt, J = 10.2, 5.8 Hz, 3H), 3.84 (s, 2H), 3.53 (t, J = 5.2 Hz, 2H), 3.38 (d, J = 11.5 Hz, 2H), 3.09 (d, J = 7.6 Hz, 2H), 2.75 (s, 3H), 2.08 – 1.64 (m, 4H), 1.07 – 0.78 (m, 4H).

LC-MS: 1.76 min, ES (+), m/z: 434.197

Example 189:

15 N-[[[(2R)-1-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.5, 2.3 Hz, 1H), 6.60 (dd, J = 3.7, 1.7 Hz, 1H), 4.19 – 4.00 (m, 3H), 3.91 (d, J = 4.0 Hz, 2H), 3.86 – 3.81 (m, 2H), 3.58 – 3.37 (m, 4H), 3.18 – 3.05 (m, 2H), 2.75 (s, 3H), 1.97 – 1.77 (m, 4H), 1.06 – 0.79 (m, 4H).

LC-MS: 1.85 min, ES (+), m/z: 473.209

Example 190:

N-[[[(2R)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




5

LC-MS: 1.75 min, ES (+), m/z: 478.221

Example 191:

N-[[[(2S)-1-formylpyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide

10



Prepared in a similar manner as example 123, using intermediate 52, instead of intermediate 25.

15

¹H NMR (300 MHz, DMSO) δ 11.71 (s, 1H), 8.25 – 8.07 (m, 2H), 7.19 (dd, J = 3.5, 1.8 Hz, 1H), 6.62 – 6.55 (m, 1H), 4.17 – 3.99 (m, 3H), 3.83 (s, 2H), 3.52 (t, J = 5.1 Hz, 2H), 3.11 (d, J = 7.1 Hz, 2H), 2.74 (s, 3H), 2.00 – 1.69 (m, 4H), 1.01 – 0.78 (m, 4H).


LC-MS: 1.76 min, ES (+), m/z: 434.197

20

Using this procedure the following compounds were obtained:

Example 192:


N-[[[(2S)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



5 LC-MS: 1.76 min, ES (+), m/z: 464.189

Example 193:

N-[[[(2S)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




10

LC-MS: 1.75 min, ES (+), m/z: 478.223

Example 194:

15 N-methyl-N-[[[(2S)-1-methylsulfonylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



Prepared in a similar manner as example 118, using intermediate 52, instead of intermediate 25.


¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.14 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.7 Hz, 1H), 4.05 (d, J = 4.6 Hz, 2H), 3.83 (d, J = 2.7 Hz, 3H), 3.53 (t, J = 5.2 Hz, 2H), 3.26 (s, 2H), 3.18 – 3.03 (m, 2H), 2.93 (s, 3H), 2.74 (s, 3H), 1.96 – 1.77 (m, 4H), 1.12 – 0.83 (m, 4H).

LC-MS: 1.91 min, ES (+), m/z: 484.182

10

Example 168:

N-[(1,1-dioxothian-4-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



15 Prepared in a similar manner as example 143, using intermediate 44, instead of intermediate 2.


¹H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.13 (s, 1H), 7.19 (dd, J = 3.6, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.05 (t, J = 5.2 Hz, 2H), 3.83 (s, 2H), 3.53 (t, J = 5.2, 2H), 3.19 – 2.96 (m, 6H), 2.69 (s, 3H), 2.06 – 1.84 (m, 3H), 1.69 – 1.47 (m, 2H), 1.06 – 0.74 (m, 4H).

20

LC-MS: 1.81 min, ES (+), m/z: 469.170

25 Example 169:

N-(cyanomethyl)-N-[(1,1-dioxothian-4-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




1H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.15 (s, 1H), 7.20 (dd, J = 3.5, 2.3 Hz, 1H), 6.59 (dd, J = 3.5, 1.8 Hz, 1H), 4.33 (s, 2H), 4.07 (t, J = 5.1 Hz, 2H), 3.83 (s, 2H), 3.54 (s, 2H), 3.15 (d, J = 6.9 Hz, 2H), 3.13 – 3.03 (m, 4H), 2.06 – 1.89 (m, 3H), 1.70 – 1.53 (m, 2H), 1.10 – 0.87 (m, 4H).

LC-MS: 1.84 min, ES (+), m/z : 494.166

Example 170:


- 10 N-[(1,1-dioxothian-4-yl)methyl]-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



LC-MS: 1.70 min, ES (+), m/z : 499.176

- 15 Example 171:

N-(2-cyanoethyl)-N-(cyanomethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide



- 20 Prepared in a similar manner as example 143, using intermediate 45, instead of intermediate 2.

186

¹H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.15 (s, 1H), 7.20 (dd, J = 3.6, 2.4 Hz, 1H), 6.60 (dd, J = 3.5, 1.8 Hz, 1H), 4.40 (s, 2H), 4.07 (t, J = 5.1 Hz, 2H), 3.84 (s, 2H), 3.59 (t, J = 5.3 Hz, 2H), 3.47 (t, J = 6.6 Hz, 2H), 2.86 (t, J = 6.4 Hz, 2H), 1.20 – 0.81 (m, 4H).

5


LC-MS: 1.85 min, ES (+), m/z : 401.147

Example 172:

N-[(1,1-dioxothiolan-3-yl)methyl]-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

10

diazaspiro[2.5]octan-8-yl)sulfonyl]acetamide



Prepared in a similar manner as example 132, using intermediate 42, instead of intermediate 4.

15

¹H NMR (300 MHz, DMSO) δ 11.75 (s, 1H), 8.15 (s, 1H), 7.24 – 7.18 (m, 1H), 6.61 (dd, J = 3.7, 1.8 Hz, 1H), 4.15 – 4.00 (m, 2H), 3.90 – 3.80 (m, 4H), 3.75 – 3.66 (m, 2H), 3.27 – 3.16 (m, 2H), 3.15 – 2.99 (m, 1H), 2.87 (dd, J = 12.9, 10.1 Hz, 1H), 2.78 – 2.63 (m, 1H), 2.32 (s, 3H), 2.29 – 2.12 (m, 1H), 1.96 – 1.75 (m, 1H), 1.04 – 0.90 (m, 4H).

20


LC-MS: 1.87 min, ES (+), m/z : 483.147

Example 173:

N-[(1,1-dioxothian-4-yl)methyl]-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

25

diazaspiro[2.5]octan-8-yl)sulfonyl]acetamide




Prepared in a similar manner as example 132, using intermediate 44, instead of intermediate 4.

- 5 ¹H NMR (300 MHz, DMSO) δ 11.75 (s, 1H), 8.15 (s, 1H), 7.36 – 7.09 (m, 1H), 6.61 (dd, J = 3.7, 1.8 Hz, 1H), 4.07 (s, 2H), 3.87 (s, 2H), 3.75 – 3.65 (m, 4H), 3.20 – 2.97 (m, 4H), 2.30 (s, 3H), 1.97 (d, J = 13.3 Hz, 3H), 1.74 – 1.53 (m, 2H), 1.04 – 0.86 (m, 4H).
- 10 LC-MS: 1.86 min, ES (+), m/z: 497.163

Example 174:

N-benzyloxy-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




15

Prepared in a similar manner as example 58, using intermediate 46, instead of intermediate 6.

- ¹H NMR (300 MHz, DMSO) δ 11.74 (s, 1H), 8.14 (s, 1H), 7.38 (d, J = 2.4 Hz, 5H), 7.20 (dd, J = 3.6, 2.3 Hz, 1H), 6.60 (dd, J = 3.5, 1.8 Hz, 1H), 4.84 (s, 2H), 4.05 (t, J = 5.0 Hz, 2H), 3.85 (s, 2H), 3.66 (t, J = 5.0 Hz, 2H), 2.75 (s, 3H), 1.14 – 1.05 (m, 2H), 0.94 – 0.83 (m, 2H).

Example 175:

N-[[[(2S)-1-benzylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




tert-butyl 4-[8-[[[(2S)-1-benzylpyrrolidin-2-yl]methyl-tert-butoxycarbonyl-sulfamoyl]-
 5,8-diazaspiro[2.5]octan-5-yl]pyrrolo[2,3-d]pyrimidine-7-carboxylate (Intermediate
 48) (0.57 mmol) was dissolved in DCM (10 mL) and added TFA (1 mL). The reaction
 mixture was stirred at rt for 16h, then added NaHCO₃ (15 mL) and extracted with
 EtOAc (2 x 25 mL). The combined organic phases were dried over Na₂SO₄, filtered and
 concentrated *in vacuo*. The product was purified by flash chromatography on silica
 using EtOAc and MeOH in heptane as eluent.

¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 8.13 (s, 1H), 7.37 – 7.13 (m, 7H), 6.59
 (dd, J = 3.5, 1.5 Hz, 1H), 4.04 (t, J = 5.2 Hz, 2H), 3.89 (d, J = 13.1 Hz, 1H), 3.82 (s,
 2H), 3.52 (t, J = 5.2 Hz, 2H), 2.92 – 2.81 (m, 1H), 2.81 – 2.70 (m, 1H), 2.69 – 2.54
 (m, 2H), 2.21 – 2.08 (m, 1H), 1.93 – 1.79 (m, 1H), 1.73 – 1.48 (m, 3H), 1.03 – 0.75
 (m, 4H).

LC-MS: 1.75 min, ES (+), m/z: 482.232

20 Example 176:

N-[[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]formamide



Formic acid (0.24 mmol) was dissolved in dry THF (0.5 mL), added di(imidazol-1-yl)methanone (0.29 mmol) and then stirred at 50°C for 30 min. before being cooled to rt and added 4-(4-Sulfamoyl-4,7-diaza-spiro[2.5]oct-7-yl)-pyrrolo[2,3-d]pyrimidine-7-


5 The reaction mixture was stirred at rt for 16h. The pure compounds were obtained by standard preparative HPLC purification of the reaction mixture.

1H NMR (300 MHz, DMSO) δ 12.69 (s, 1H), 11.72 (s, 1H), 8.56 (s, 1H), 7.19 (dd, J = 3.7, 2.3 Hz, 1H), 6.59 (dd, J = 3.6, 1.8 Hz, 1H), 4.05 (t, J = 5.2 Hz, 2H), 3.82 (s, 2H),
10 3.66 (dd, J = 6.7, 3.8 Hz, 2H), 1.17 – 1.03 (m, 2H), 0.87 (b, 2H).

LC-MS: 1.64 min, ES (+), m/z: 337.110

Example 195:

15 N-[(4-methoxyphenyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide




(NZ)-N-[(4-methoxyphenyl)methylene]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide (intermediate 49) was dissolved in MeOH, added
20 NaBH₄ (1 eq) and stirred at rt for 2h. The pure compound was obtained by standard preparative HPLC purification of the reaction mixture.

1H NMR (300 MHz, DMSO) δ 11.72 (s, 1H), 8.12 (s, 1H), 7.81 (m, 1H), 7.21 (d, 2H), 7.18 (m, 1H), 6.88 (d, 2H), 6.58 (m, 1H), 4.03 (m, 2H), 3.91 (m, 2H), 3.82 (s, 2H),
25 3.72 (s, 3H), 3.48 (m, 2H), 0.94 (m, 2H), 0.80 (m, 2H).

LC-MS: 2.06 min, ES (+), m/z: 429.173

Example 196:

30 tert-butyl N-(3-methylsulfonylpropyl)-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]carbamate



Tert-butyl N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]carbamate (Intermediate 53)(0.12 mmol) was dissolved in dry THF (1 mL) and added 3-methylsulfonylpropan-1-ol (0.13 mmol) and triphenylphosphine (0.15 mmol). The reaction mixture was cooled to 0°C and slowly added isopropyl (NZ)-N-isopropoxycarbonyliminocarbamate (0.15 mmol). The reaction mixture was allowed to warm up freely to rt and stirred at rt for 16h. The crude mixture was treated with water (50 mL) and extracted with EtOAc (3x50 mL). The combined organic phases were washed with H₂O (2x50 mL), brine (2x50 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo*. The product was purified by flash chromatography on silica using EtOAc in heptane as eluent.

¹H NMR (300 MHz, DMSO) δ 11.73 (s, 1H), 8.14 (s, 1H), 7.20 (dd, J = 3.5, 2.3 Hz, 1H), 6.61 (dd, J = 3.4, 1.8 Hz, 1H), 4.06 (dd, J = 6.6, 3.7 Hz, 2H), 3.88 – 3.66 (m, 6H), 3.19 – 3.09 (m, 2H), 3.00 (s, 3H), 2.01 (p, J = 8.8, 8.4 Hz, 2H), 1.42 (s, 9H), 1.04 – 0.91 (m, 4H).

JAK kinase assays:

20

Human baculovirus-expressed JAK1, 2, 3 and TYK2 were purchased from Carna Biosciences, Inc. All four purified enzymes contain only the catalytic domain. JAK1 (aa 850-1154) and TYK2 (aa 871-1187) are expressed with an N-terminally fused GST-tag, and JAK2 and JAK3 with an N-terminally fused His-tag.

25



Inhibition of phosphorylation of a synthetic peptide was measured in an HTRF-based assay using the TK substrate-Biotin from the Cisbio HTRFKinEASE TK kit. First, 2 µl of TK solution (TK substrate-biotin in kinase buffer [1x enzymatic buffer from HTRFKinEASE TK kit, 1 mM DTT]) is added to a plate containing 1 µl prediluted compound (final assay concentration DMSO: 0.75%). Then, 5 µl kinase-ATP mix (prepared in kinase buffer) is added to the wells and the plates are incubated at RT for






30






20-30 min. For all four kinases a concentration of ATP that corresponded to the K_m for ATP was used. The final concentrations of buffers, substrate, kinase and ATP were: JAK1: 50 mM Hepes buffer pH 7.0, 0.01% BSA, 10 mM $MgCl_2$, 1 mM DTT, 7 μM ATP, 50 nM SEB, 1 μM TK Substrate-Biotin and 5 ng JAK1; JAK2: 50mM Hepes buffer pH 7.0, 0.01% BSA, 5 mM $MgCl_2$, 1 mM DTT, 4 μM ATP, 1 μM TK Substrate-Biotin and 0.1 ng JAK2; JAK3: 50 mM Hepes buffer pH 7.0, 0.01% BSA, 5 mM $MgCl_2$, 1 mM DTT, 2 μM ATP, 1 μM TK Substrate-Biotin and 0.3 ng JAK3; TYK2: 50 mM Hepes buffer pH 7.0, 0.01% BSA, 5 mM $MgCl_2$, 1 mM DTT, 13 μM ATP, 50 nM SEB, 1 μM TK Substrate-Biotin and 0.8 ng TYK2. Thereafter, the kinase reaction is stopped by adding 4 μl detection mix (final concentrations: 50mM Hepes buffer pH 7.0, 0.01% BSA, 0.8 M KF, 20 mM EDTA, 42 nM Streptavidin-XL665 and 1:400 STK Ab Cryptate) and the plates are incubated overnight in the dark. The HTRF signal is read using an Envision plate reader.






In Table 1 selected JAK kinase inhibitory activities are listed with the following indicators: I: $EC_{50} < 100$ nM, II: 100 nM $\leq EC_{50} \leq 500$ nM and III: $EC_{50} > 500$ nM






Table 1:





Example number	Structure	JAK1	JAK2	JAK3	TYK2
Int 1		I	I	I	II
Int 3		I	I	I	II





Int 5		I	I	II	III
Int 15		II	I	III	III
Int 25		I	I	II	III
Int 26		I	I	II	III
Int 27		II	II	III	III






Int 28		I	I	I	I
Int 30		I	I	II	III
Int 37		I	I	I	III
Int 38		I	I	I	III
Int 40		I	I	I	III





Int 41		I	I	I	II
Int 46		I	I	II	II
Int 49		I	I	I	II
Int 50		I	I	II	III
Int 51		II	II	III	III





Int 52		I	I	II	III
Int 53		I	I	I	III
1		I	I	I	II
2		I	I	II	III
3		II	I	II	III






4		I	I	II	III
5		I	I	I	II
6		II	I	II	III
7		I	I	II	III






8		III	III	III	III
9		III	II	III	III
10		I	I	II	III
11		I	I	II	III






12		I	I	II	III
13		I	I	I	II
14		I	I	II	I
15		I	I	I	II
16		I	I	I	II






17		I	I	I	I
18		II	II	III	III
19		I	I	I	I
20		I	I	I	

21		I	I	II	III
22		I	I	I	II
23		I	I	II	III
24		I	I	I	II





25		I	I	I	I
26		I	I	I	I
27		I	I	I	II
28		I	I	II	II
29		I	I	II	III






30		I	I	II	III
31		I	I	II	II
32		I	I	I	II
33		I	I	I	
34		I	I	I	II





35		I	I	I	I
36		I	I	II	II
37		I	I	I	II
38		II	I	II	II
39		I	I	II	III





40		I	I	II	II
41		I	I	I	
42		I	I	II	III
45		I	I	I	II
46		I	I	II	III






205

47		II	II	III	III
48		II	II	III	III
49		I	I	II	III
50		II	I	II	II






51		I	I	I	II
52		I	I	I	II
53		I	I	I	
54		I	I	I	II
55		I	I	I	II






56		I	I	I	II
57		I	I	I	III
58		I	I	I	II
59		I	I	I	I






60		I	I	I	I
61		I	I	I	II
62		I	I	I	I
63		I	I	I	II






64		I	I	II	II
65		I	I	II	II
66		I	I	I	II
67		I	I	I	II
68		I	I	I	II






210






69		I	I	II	III
70		I	I	II	III
71		I	I	II	III
72		I	I	II	III
73		I	I	I	I






74		I	I	II	II
75		I	I	I	II
76		I	I	I	II
77		I	I	II	II
78		I	I	I	II






79		I	I	I	II
80		II	II	III	III
81		I	I		III
82		I	I	I	I
83		I	I	I	I






84		III	III	III	III
85		I	I	I	I
86		I	I	I	I
87		I	I	I	II
88		I	I	II	II






89		I	I	II	II
90		I	I	I	I
91		I	I	I	I
92		I	I	I	II
93		I	I	II	II






94		I	I	II	III
95		II	I	II	III
96		I	I	II	III
97		I	I	II	III
98		I	I	II	II

99		I	I	II	I
100		I	I	I	I
101		I	I	I	I
102		I	I	I	II
103		I	I	II	II






104		I	I	II	II
105		II	I	III	III
106		I	I	II	III
107		I	I	I	II
108		I	I	I	II






109		I	I	II	II
110		I	I	I	II
111		II	I	II	III
112		I	I	I	II
113		I	I	I	I

114		I	I	I	I
115		I	I	I	II
116		I	I	II	III
117		I	I	I	II
118		I	I	I	II






119		I	I	I	II
120		I	I	I	II
121		I	I	I	II
122		I	I	I	II
123		I	I	II	III






221






124		I	I	II	III
125		I	I	II	III
126		I	I	II	III
127		I	I	II	III
128		I	I	I	III





129		I	I	II	II
130		I	I	I	II
131		I	I	II	I
132		I	I	II	II
133		I	I	II	II






134		I	II	III	III
135		I	I	I	II
136		I	I	II	III
137		I	I	II	III





138		I	I	II	III
139		I	I	I	I
140		I	I	II	III
141		I	I	II	II
142		I	I	I	II






143		I	I	II	III
144		I	I	II	II
145		I	I	I	II
146		II	II	III	III
147		I	I	II	II






148		I	I	I	II
149		I	I	I	III
150		II	I	II	III
151		I	I	II	II
152		I	I	II	III






153		I	I	II	III
154		I	I	I	II
155		I	I	I	I
156		I	I	I	I






157		I	I	I	I
158		I	I	I	II
159		I	I	I	II
160		I	I	I	II
161		I	I	II	III





162		I	I	I	I
163		I	I	I	I
164		I	I	I	I
165		I	I	I	II





166		I	I	I	I
167		I	I	I	II
168		I	I	I	I
169		I	I	I	I
170		I	I	I	I




171		I	I	I	I
172		I	I	I	II
173		I	I	I	II
174		I	I	II	II
175		I	I	II	II

176		I	I	II	III
177		I	I	I	I
178		I	I	I	II
179		I	I	II	II
180		I	I	I	I

181		I	I	I	I
182		I	I	I	I
183		I	I	I	I
184		I	I	I	I
185		I	I	I	I

186		I	I	I	I
187		I	I	II	II
188		I	I	I	II
189		I	I	I	II


190		I	I	II	II
191		I	I	I	II
192		I	I	I	I
193		I	I	I	II

194		I	I	I	II
195		II	II	III	III
196		II	II	III	III

CLAIMS

A compound of general formula I

5



wherein

10 m is 0, 1 or 2;

n is 2 or 4;

15 R₁ is selected from the group consisting of hydrogen, halogen, cyano, -NH₂, -SO₂NH₂, -SONH₂, and -CONH₂;

or R₁ is selected from the group consisting of alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, R_{1a}O-, R_{1a}S-, (R_{1a})₂N-, R_{1b}-C(=O)N(R_{1c})-, R_{1b}O-C(=O)N(R_{1c})-, R_{1b}O-C(=O)-, (R_{1b})₂N-C(=O)N(R_{1c})-, R_{1b}-S(=O)₂N(R_{1c})- and (R_{1b})₂N-S(=O)₂N(R_{1c})- either of which may be optionally substituted with one or more R_{1d};

20

R_{1a} is hydrogen;

or R_{1a} independently at each occurrence is selected from the group consisting of alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl- either of which may be optionally substituted with one or more R_{1e};

25

or in the case where two R_{1a}s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more R_{1e};

R_{1b} and R_{1c} independently at each occurrence are selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl- either of which may be optionally substituted with one or more R_{1e} ;

5

or in the case where two R_{1b} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more R_{1e} ;

10 R_{1d} and R_{1e} independently at each occurrence are selected from the group consisting of halogen, cyano, hydroxy, oxo, $-NH_2$, $-SO_2NH_2$, $-CONH_2$, (C_1-C_4) alkyl-, heteroalkyl-, (C_3-C_6) cycloalkyl-, heterocyclyl-, $R_{1f}O-$, $R_{1f}S-$, $(R_{1f})_2N-$, $R_{1f}O-C(=O)-$, $(R_{1f})_2N-C(=O)-$, $R_{1f}-C(=O)N(R_{1f})-$, $R_{1f}O-C(=O)N(R_{1f})-$, $(R_{1f})_2N-C(=O)N(R_{1f})-$, $R_{1f}-C(=O)O-$, $(R_{1f})_2N-C(=O)O-$, $(R_{1f})_2N-S(=O)_2-$ and $R_{1f}-S(=O)_2N(R_{1f})-$;

15

R_{1f} independently at each occurrence is selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl-;

or in the case where two R_{1f} s are attached to the same N, they may together with the N
20 atom to which they are attached form a heterocycle;

R_2 is independently at each occurrence a covalent bond or alkyl- or heteroalkyl- group, where any two R_2 s are attached to the same C ring atom, and together with this C ring atom said two R_2 s form a carbocycle or heterocycle, hence always forming a spirocyclic
25 piperazine;

R_3 independently at each occurrence is selected from the group consisting of halogen, cyano, hydroxy, oxo, alkyl-, heteroalkyl-, cycloalkyl-, heterocyclyl-, $R_{3a}O-$, $R_{3a}S-$, $(R_{3a})_2N-$, $R_{3a}-C(=O)-$, $R_{3a}O-C(=O)-$, $(R_{3a})_2N-C(=O)-$, $R_{3a}-C(=O)N(R_{3b})-$, $R_{3a}O-C(=O)N(R_{3b})-$, $R_{3a}-C(=O)O-$, $(R_{3a})_2N-C(=O)O-$, $R_{3a}-S(=O)-$, $R_{3a}-S(=O)_2-$, $(R_{3a})_2N-S(=O)_2-$ and $R_{3a}-S(=O)_2N(R_{3b})-$;

30

R_{3a} and R_{3b} independently at each occurrence are selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, cycloalkyl- and heterocyclyl-

35

or in the case where two R_{3a} s are attached to the same N, they may together with the N atom to which they are attached form a heterocycle;

R₄ and R₅ independently at each occurrence is selected from the group consisting of alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-, arylalkyl-, aryloxyalkyl-, heteroarylalkyl-, heteroaryloxyalkyl-, R₆O-L-,
 5 , R₆S-L-, (R₆)₂N-L-, R₆-C(=O)-L-, R₆O-C(=O)-L-, (R₆)₂N-C(=O)-L-, R₆-C(=O)N(R₆)-L-, R₆O-C(=O)N(R₆)-L-, (R₆)₂N-C(=O)N(R₆)-L-, R₆-C(=O)O-L-, (R₆)₂N-C(=O)O-L-, R₆-S(=O)₂-L-, (R₆)₂N-S(=O)₂-L-, R₆-S(=O)₂N(R₆)-L- and (R₆)₂N-S(=O)₂N(R₆)-L either of which may be optionally substituted with one or more R₇;

10 or R₄ and R₅ can together with the N atom to which they are attached form a heterocyclic ring which may be optionally substituted with one or more R₇;

or R₄ and R₅ independently can be hydrogen;

15 L is independently at each occurrence selected from the group consisting of alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-, arylalkyl-, aryloxyalkyl-, heteroarylalkyl- and heteroaryloxyalkyl-;
 or when R₄ or R₅ is selected from R₆O-L-, L can also be a bond;

20

R₆ independently at each occurrence is selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, heterocyclyl-, aryl-, arylalkyl- and heteroaryl-, cycloalkylalkyl- either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano,
 25 hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂, -CONH₂ and -O(C₁-C₄);

or in the case where two R₆ are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of
 30 halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂;

R₇ independently at each occurrence is selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂, -CONH₂ and =CH₂,
 or R₇ is selected from the group consisting of alkyl-, heteroalkyl-, alkenyl-, alkynyl-,
 35 cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl, alkylcycloalkyl-, alkylheterocyclyl-, aryl-, heteroaryl-, arylalkyl-, alkoxy-, aryloxyalkyl-, heteroarylalkyl-, heteroaryloxyalkyl-, R₈O-L-, R₈S-L-, (R₈)₂N-L-, R₈-C(=O)-L-, R₈O-C(=O)-L-, (R₈)₂N-C(=O)-L-, R₈-C(=O)N(R₈)-L-, R₈O-C(=O)N(R₈)-L-,

$(R_8)_2N-C(=O)N(R_8)-L-$, $R_8-C(=O)O-L-$, $(R_8)_2N-C(=O)O-L-$, $R_8-S(=O)_2-L-$, $(R_8)_2N-S(=O)_2-L-$, $R_8-S(=O)_2N(R_8)-L-$ and $(R_8)_2N-S(=O)_2N(R_8)-L$

either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$;

R_8 independently at each occurrence is selected from the group consisting of hydrogen, alkyl-, heteroalkyl-, alkenyl-, alkynyl-, cycloalkyl-, heterocyclyl-, cycloalkylalkyl-, heterocyclalkyl-, aryl-, arylalkyl-, heteroaryl-, and heteroarylalkyl- either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$;

or in the case where two R_8 are attached to the same N, they may together with the N atom to which they are attached form a heterocycle which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$;

and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof;

with the proviso that when R_1 is hydrogen, and m is 0, and n is 2, and the two R_2 's form a cyclopropyl ring together with the carbon atom to which they are attached, and R_4 is methyl, R_5 is not selected from the group consisting of cyanoethyl or cyclohexyl;

and with the proviso that when R_1 is hydrogen, and m is 0, and n is 2, and the two R_2 's form a cyclopropyl ring together with the carbon atom to which they are attached, and R_5 is methyl, R_4 is not selected from the group consisting of cyanoethyl or cyclohexyl;

and with the proviso that when R_1 is hydrogen, and m is 0, and n is 2, and the two R_2 's form a cyclopropyl ring together with the carbon atom to which they are attached, and R_4 is ethyl, R_5 is not ethyl.

2. The compound according to claim 1 wherein one of R_4 and R_5 is selected from the group consisting of (C_1-C_2) alkyl-, heteroalkyl-, (C_2-C_4) alkenyl-, (C_2-C_4) alkynyl-, (C_3-C_8) cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkyl(C_1-C_4)alkyl-, heterocycl(C_1-C_4)alkyl, (C_1-C_4) alkyl(C_3-C_8)cycloalkyl-, (C_1-C_4) alkylheterocyclyl-, aryl-, heteroaryl-, aryl(C_1-C_4)alkyl-, aryloxy(C_1-C_4)alkyl-, heteroaryl(C_1-C_4)alkyl-, heteroaryloxy(C_1-C_4)alkyl-, R_6O-L- , R_6S-L- , $(R_6)_2N-L-$, $R_6-C(=O)-L-$, $R_6O-C(=O)-L-$,

$(R_6)_2N-C(=O)-L-$, $R_6-C(=O)N(R_6)-L-$, $R_6O-C(=O)N(R_6)-L-$, $(R_6)_2N-C(=O)N(R_6)-L-$, $R_6-C(=O)O-L-$, $(R_6)_2N-C(=O)O-L-$, $R_6-S(=O)_2-L-$, $(R_6)_2N-S(=O)_2-L-$, $R_6-S(=O)_2N(R_6)-L-$ and $(R_6)_2N-S(=O)_2N(R_6)-L$ either of which may be optionally substituted with one or more R_7 ;

- 5 and wherein the other R_4 or R_5 is selected from the group consisting of (C_3-C_5) alkyl-, heteroalkyl-, (C_2-C_4) alkenyl-, (C_2-C_4) alkynyl-, (C_3-C_5) cycloalkyl-, cycloalkenyl-, cycloalkynyl-, heterocyclyl-, cycloalkyl(C_1-C_4)alkyl-, heterocyclyl(C_1-C_4)alkyl, (C_1-C_4) alkyl(C_3-C_8)cycloalkyl-, (C_1-C_4) alkylheterocyclyl-, aryl-, heteroaryl-, aryl(C_1-C_4)alkyl-, aryloxy(C_1-C_4)alkyl-, heteroaryl(C_1-C_4)alkyl-, heteroaryloxy(C_1-C_4)alkyl-, R_6O-L- , R_6S-
 10 $L-$, $(R_6)_2N-L-$, $R_6-C(=O)-L-$, $R_6O-C(=O)-L-$, $(R_6)_2N-C(=O)-L-$, $R_6-C(=O)N(R_6)-L-$, $R_6O-C(=O)N(R_6)-L-$, $(R_6)_2N-C(=O)N(R_6)-L-$, $R_6-C(=O)O-L-$, $(R_6)_2N-C(=O)O-L-$, $R_6-S(=O)_2-L-$, $(R_6)_2N-S(=O)_2-L-$, $R_6-S(=O)_2N(R_6)-L-$ and $(R_6)_2N-S(=O)_2N(R_6)-L$ either of which may be optionally substituted with one or more R_7 ;

15

or R_4 and R_5 can together with the N atom to which they are attached form a heterocyclic ring which may be optionally substituted with one or more R_7 ;

or R_4 and R_5 independently can be hydrogen.

20

3. The compound according to claim 1 or 2 wherein m is 0 or 1.

4. The compound according to claim 1-3 wherein m is 0.

25

5. The compound according to any of the preceding claims wherein n is 2.

6. The compound according to any of the preceding claims wherein R_1 is selected from the group consisting of hydrogen, $-NH_2$, $-SO_2NH_2$, $-SONH_2$, and $-CONH_2$.


30

7. The compound according to claim 6 wherein R_1 is hydrogen.

8. The compound according to any of claims 1-5 wherein R_1 is selected from the group consisting $(R_{1a})_2N-$, $R_{1b}-C(=O)N(R_{1c})-$, $R_{1b}O-C(=O)N(R_{1c})-$, $R_{1b}O-C(=O)-$, $(R_{1b})_2N-C(=O)N(R_{1c})-$, $R_{1b}-S(=O)_2N(R_{1c})-$ and $(R_{1b})_2N-S(=O)_2N(R_{1c})-$ either of which may be
 35 optionally substituted with one or more R_{1d} .


9. The compound according to claim 8, wherein R_{1a} is hydrogen.

10. The compound according to any of the preceding claims wherein each R_2 independently at each occurrence is selected from the group consisting of



5

11. The compound according to any of the preceding claims wherein R_2 is



10 12. The compound according to claims 10-11 wherein $m = 0$ and wherein R_1 is hydrogen.

13. The compound according to claims 1-3 and 5-11 wherein R_3 independently at each occurrence is selected from the group consisting of cyano, hydroxy, oxo, (C_1-C_4) alkyl-,
15 heteroalkyl-, and $R_{3a}O$ -.

14. The compound according to claims 1 or 3-13 wherein R_4 and R_5 independently at each occurrence is selected from the group consisting of (C_1-C_5) alkyl-, heteroalkyl-, (C_3-C_8) cycloalkyl-, heterocyclyl-, (C_3-C_8) cycloalkyl (C_1-C_4) alkyl-, heterocyclyl (C_1-C_4) alkyl-, (C_1-C_4) alkyl (C_3-C_8) cycloalkyl-, (C_1-C_4) alkylheterocyclyl-, aryl-, heteroaryl-,
20 aryl (C_1-C_4) alkyl-, aryloxy (C_1-C_4) alkyl-, heteroaryl (C_1-C_4) alkyl-, heteroaryloxy $(C_1-$

C₄)alkyl-, R₆O-L-, R₆S-L-, (R₆)₂N-L-, R₆O-C(=O)-L-, (R₆)₂N-C(=O)-L-, R₆-C(=O)N(R₆)-L-, R₆O-C(=O)N(R₆)-L-, (R₆)₂N-C(=O)N(R₆)-L-, R₆-C(=O)O-L-, (R₆)₂N-C(=O)O-L-, R₆-S(=O)₂-L-, (R₆)₂N-S(=O)₂-L-, R₆-S(=O)₂N(R₆)-L- and (R₆)₂N-S(=O)₂N(R₆)-L either of which may be optionally substituted with one or more R₇.

5

15. The compound according to any of the preceding claims wherein at least one of R₄ and R₅ is selected from the group consisting of heteroalkyl-, heterocyclyl(C₁-C₄)alkyl-, aryl(C₁-C₄)alkyl- and heteroaryl(C₁-C₄)alkyl-, wherein said heteroalkyl-, heterocyclyl(C₁-C₄)alkyl-, aryl(C₁-C₄)alkyl- and heteroaryl(C₁-C₄)alkyl- is substituted

10

with one or more R₇.

16. The compound according to claim 15 wherein at least one of R₄ and R₅ is benzyl.

17. The compound according to claims 1-14 wherein at least one of R₄ and R₅ is

15

selected from the group consisting of R₆O-L-, R₆S-L-, (R₆)₂N-L-, R₆-C(=O)-L-, R₆O-C(=O)-L-, (R₆)₂N-C(=O)-L-, R₆-C(=O)N(R₆)-L-, R₆O-C(=O)N(R₆)-L-, (R₆)₂N-C(=O)N(R₆)-L-, R₆-C(=O)O-L-, (R₆)₂N-C(=O)O-L-, R₆-S(=O)₂-L-, (R₆)₂N-S(=O)₂-L-, R₆-S(=O)₂N(R₆)-L- and (R₆)₂N-S(=O)₂N(R₆)-L-, either of which may be optionally substituted with one or more R₇; wherein L independently at each occurrence is

20

selected from the group consisting of heterocyclyl-, heterocyclyl(C₁-C₄)alkyl, (C₁-C₄)alkylheterocyclyl-, aryl(C₁-C₄)alkyl- and heteroaryl(C₁-C₄)alkyl-.

18. The compound according to claims 1-14 wherein one of R₄ and R₅ is selected from the group consisting of dioxothiolanylmethyl, dioxothiolanylethyl, dioxothianylmethyl and dioxothianylethyl.

25

19. The compound according to claim 18 wherein one of R₄ and R₅ is dioxothiolanylmethyl.

30

20. The compound according to claims 18 wherein one of R₄ and R₅ is dioxothianylmethyl.

21. The compound according to claim 17 wherein at least one of R₄ and R₅ is selected from R₆-C(=O)-L-, R₆-S(=O)₂-L- or (R₆)₂N-S(=O)₂-L-, which may be optionally substituted with one or more R₇; wherein L is selected from the group consisting of heterocyclyl-, heterocyclyl(C₁-C₄)alkyl, (C₁-C₄)alkylheterocyclyl-, aryl(C₁-C₄)alkyl- and heteroaryl(C₁-C₄)alkyl-.

35

22. The compound according to claim 21 wherein L is selected from the group consisting of piperidinylmethyl, pyrrolidinylmethyl, benzyl and azetidiny; and wherein R₆ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, cyclopropylmethyl, hydroxymethyl, hydroxyethyl, cyanoethyl, cyanopropyl.

5

23. The compound according to claims 21-22 wherein R₆-C(=O)-L-, R₆-S(=O)₂-L- and (R₆)₂N-S(=O)₂-L- is substituted with at least two fluoro.

10

24. The compound according to claims 1-14 wherein one of R₄ and R₅ is selected from the group consisting of heterocyclyl(C₁-C₄)alkyl and (C₃-C₆)cycloalkyl(C₁-C₄)alkyl wherein said heterocyclyl(C₁-C₄)alkyl and (C₃-C₆)cycloalkyl(C₁-C₄)alkyl is substituted with two or more R₇'s; wherein at least two R₇'s are fluoro.

15

25. The compound according to claim 24 wherein one of R₄ and R₅ is selected from the group consisting of cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl and pyrrolidinylmethyl.

20

26. The compound according to any of claims 1-13 wherein R₄ and R₅ together with the N atom to which they are attached form a heterocyclic ring which may be optionally substituted with one or more R₇.

27. The compound according to any of claims 1-13 wherein R₄ is hydrogen.

28. The compound according to any of claims 1-13 wherein R₅ is hydrogen.

25

29. The compound according to any of claims 1-25 wherein R₄ is methyl.

30. The compound according to any of claims 1-25 wherein R₅ is methyl.

30

31. The compound according to claims 1-14 wherein L is independently at each occurrence selected from the group consisting of (C₁-C₄)alkyl-, heteroalkyl-, (C₃-C₈)cycloalkyl-, heterocyclyl-, (C₃-C₈)cycloalkyl(C₁-C₄)alkyl-, heterocyclyl(C₁-C₄)alkyl, alkyl(C₃-C₈)cycloalkyl-, (C₁-C₄)alkylheterocyclyl-, aryl(C₁-C₄)alkyl- and heteroaryl(C₁-C₄)alkyl-.

35

32. The compound according to any of claims 1 and 3-14, wherein R₄ and R₅ independently are selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, isoamyl, pentyl, benzyl, butynyl, cyclopropyl,

cyclobutyl, cyclopentyl, oxetanyl, phenyl, phenylpropyl, phenethyl, pyridylmethyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cubanylmethyl, tetrahydrofuranylmethyl, tetrahydropyranylmethyl, morpholinylethyl,

5 dioxothiolanylmethyl, dioxothiolanylethyl, dioxothianyl, dioxothianylmethyl, dioxothianylethyl, azetidiny, pyrrolidinylmethyl, piperidinylmethyl, pyrazolylmethyl, pyrazolyethyl, pyrrolylethyl, isoxazolylmethyl, isoxazolylethyl, imidazolylethyl, $R_6O-C(=O)-L-$, $R_6-C(=O)N(R_6)-L-$, R_6O-L- , $(R_6)_2N-C(=O)-L-$, $(R_6)_2N-L-$, $(R_6)_2N-S(=O)_2-L-$, $R_6-S(=O)_2-L-$, $R_6-C(=O)-L-$, either of which may be optionally substituted with one or

10 more R_7 ; and wherein L is selected from the group consisting of methyl, ethyl, propyl, furanylmethyl, benzyl, azetidiny, pyrrolidinylmethyl, piperidinylmethyl; and wherein R_6 is independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isobutyl, tert-butyl, phenyl, benzyl, trifluoromethyl, cyclopropylmethyl, either of which R_6 may be optionally substituted with one or more

15 substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$, $-O(C_1-C_4)$.

33. The compound according to any of the preceding claims wherein R_7 independently at each occurrence is selected from the group consisting of fluoro, chloro, cyano,

20 hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$, $-CONH_2$, and $=CH_2$.

34. The compound according to any of claims 1-22 and 25-32 wherein R_7 is selected from the group consisting of (C_1-C_4) alkyl-, heteroalkyl-, (C_2-C_4) alkynyl-, (C_3-C_8) cycloalkyl-, heterocyclyl-, (C_3-C_8) cycloalkyl (C_1-C_4) alkyl-, heterocyclyl (C_1-C_4) alkyl-,

25 (C_1-C_4) alkyl (C_3-C_8) cycloalkyl-, (C_1-C_4) alkylheterocyclyl-, aryl (C_1-C_4) alkyl-, R_8O- , R_8S- , $(R_8)_2N-$, $R_8O-C(=O)-$, $(R_8)_2N-C(=O)-$, $R_8-C(=O)N(R_8)-$, $R_8O-C(=O)N(R_8)-$, $(R_8)_2N-C(=O)N(R_8)-$, $R_8-C(=O)O-$, $(R_8)_2N-C(=O)O-$, $R_8-S(=O)_2-$, $(R_8)_2N-S(=O)_2-$, $R_8-S(=O)_2N(R_8)-$ and $(R_8)_2N-S(=O)_2N(R_8)-$ either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano,

30 hydroxy, trifluoromethyl, oxo, $-NH_2$, $-SO_2NH_2$, $-SONH_2$ and $-CONH_2$.

35. The compound according to claim 34 wherein R_7 is selected from the group consisting of methyl, tert-butyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxothiolanyl, dioxothianyl,

35 pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, pyridyl, imidazolyl, benzyl, $R_8O-C(=O)-$, R_8O- , $(R_8)_2N-C(=O)-$ and $(R_8)_2N-$, either of which may be optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro, cyano, hydroxy, trifluoromethyl and oxo;

and wherein R₈ is selected from the group consisting of methyl, ethyl and phenyl.

36. The compound according to claims 1-34 wherein R₈ independently at each occurrence is selected from the group consisting of hydrogen, (C₁-C₄)alkyl-, heteroalkyl-, (C₃-C₆)cycloalkyl-, heterocyclyl-, (C₃-C₆)cycloalkyl(C₁-C₄)alkyl-, heterocyclyl(C₁-C₄)alkyl-, aryl-, aryl(C₁-C₄)alkyl-, heteroaryl-, and heteroaryl(C₁-C₄)alkyl- either of which may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, trifluoromethyl, oxo, -NH₂, -SO₂NH₂, -SONH₂ and -CONH₂.

10

37. The compound according to any of the preceding claims which is selected from the group consisting of

- 15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid amide, 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methylamide, 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-amide,
- 20 4-[4-(Imidazole-1-sulfonyl)-4,7-diaza-spiro[2.5]oct-7-yl]-7H-pyrrolo[2,3-d]pyrimidine, N-methyl-N-(pyrrolidin-3-ylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide, N-methyl-N-(4-piperidylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formic acid salt,
- 25 N-methyl-N-(3-piperidylmethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formic acid salt, N-[(2S)-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide as formic acid salt, N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-
- 30 sulfonamide, N-[(1,1-dioxothiolan-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide, N-[(1,1-dioxothian-4-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 35 N-(2-cyanoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide, N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N-benzyloxy-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
 (NZ)-N-[(4-methoxyphenyl)methylene]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 5 N-(azetidin-3-yl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
 N-methyl-N-[[[(2R)-pyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
 N-methyl-N-[[[(2S)-pyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
- 10 diazaspiro[2.5]octane-8-sulfonamide as formic acid salt,
 tert-butyl N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]carbamate,
 4-{4-[Phenethyl-(3-phenyl-propyl)-sulfamoyl]-4,7-diaza-spiro[2.5]oct-7-yl}-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid tert-butyl ester,
- 15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 cyclopropylmethyl-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 cyclobutylmethyl-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-oxo-
- 20 butyl)-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-hydroxy-propyl)-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 isobutyl-phenethyl-amide ,
- 25 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 phenethyl-propyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 cyclohexylmethyl-phenethyl-amide,
- 30 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 diphenethylamide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 cyanomethyl-phenethyl-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (4-cyano-butyl)-phenethyl-amide ,
- 35 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid
 phenethyl-(tetrahydro-pyran-2-ylmethyl)-amide ,
 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-methoxy-ethyl)-phenethyl-amide ,

- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid but-2-ynyl-phenethyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-(2-pyrazol-1-yl-ethyl)-amide ,
- 5 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-hydroxy-ethyl)-phenethyl-amide ,
- {Phenethyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetic acid ethyl ester ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(4-fluoro-phenyl)-ethyl]-phenethyl-amide ,
- 10 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3-fluoro-phenyl)-ethyl]-phenethyl-amide ,
- N-Benzyl-2-{phenethyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetamide ,
- 15 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(3-phenyl-propyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-cyclohexyl-ethyl)-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-
- 20 (2-oxo-2-phenyl-ethyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-benzyl)-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-cyano-benzyl)-methyl-amide ,
- 25 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid cyclohexylmethyl-methyl-amide,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(4-fluoro-phenyl)-ethyl]-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3-fluoro-phenyl)-ethyl]-methyl-amide ,
- 30 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(2-pyrrol-1-yl-ethyl)-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(3-methyl-butyl)-amide ,
- 35 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-pyridin-2-ylmethyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [3-(4-cyano-phenyl)-propyl]-methyl-amide ,

- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [3-(3-cyano-phenyl)-propyl]-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-(2-phenoxy-ethyl)-amide ,
- 5 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3,5-dimethyl-isoxazol-4-yl)-ethyl]-methyl-amide ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-phenethyl-amide ,
- {Methyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-
- 10 amino}-acetic acid methyl ester ,
- 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-methyl-amide ,
- N,N-Dimethyl-2-{methyl-[7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-amino}-acetamide,
- 15 N-(cyclopropylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-(cyclobutylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-cyclopentyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-
- 20 8-sulfonamide,
- N-[(4,4-difluorocyclohexyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-(2-phenylpropyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 25 N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydropyran-2-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[[5-(dimethylsulfamoyl)-2-furyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-(2-pyrazol-1-ylethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
- 30 diazaspiro[2.5]octane-8-sulfonamide,
- N-methyl-N-[(3-methylisoxazol-5-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-(isoxazol-5-ylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- 35 N-[2-(4-chlorophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
- N-[2-(2-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N-[2-(3-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[2-(4-cyanophenoxy)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
5 N-(cyclopentylmethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(2-cyclopentylethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[2-(1,1-dioxothiolan-3-yl)ethyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
10 diazaspiro[2.5]octane-8-sulfonamide,
N-[(1,1-dioxothian-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(2-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
15 N-[(3-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(4-fluorophenyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-
20 5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[[4-(trifluoromethyl)phenyl]methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(2-cyclopropylethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
25 N-methyl-N-[(4-methylsulfonylphenyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(4-tert-butylcyclohexyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(3,3-difluorocyclobutyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-
30 diazaspiro[2.5]octane-8-sulfonamide,
N-[(2,2-difluorocyclopropyl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[(4-methylenecyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
35 N-methyl-N-[(3-oxocyclobutyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydropyran-4-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[(3-sulfamoylphenyl)methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-[(4-sulfamoylphenyl)methyl]-5,8-diazaspiro[2.5]octane-8-sulfonamide,

5 N-[[1-(difluoromethyl)-3H-pyrazol-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[1-(2,2-difluoroethyl)-3H-pyrazol-3-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (4-cyano-benzyl)-methyl-amide ,

4-[4-(Piperidine-1-sulfonyl)-4,7-diaza-spiro[2.5]oct-7-yl]-7H-pyrrolo[2,3-d]pyrimidine, 1-[7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-piperidine-4-carbonitrile,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-phenyl-amide ,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-cyano-ethyl)-cyclopropyl-amide ,

1-[7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonyl]-piperidine-3-carbonitrile ,

20 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amide,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid benzyl-methyl-amide,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid dimethylamide ,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid isopropylamide ,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid phenethyl-(3-phenyl-propyl)-amide ,

30 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (2-hydroxy-ethyl)-amide ,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid bis-(2-hydroxy-ethyl)-amide ,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-amide,

35 7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid bis-(3-cyano-propyl)-amide,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid (3-cyano-propyl)-(3-phenyl-propyl)-amide,

7-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-4,7-diaza-spiro[2.5]octane-4-sulfonic acid methyl-phenethyl-amide,

5 N-isopropyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-ethyl-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-(cyanomethyl)-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

10 diazaspiro[2.5]octane-8-sulfonamide,

N-(2-hydroxyethyl)-N-isopropyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

15 N-cyclobutyl-N-ethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-(cyanomethyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

20 diazaspiro[2.5]octane-8-sulfonamide,

N-(3-cyanopropyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-(2-methoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

25 N-cyclobutyl-N-(2-imidazol-1-ylethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-[3-(dimethylamino)propyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-cyclobutyl-N-(2-morpholinoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-

30 diazaspiro[2.5]octane-8-sulfonamide,

N-(1-cyanoethyl)-N-cyclobutyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-(cyanomethyl)-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

35 N-(2-hydroxyethyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-(3-cyanopropyl)-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N-(2-hydroxyethyl)-N-(2-phenoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
5 N-(cyanomethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(3-cyanopropyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(oxetan-3-yl)-N-(2-phenoxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
10 N-(2-hydroxyethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(1-cyanoethyl)-N-(oxetan-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
15 N-methyl-N-[(1-propylsulfonylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[(1-methylsulfonylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[1-(2-methoxyethylsulfonyl)pyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
20 N-[[1-(3-cyanopropylsulfonyl)pyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[1-(cyclopropylmethylsulfonyl)pyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
25 N-[[1-(3-hydroxypropanoyl)pyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[1-(3-hydroxybutanoyl)pyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[(1-propanoylpyrrolidin-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
30 N-[[1-(3-cyanopropanoyl)pyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[1-(2,3-dihydroxypropanoyl)pyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
35 N-[(1-formylpyrrolidin-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
3,3,3-trifluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]propanamide,

- 4,4-difluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]cyclohexanecarboxamide,
4,4,4-trifluoro-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]butanamide,
5 N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiolane-3-carboxamide,
2-(1,1-dioxothian-4-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
3-(1,1-dioxothioloan-3-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]propanamide,
10 2-(1,1-dioxothioloan-3-yl)-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiane-4-carboxamide,
15 N-methyl-1,1-dioxo-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]thiane-3-carboxamide,
N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]cyclopentanecarboxamide,
2-cyclopentyl-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
20 3-cyclopentyl-N-methyl-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]propanamide,
N-cyclopropyl-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
25 N-(2-cyanoethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-(tetrahydrofuran-2-ylmethyl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(1-methylbutyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-cyclopentyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
30 N,N-bis(cyanomethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N,N-dibenzyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
35 N-benzyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[(4,4-difluorocyclohexyl)methyl]-N-ethyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N,N-bis[(4,4-difluorocyclohexyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

5 N-[[1-(3-hydroxypropanoyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[1-(3-cyanopropanoyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

10 N-[[1-(3-cyanopropanoyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[1-(3-hydroxypropanoyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[2S]-4,4-difluoro-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

15 N-[[2S]-1-(3-cyanopropanoyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[2S]-4,4-difluoro-1-formyl-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

20 N-methyl-N-[(1-methylsulfonyl-4-piperidyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[1-(3-cyanopropylsulfonyl)-4-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-methyl-N-[(1-methylsulfonyl-3-piperidyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

25 N-[[1-(3-cyanopropylsulfonyl)-3-piperidyl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[2S]-4,4-difluoro-1-methylsulfonyl-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

30 N-[[2S]-1-(3-cyanopropylsulfonyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[2S]-1-(cyclopropylmethylsulfonyl)-4,4-difluoro-pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[(1,1-dioxothiolan-3-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

35 N-(cyanomethyl)-N-[(1,1-dioxothiolan-3-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[(1,1-dioxothiolan-3-yl)methyl]-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

- N-[(1,1-dioxothian-4-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(cyanomethyl)-N-[(1,1-dioxothian-4-yl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
5 N-[(1,1-dioxothian-4-yl)methyl]-N-(2-hydroxyethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-(2-cyanoethyl)-N-(cyanomethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[(1,1-dioxothiolo-3-yl)methyl]-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
10 N-[(1,1-dioxothian-4-yl)methyl]-N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]acetamide,
N-benzyloxy-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
15 N-[[[(2S)-1-benzylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]formamide,
N-[(4-cyanocuban-1-yl)methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
20 N-[1-(2-hydroxyacetyl)azetidin-3-yl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[1-(3-hydroxypropanoyl)azetidin-3-yl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
25 N-methyl-N-(1-methylsulfonylazetidin-3-yl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[[[(2R)-1-methylsulfonylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[[(2R)-1-(3-cyanopropylsulfonyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
30 N-methyl-N-[[[(2S)-5-oxopyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-methyl-N-[[[(2R)-5-oxopyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
35 N-[[[(2R)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,
N-[[[(2R)-1-(2,3-dihydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2R)-1-(3-cyanopropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2R)-1-formylpyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

5 N-[[[(2R)-1-(2-cyanoacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2R)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

10 N-[[[(2S)-1-formylpyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2S)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[[[(2S)-1-(3-hydroxypropanoyl)pyrrolidin-2-yl]methyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

15 N-methyl-N-[[[(2S)-1-methylsulfonylpyrrolidin-2-yl]methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide,

N-[(4-methoxyphenyl)methyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octane-8-sulfonamide and

20 tert-butyl N-(3-methylsulfonylpropyl)-N-[[[5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,8-diazaspiro[2.5]octan-8-yl]sulfonyl]carbamate

38. A pharmaceutical composition comprising a compound according to any of the preceding claims or a pharmaceutically acceptable salt, hydrate, or solvate thereof
25 together with a pharmaceutically acceptable vehicle or excipient.

39. The composition according to claim 38 further comprising another therapeutically active compound.

30 40. The compound according to any one of claims 1-37 for use in therapy.

41. The compound according to any one of claims 1-37 for use in the prophylaxis, treatment and/or amelioration of diseases of the immune system, such as autoimmune diseases.

35

42. The compound according to claim 41 for use in the prophylaxis, treatment and/or amelioration of skin diseases, such as psoriasis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes and complications from diabetes, asthma, atopic

dermatitis, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases.

5 43. The compound according to claim 41 for use in the prophylaxis, treatment and/or amelioration of a dermal disease or condition selected from the group consisting of proliferative and inflammatory skin disorders, psoriasis, cancer, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact
10 dermatitis, urticaria, pruritis, and eczema.

44. Use of a compound according to any one of claims 1-37 for the manufacture of a medicament for the prophylaxis, treatment and/or amelioration of diseases of the immune system, such as autoimmune diseases.

15

45. The use according to claim 44 for the manufacture of a medicament for the prophylaxis, treatment and/or amelioration of skin diseases, such as psoriasis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes and complications from diabetes, asthma, atopic dermatitis, cancer, autoimmune thyroid disorders, ulcerative
20 colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases.

46. The use according to any one of claims 44-45 wherein the medicament further comprises another therapeutically active compound.

25

47. The compound according to any one of claims 1-37 for use as an anti-inflammatory agent capable of modulating the activity of a protein tyrosin kinase of the JAK family of protein tyrosine kinases.

30 48. The compound according to claim 47 for use as an anti-inflammatory agent capable of modulating the activity of JAK1, JAK2, JAK3 or TYK2 protein tyrosine kinases.

49. The compound according to any one of claims 47-48 for use in the treatment, amelioration or prophylaxis of non-infectious inflammatory or autoimmune diseases or
35 conditions wherein the non-infectious inflammatory diseases or conditions are selected from the group consisting of acute inflammatory diseases such as acute lung injury, acute respiratory distress syndrome, allergy, anaphylaxis, sepsis or graft-vs-host disease, or chronic inflammatory diseases such as osteoarthritis, gout, psoriatic

arthritis, hepatic cirrhosis, multiple sclerosis, or ocular diseases or conditions such as non-infectious (e.g. allergic) conjunctivitis, uveitis, iritis, keratitis, scleritis, episcleritis, sympathetic ophthalmitis, blepharitis, keratoconjunctivitis sicca, or immunological cornea graft rejection, and the autoimmune diseases or conditions are selected from
5 the group consisting of autoimmune gastritis, Addison's disease, autoimmune hemolytic anemia, autoimmune thyroiditis, chronic idiopathic urticaria, chronic immune polyneuropathy, diabetes, diabetic nephropathy, myasthenia gravis, pemphigus vulgaris, pernicious anemia, primary biliary cirrhosis, systemic lupus erythematosus and thyroid eye disease.

10

50. A method of preventing, treating or ameliorating diseases of the immune system, such as autoimmune diseases, the method comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1-37.

15

51. The method according to claim 50 of preventing, treating or ameliorating skin diseases, such as psoriasis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes and complications from diabetes, asthma, atopic dermatitis, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well
20 as other autoimmune diseases.

